Oxytocin receptor antagonists for inhibiting preterm labour (Review) by Flenady, Vicki et al.
Cochrane Database of Systematic Reviews
Oxytocin receptor antagonists for inhibiting preterm labour
(Review)
Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DNM
Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DNM.
Oxytocin receptor antagonists for inhibiting preterm labour.
Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD004452.
DOI: 10.1002/14651858.CD004452.pub3.
www.cochranelibrary.com
Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
18DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 1 Birth less than 48
hours after trial entry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Analysis 1.2. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 2 Perinatal mortality
(stillbirth and neonatal death up to 28 days). . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 1.3. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 3 Stillbirth. . 54
Analysis 1.4. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 4 Neonatal death. 55
Analysis 1.5. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 5 Infant death (up
to 12 months). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Analysis 1.6. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 6 Maternal death. 56
Analysis 1.7. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 7 Maternal adverse
effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.8. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 8 Maternal adverse
effects requiring cessation of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . 58
Analysis 1.9. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 9 Caesarean
section. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 1.10. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 10 Preterm birth
(before completion of 37 weeks of gestation). . . . . . . . . . . . . . . . . . . . . . . . 60
Analysis 1.11. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 11 Extremely
preterm birth (before completion of 28 weeks of gestation). . . . . . . . . . . . . . . . . . . 61
Analysis 1.12. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 12 Gestational age
(weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Analysis 1.13. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 13 Birthweight
(grams). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Analysis 1.14. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 14 Respiratory
distress syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Analysis 1.15. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 15 Intraventricular
haemorrhage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Analysis 1.16. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 16 Necrotising
enterocolitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Analysis 1.17. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 17 Neonatal
jaundice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Analysis 1.18. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 18 Admission to
neonatal intensive care unit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.1. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 1 Birth less than 48 hours after trial entry. . . . . . . . . . . . . . . . . . 67
iOxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 2 Perinatal mortality. . . . . . . . . . . . . . . . . . . . . . . . . 68
Analysis 2.3. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 3 Very preterm birth (before completion of 34 weeks of gestation). . . . . . . . . 69
Analysis 2.4. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 4 Stillbirth. . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Analysis 2.5. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 5 Neonatal death. . . . . . . . . . . . . . . . . . . . . . . . . . 71
Analysis 2.6. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 6 Maternal death. . . . . . . . . . . . . . . . . . . . . . . . . . 72
Analysis 2.7. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 7 Maternal adverse effects. . . . . . . . . . . . . . . . . . . . . . . 73
Analysis 2.8. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 8 Maternal adverse effects requiring cessation of treatment. . . . . . . . . . . . 74
Analysis 2.9. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 9 Caesarean section. . . . . . . . . . . . . . . . . . . . . . . . . 75
Analysis 2.10. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 10 Interval between trial entry and birth (days). . . . . . . . . . . . . . . . 76
Analysis 2.11. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 11 Preterm birth (before completion of 37 weeks of gestation). . . . . . . . . . 77
Analysis 2.12. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 12 Extremely preterm birth (before completion of 28 weeks of gestation). . . . . . . 78
Analysis 2.13. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 13 Gestational age (weeks). . . . . . . . . . . . . . . . . . . . . . . 79
Analysis 2.14. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 14 Birthweight (grams). . . . . . . . . . . . . . . . . . . . . . . . 80
Analysis 2.15. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 15 Apgar score less than 7 at 5 minutes. . . . . . . . . . . . . . . . . . 81
Analysis 2.16. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 16 Respiratory distress syndrome. . . . . . . . . . . . . . . . . . . . . 82
Analysis 2.17. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 17 Use of mechanical ventilation. . . . . . . . . . . . . . . . . . . . . 83
Analysis 2.18. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 18 Duration of mechanical ventilation (days). . . . . . . . . . . . . . . . 84
Analysis 2.19. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 19 Intraventricular haemorrhage. . . . . . . . . . . . . . . . . . . . . 85
Analysis 2.20. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 20 Necrotising enterocolitis. . . . . . . . . . . . . . . . . . . . . . 86
Analysis 2.21. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 21 Retinopathy of prematurity. . . . . . . . . . . . . . . . . . . . . 87
Analysis 2.22. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 22 Neonatal sepsis. . . . . . . . . . . . . . . . . . . . . . . . . . 88
Analysis 2.23. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 23 Admission to neonatal intensive care unit. . . . . . . . . . . . . . . . . 89
Analysis 2.24. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other
tocolytic), Outcome 24 Neonatal length of hospital stay (days). . . . . . . . . . . . . . . . . . 90
90APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
91FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
99WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
99HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
100CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
100DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
100SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiOxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
101DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
101INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiiOxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Oxytocin receptor antagonists for inhibiting preterm labour
Vicki Flenady1, Hanna E Reinebrant1 , Helen G Liley2, Eashan G Tambimuttu3 , Dimitri NM Papatsonis4
1Translating Research Into Practice (TRIP) Centre, Mater Research Institute - The University of Queensland (MRI-UQ), Brisbane,
Australia. 2Mater Mothers’ Hospital, Mater Research, The University of Queensland, South Brisbane, Australia. 3Department of
Gynaecology Oncology/Obstetrics and Gynaecology, Royal Brisbane and Women’s Hospital, Brisbane, Australia. 4Department of
Obstetrics and Gynaecology, Amphia Hospital Breda, Breda, Netherlands
Contact address: Vicki Flenady, Translating Research Into Practice (TRIP) Centre, Mater Research Institute - The University of
Queensland (MRI-UQ), Level 2 Aubigny Place, Mater Health Services, Annerley Road, Woolloongabba, Brisbane, Queensland, 4102,
Australia. vflenady@mmri.mater.org.au.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 6, 2014.
Review content assessed as up-to-date: 1 December 2013.
Citation: Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DNM. Oxytocin receptor antagonists
for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD004452. DOI:
10.1002/14651858.CD004452.pub3.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Preterm birth, defined as birth between 20 and 36 completed weeks, is a major contributor to perinatal morbidity and mortality
globally. Oxytocin receptor antagonists (ORA), such as atosiban, have been specially developed for the treatment of preterm labour.
ORA have been proposed as effective tocolytic agents for women in preterm labour to prolong pregnancy with fewer side effects than
other tocolytic agents.
Objectives
To assess the effects on maternal, fetal and neonatal outcomes of tocolysis with ORA for women with preterm labour compared with
placebo or any other tocolytic agent.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (1 December 2013).
Selection criteria
We included all randomised controlled trials (published and unpublished) of ORA for tocolysis of labour between 20 and 36 completed
weeks’ gestation.
Data collection and analysis
Two review authors independently evaluated methodological quality and extracted trial data. When required, we sought additional
data from trial authors. Results are presented as risk ratio (RR) for categorical and mean difference (MD) for continuous data with the
95% confidence intervals (CI). Where appropriate, the number needed to treat for benefit (NNTB) and the number needed to treat
for harm (NNTH) were calculated.
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Main results
This review update includes eight additional studies (790 women), giving a total of 14 studies involving 2485 women.
Four studies (854 women) compared ORA (three used atosiban and one barusiban) with placebo. Three studies were considered at low
risk of bias in general (blinded allocation to treatment and intervention), the fourth study did not adequately blind the intervention.
No difference was shown in birth less than 48 hours after trial entry (average RR 1.05, 95% CI 0.15 to 7.43; random-effects, (two
studies, 152 women), perinatal mortality (RR 2.25, 95% CI 0.79 to 6.38; two studies, 729 infants), or major neonatal morbidity. ORA
(atosiban) resulted in a small reduction in birthweight (MD -138.86 g, 95% CI -250.53 to -27.18; two studies with 676 infants). In
one study, atosiban resulted in an increase in extremely preterm birth (before 28 weeks’ gestation) (RR 3.11, 95% CI 1.02 to 9.51;
NNTH 31, 95% CI 8 to 3188) and infant deaths (up to 12 months) (RR 6.13, 95% CI 1.38 to 27.13; NNTH 28, 95% CI 6 to
377). However, this finding may be confounded due to randomisation of more women with pregnancy less than 26 weeks’ gestation
to atosiban. ORA also resulted in an increase in maternal adverse drug reactions requiring cessation of treatment in comparison with
placebo (RR 4.02, 95% CI 2.05 to 7.85; NNTH 12, 95% CI 5 to 33). No differences were shown in preterm birth less than 37 weeks’
gestation or any other adverse neonatal outcomes. No differences were evident by type of ORA, although data were limited.
Eight studies (1402 women) compared ORA (atosiban only) with betamimetics; four were considered of low risk of bias (blinded
allocation to treatment and to intervention). No statistically significant difference was shown in birth less than 48 hours after trial
entry (RR 0.89, 95% CI 0.66 to 1.22; eight studies with 1389 women), very preterm birth (RR 1.70, 95% CI 0.89 to 3.23; one
study with 145 women), extremely preterm birth (RR 0.84, 95% CI 0.37 to 1.92; one study with 244 women) or perinatal mortality
(RR 0.55, 95% CI 0.21 to 1.48; three studies with 816 infants). One study (80 women), of unclear methodological quality, showed
an increase in the interval between trial entry and birth (MD 22.90 days, 95% CI 18.03 to 27.77). No difference was shown in any
reported measures of major neonatal morbidity (although numbers were small). ORA (atosiban) resulted in less maternal adverse effects
requiring cessation of treatment (RR 0.05, 95% CI 0.02 to 0.11; NNTB 6, 95% CI 6 to 6; five studies with 1161 women).
Two studies including (225 women) compared ORA (atosiban) with calcium channel blockers (CCB) (nifedipine only). The studies
were considered as having high risk of bias as neither study blinded the intervention and in one study it was not known if allocation
was blinded. No difference was shown in birth less than 48 hours after trial entry (average RR 1.09, 95% CI 0.44 to 2.73, random-
effects; two studies, 225 women) and extremely preterm birth (RR 2.14, 95% CI 0.20 to 23.11; one study, 145 women). No data were
available for the outcome of perinatal mortality. One small trial (145 women), which did not employ blinding of the intervention,
showed an increase in the number of preterm births (before 37 weeks’ gestation) (RR 1.56, 95% CI 1.13 to 2.14; NNTH 5, 95% CI
3 to 19), a lower gestational age at birth (MD -1.20 weeks, 95% CI -2.15 to -0.25) and an increase in admission to neonatal intensive
care unit (RR 1.70, 95% CI 1.17 to 2.47; NNTH 5, 95% CI 3 to 20). ORA (atosiban) resulted in less maternal adverse effects (RR
0.38, 95% CI 0.21 to 0.68; NNTB 6, 95% CI 5 to 12; two studies, 225 women) but not maternal adverse effects requiring cessation
of treatment (RR 0.36, 95% CI 0.01 to 8.62; one study, 145 women). No longer-term outcome data were included.
Authors’ conclusions
This review did not demonstrate superiority of ORA (largely atosiban) as a tocolytic agent compared with placebo, betamimetics or
CCB (largely nifedipine) in terms of pregnancy prolongation or neonatal outcomes, although ORA was associated with less maternal
adverse effects than treatment with the CCB or betamimetics. The finding of an increase in infant deaths and more births before
completion of 28 weeks of gestation in one placebo-controlled study warrants caution. However, the number of women enrolled at very
low gestations was small. Due to limitations of small numbers studied and methodological quality, further well-designed randomised
controlled trials are needed. Further comparisons of ORA versus CCB (which has a better side-effect profile than betamimetics) are
needed. Consideration of further placebo-controlled studies seems warranted. Future studies of tocolytic agents should measure all
important short- and long-term outcomes for women and infants, and costs.
P L A I N L A N G U A G E S U M M A R Y
Oxytocin receptor antagonists for inhibiting preterm labour
Tocolytic drugs suppress preterm labour and have the potential to postpone preterm birth long enough to, hopefully, improve infant
outcome. This may be by allowing normal growth and maturation of the baby, or by allowing time for administration of magnesium
sulphate to reduce risk of cerebral palsy and corticosteroids to help the baby’s lungs and other organs to mature. They may also provide
the opportunity, if necessary, for the mother to be transferred to a hospital that has facilities to provide neonatal intensive care. However,
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prolonging pregnancy may instead have adverse outcomes for the baby and so it is important to assess infant outcomes alongside
duration of pregnancy. Oxytocin receptor antagonists (ORAs) are a group of tocolytic drugs, and we undertook this review to see if
ORAs prolonged pregnancy and improved outcomes for infants compared with no treatment or with other tocolytic drugs.
The tocolytic drugs, atosiban and barusiban, were the only ORAs we found that had been studied in trials; some trials compared
with no treatment and others compared atosiban with betamimetics (another group of tocolytic drugs). We identified 14 studies,
involving 2485 women. We found that, although atosiban resulted in fewer maternal side effects than other tocolytic drugs (especially
betamimetics), atosiban was not effective in delaying or preventing preterm birth or improving neonatal outcome, and may possibly
contribute to poorer infant outcomes. Further well-designed studies would be helpful, especially in women with threatened preterm at
low gestations where preterm birth puts babies at particularly high risk of death or disability.
Atosiban is no better than placebo or other drugs in delaying or preventing preterm birth but it has fewer maternal side effects compared
to other tocolytics.
B A C K G R O U N D
Description of the condition
Preterm birth, defined as birth occurring between 20 and 36 com-
pleted weeks, is a major contributor to perinatal mortality and
morbidity (Liu 2012; WHO 2012). Worldwide, it is estimated
that more than one in 10 births is preterm, affecting 15 million
babies annually (Blencowe 2012; WHO 2012). The incidence of
preterm birth is 8.6% of births in high-resource countries, and be-
tween 7.4% to 13.3% in low-resource countries, and rose in both
at least until the middle of the last decade (Chang 2013; WHO
2012).
In high-income countries, very preterm birth (i.e. birth before 32
weeks’ gestation) has an incidence of 1% to 2% (Tucker 2004)
but despite the availability of perinatal and neonatal care, it is
responsible for approximately one third to one half of all perinatal
deaths (Dorling 2008; Zeitlin 2008). In high-income countries,
almost 95% of neonates born between 28 and 32 weeks’ gestation
will survive, with more than 90% surviving without impairment.
In contrast, in many low-income countries, only 30% of neonates
born between 28 and 32 weeks will survive (WHO 2012).
Preterm birth is associated not only with high immediate costs at-
tributable to neonatal intensive care, but alsowith substantial long-
term costs, including costs for special education (Petrou 2011),
and other services for infants and children with intellectual and
physical disability (Petrou 2011). In addition to the lengthy neona-
tal intensive care treatment required for many preterm infants,
preterm birth often places stress on parents, which is greater with
decreasing gestational age (Schappin 2013).
Approximately 65% to 70% are spontaneous preterm births ei-
ther following spontaneous preterm labour (40% to 45%) and
those following preterm rupture of membranes (25% to 30%)
(Goldenberg 2008).While the cause of spontaneous pretermbirth
is often unclear, some risk factors have been identified including:
maternal age (adolescence and advanced age); history of preterm
birth; race; multiple pregnancy, short inter-pregnancy interval; in-
fections; medical conditions; poor nutrition; psychological factors
and genetic predisposition (Goldenberg 2008; Plunkett 2008).
There has been little progress in reducing the incidence of preterm
birth, even in high-income countries despite intensive antena-
tal care programs aimed at high-risk groups, the widespread use
of pharmacological agents to inhibit preterm birth (tocolytics)
and other preventive and therapeutic interventions. Nevertheless,
short-term prolongation of pregnancy has the potential to allow
other interventions to improve outcomes, including maternal cor-
ticosteroid administration to accelerate maturation of fetal lungs
(Roberts 2006) and other organs (Crowley 1996), magnesium sul-
phate administration to reduce risk of cerebral palsy (Doyle 2009)
and maternal transfer before birth to a centre that can provide
appropriate neonatal special or intensive care (Lasswell 2010). For
these reasons, short-term tocolytic therapy is commonly used to
inhibit preterm labour and postpone preterm birth.
Description of the intervention
A range of tocolytic agents that have been used to inhibit preterm
labour are the topics of Cochrane systematic reviews includ-
ing: nitric oxide donors (glyceryl trinitrate) (Duckitt 2002), cal-
cium channel blockers (CCB) (commonly nifedipine) (update
of King 2003 in progress), betamimetics (Anotayanonth 2006),
magnesium sulphate (Crowther 2002), cyclo-oxygenase (COX)
inhibitors (Khanprakob 2012) and progesterone (Su 2010). The
betamimetics (ritodrine, salbutamol and terbutaline) have been
shown to be effective in delaying delivery by seven days and longer,
although no impact has yet been shown on perinatal mortality
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(Anotayanonth 2006; Gyetvai 1999; King 1988). Furthermore,
betamimetics have a high frequency of unpleasant, sometimes
severe maternal side effects including tachycardia, hypotension,
tremor and a range of biochemical disturbances, and they have
been associated with life-threatening cardiovascular and respira-
tory events and deaths (FDA 2011). Compared with other to-
colytic agents (mostly betamimetics), CCB prolonged pregnancy
and improved short-term neonatal outcomes, with fewer maternal
adverse effects (update of King 2003 in progress). However, a fifth
of women still delivered within 48 hours of CCB treatment, and
nearly a third within seven days, so there is still a need for other
safe, effective tocolytic agents, particularly at very early gestations.
A number of oxytocin receptor antagonists have been developed,
and of these, three, atosiban, barusiban and retosiban have been
investigated in humans as tocolytic agents. To date, only atosiban
is in use outside of clinical trials. Atosiban is an oxytocin receptor
antagonist which was specifically developed for the treatment of
preterm labour (Melin 1994). Early reports of the use of atosiban
for tocolysis showed promise both in vitro and in animal studies,
and preliminary studies in pregnant and non-pregnant humans
suggested a very low incidence of maternal side effects (Goodwin
1996b; Goodwin 1998b). Potential maternal side effects include
adverse injection site reaction, nausea, vomiting, headache, chest
pain and hypotension (Moutquin 2000; Tsatsaris 2004).
How the intervention might work
Oxytocin is a peptide hormone produced in the pituitary, uterus,
placenta and amnion. It has a variety of functions, which include
stimulating myometrial activity (uterine contractions) as part of
the pathway to normal and preterm labour. It binds receptors on
myometrial cells, activating several intracellular pathways, which
include protein kinase C phosphorylation of various proteins and a
rise in intracellular calcium ions, both from intracellular stores via a
GTP/phospholipase/inositol phosphate pathway andby activating
voltage gated membrane channels allowing entry of extracellular
calcium ions. Calcium ion binding to calmodulin then activates
myosin light chain kinase, causing myometrial muscle contraction
(Vrachnis 2011).
The oxytocin receptor antagonist, atosiban, is a peptide analogue
of oxytocin that binds oxytocin receptors in the myometrial cell
membrane, preventing the oxytocin-induced rise in intracellular
calcium and leading to relaxation of the myometrium (Melin
1994). Atosiban is an antagonist with high affinity to both the
vasopressin receptor (V1a ) and oxytocin receptor (Akerlund 1999).
Goodwin 1994 first described in 1994 the use of atosiban in
humans for tocolysis. A previous review suggested that oxy-
tocin antagonists could be effective and safe in preterm labour
(Coomarasamy 2003). It has not been established whether the
tocolytic effects of atosiban is due to its oxytocin or vasopressin
receptor antagonist properties.
Barusiban is a selective oxytocin receptor antagonist with its ef-
fect on the vasopressin receptor (Nilsson 2003). Both atosiban
and barusiban have a molecular structure very similar to the oxy-
tocinmolecule (a nonapeptide) (Vrachnis 2011).However, as pep-
tide antagonists lack oral bioavailability, development of novel
non-peptide compounds with high oxytocin receptor selectivity
is currently ongoing. Non-peptides such as retosiban are small
molecules, structurally not related to oxytocin (Borthwick 2013).
It is currently not established how the molecular structure affects
signalling pathways. It is plausible that the tocolytic effects of non-
apeptides may differ from non-peptide compounds based on their
different binding affinity and selectivity to oxytocin receptors and
also other receptors (Borthwick 2013; Vrachnis 2011).
Why it is important to do this review
Preterm labour is often insidious in onset and difficult to antici-
pate, and the causes are likely to be multifactorial, so prevention
by treating the underlying causes has proved elusive. Therefore,
effective tocolysis in suspected or established preterm labour is
likely to remain critical to reducing infant morbidity and mortal-
ity associated with preterm birth, and to mitigating the long-term
consequences of prematurity on developmental and health out-
comes. Since oxytocin receptor antagonists have undergone clini-
cal trials and are available in some countries for the management
of women in preterm labour, this updated review is important to
assist clinicians and women in informed decision making about
which tocolytic to use.
O B J E C T I V E S
Primary objectives of the review
1. To assess the effects on maternal, fetal and neonatal
outcomes of any oxytocin receptor antagonist administered as a
tocolytic agent to women in preterm labour when compared
with placebo.
2. To assess the effects on maternal, fetal and neonatal
outcomes of any oxytocin receptor antagonist administered as a
tocolytic agent to women in preterm labour when compared
with other classes of tocolytic agents.
Secondary objective
A secondary objective of the review is to determine whether the
effects of oxytocin receptor antagonists, when compared with
placebo or any other tocolytic agent, are influenced by different
population characteristics and duration of tocolytic therapy as fol-
lows:
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(i) women randomised before 28 weeks’ gestation versus those
randomised at 28 weeks or after;
(ii) women with ruptured membranes at randomisation versus
women with intact membranes;
(iii) women with a singleton pregnancy versus women with a mul-
tiple pregnancy;
(iv) women who received maintenance therapy* versus women
who did not; and also by type of tocolytic agent as follows:
(v) type of other tocolytic; betamimetics versus calcium channel
blockers (CCB);
(vi) type of oxytocin receptor antagonists (ORA); atosiban versus
other ORA.
(*Use of continued tocolytic agents after successful suppression of
threatened preterm labour.)
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised and cluster-ran-
domised studies in which oxytocin receptor antagonists were used
for tocolysis in the management of preterm labour. Studies using
quasi-random methods of allocation and cross-over studies were
excluded.
Types of participants
Women assessed as being in preterm labour (between 20 and 36
completed weeks’ gestation) and considered suitable for tocolysis.
Types of interventions
1. Oxytocin receptor antagonists administered as a tocolytic
by any route compared with placebo.
2. Oxytocin receptor antagonists administered as a tocolytic
by any route compared with other classes of tocolytic agents.
Types of outcome measures
This review aimed to assess the effects of oxytocin receptor antago-
nists on clinically relevant outcome measures relating to perinatal
and infant short-term and long-term outcome as well as prolon-
gation of pregnancy. Furthermore, maternal side effects and out-
comes were also examined.
Clinically relevant outcomes for trials of tocolysis for inhibiting
preterm labour have been prespecified following consultation with
the editors and authors of the individual reviews.
Consensus was reached on a set of six ‘core’ outcomes, which are
highlighted below. These will be included in all tocolysis reviews.
In addition to these core outcomes, individual teams may include
other outcomes as necessary.
Primary outcomes
Short-term and long-term serious infant outcome determined by
the presence of any of the following.
1. Serious maternal outcome (defined as death, cardiac
arrest, respiratory arrest, admission to intensive care unit).
2. Birth less than 48 hours after trial entry.
3. Serious infant outcome (defined as death or chronic lung
disease [need for supplemental oxygen at 28 days of life or later],
grade three or four intraventricular haemorrhage or
periventricular leukomalacia, major neurosensory disability
(defined as any of legal blindness, sensorineural deafness
requiring hearing aids, moderate or severe cerebral palsy, or
developmental delay/intellectual impairment [defined as
developmental quotient (DQ) or intelligence quotient (IQ) less
than 2 standard deviations below mean])).
4. Perinatal mortality (stillbirth defines as a birth not
showing signs of life defined by any gestational age and
birthweight in the trials and neonatal death up to 28 days).
5. Very preterm birth (before completion of 34 weeks of
gestation).
Secondary outcomes
These include other measures of effectiveness, complications and
health service use.
Maternal
1. Maternal adverse effects.
2. Maternal adverse effects requiring cessation of therapy.
3. Caesarean section.
4. Antepartum haemorrhage.
5. Postpartum haemorrhage.
6. Satisfaction with care.
7. Quality of life after the birth (measured by validated
instruments).
Infant/child
1. Extremely preterm birth (before completion of 28 weeks of
gestation).
2. Preterm birth (before completion of 37 weeks of gestation).
3. Preterm neonate delivered with full course of antenatal
steroids.
4. Interval between trial entry and birth.
5. Gestational age at birth.
6. Birthweight.
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7. Apgar score less than seven at five minutes.
8. Respiratory distress syndrome.
9. Use of mechanical ventilation.
10. Duration of mechanical ventilation.
11. Persistent pulmonary hypertension of the neonate.
12. Intraventricular haemorrhage.
13. Necrotising enterocolitis.
14. Retinopathy of prematurity.
15. Neonatal jaundice.
16. Neonatal sepsis.
17. Infant death.
18. Quality of life in childhood (measured by validated
instruments).
Health service use
1. Admission to neonatal intensive care unit.
2. Neonatal length of hospital stay.
3. Maternal length of hospital stay.
In this update, primary and secondary outcomes measures were
revised to enhance consistency across Cochrane tocolytic reviews
and to better reflect important outcome measures.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (1 De-
cember 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Studies identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the studies identified in the
previous version of this review, see Appendix 1.
For this update, we used the following methods when assessing all
new and previously included studies.
Selection of studies
Two review authors independently assessed all potential studies
identified from the search strategy for inclusion in this review. Any
disagreement was resolved through discussion, or via consultation
of a third author if required.
Data extraction and management
The authors used the standard methods of The Cochrane Col-
laboration and considered all potential studies for inclusion. At
least two authors (D Papatsonis, V Flenady, H Reinebrant and
E Tambimuttu) evaluated the methodological quality of studies
and independently performed data extraction, as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Any discrepancies were resolved through discussion, or via con-
sultation of a third author. We entered data into Review Manager
software (RevMan 2012) and checked for accuracy.
When information was unclear, we attempted to contact authors
of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We resolved any
disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
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(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the method as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judge that the
lack of blinding would be unlikely to affect results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the method as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or was supplied by the
trial authors, we re-included missing data in the analyses that we
undertook.
We assessed the method as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the method as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in the Handbook (Higgins
2011). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we consider it is
likely to impact on the findings. We planned to explore the impact
of the level of bias through undertaking sensitivity analyses - see
Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, results are presented as summary risk ratio
with 95% confidence intervals (CI). Where appropriate, calcula-
tions for number needed to treat for benefit (NNTB) and number
needed to treat for harm (NNTH) were performed.
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Continuous data
For continuous data, themeandifferencewas used if outcomemea-
sures were comparable between studies. The standardised mean
differencewas intended for use to combine studiesmeasuring com-
parable outcomes but using different methodology.
Unit of analysis issues
Cross-over trials
Cross-over trials were excluded from this review.
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion in
this review, but trials of this type may be identified and included
in future updates.
If cluster-randomised trials are included in future updates, theywill
be included in the analyses along with individually-randomised
trials. Their sample sizes will be adjusted using the methods de-
scribed in the Handbook (Higgins 2011) using an estimate of the
intra cluster correlation co-efficient (ICC) derived from the trial
(if possible), or from another source. If ICCs from other sources
are used, this will be reported and sensitivity analyses will be con-
ducted to investigate the effect of variation in the ICC. If both clus-
ter-randomised trials and individually-randomised trials are iden-
tified, the relevant information will be synthesised. The authors
consider it reasonable to combine the results from both if there is
little heterogeneity between the study designs and the interaction
between the effect of intervention and the choice of randomisation
unit is considered to be unlikely. Heterogeneity in the randomisa-
tion unit will also be acknowledged and a sensitivity analysis will
be performed to investigate the effects of the randomisation units.
Multi-arm studies
For the subgroup comparisons undertaken, to avoid double count-
ing, we planned to divide out data from the shared group approx-
imately evenly among the comparisons as described in the Hand-
book 16.5.4 (Higgins 2011).
One study (Thornton 2009) compared four different dosage reg-
imens of barusiban (0.3, 1, 3 or 10 mg) with placebo. For the
analyses undertaken in this review, we have combined all doses for
comparison with placebo.
Multiple pregnancy
Wheremultiple pregnancies are included, wherever possible, anal-
yses should be adjusted for clustering to take into account the
non-independence of neonates from the same pregnancy (Gates
2004). Treating neonates from multiple pregnancies as if they are
independent, when they are more likely to have similar outcomes
than neonates from different pregnancies, will overestimate the
sample size and give CIs that are too narrow. Each woman can be
considered a cluster in a multiple pregnancy, with the number of
individuals in the cluster being equal to the number of fetuses in
her pregnancy. Analysis using cluster trial methods allows calcula-
tion of relative risk and adjustment of CIs. Usually this will mean
that the confidence intervals get wider. Although this may make
little difference to the conclusion of a study, it avoids misleading
results in those studies where the difference may be substantial.
Seven studies reported outcomes for twin pregnancies (European
2001; French/Australian 2001; Goodwin 1994; Moutquin 2000;
Nonnenmacher 2009; Romero 2000; Salim 2012). Two of these
studies (Goodwin 1994; Romero 2000) compared ORA (atosi-
ban) versus placebo, one study (Salim 2012) compared ORA ver-
sus CCB, and four studies compared ORA (atosiban) versus be-
tamimetics (European 2001; French/Australian 2001; Moutquin
2000; Nonnenmacher 2009).
For the studies with twin pregnancies, the sample sizes for reported
newborn outcomes were adjusted using the methods described in
the Handbook (Higgins 2011) using an estimate of the intra-class
correlation coefficient (ICC) of 0.2 as described by Yelland et al
(Yelland 2011).
Dealing with missing data
For included studies, levels of attrition in the ’Risk of bias’ table
were noted. The authors planned to explore the impact of includ-
ing studies with high levels ofmissing data in the overall assessment
of treatment effect by using sensitivity analysis. Analyses were, as
far as possible, performed on an intention-to-treat basis for all out-
comes. Attempts weremade to include all participants randomised
to each group in the analyses, and all participants were analysed in
the group to which they were allocated, regardless of whether or
not they received the allocated intervention. The denominator for
each outcome in each study was the number randomised minus
any participants whose outcomes are known to be missing.
Assessment of heterogeneity
Statistical heterogeneity was assessed in each meta-analysis using
the Tau², I² and Chi² statistics. Heterogeneity was regarded as
substantial if the Tau² was greater than zero and either the I² was
greater than 30% or there was a low P value (less than 0.10) in the
Chi² test for heterogeneity.
Assessment of reporting biases
If 10 or more studies had contributed data to meta-analysis for any
particular outcome, we planned to assess reporting biases (such
as publication bias) using funnel plots. Possible asymmetry would
have been assessed visually, and if asymmetry was suggested, we
planned exploratory analyses for investigation. In this version of
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the review, insufficient data were available to allow us to carry out
this planned analysis.
Data synthesis
Statistical analyses were performed using the Review Manager
software (RevMan 2012). Fixed-effect meta-analysis was used for
combining data where it was reasonable to assume that studies
were estimating the same underlying treatment effect; i.e. where
studies were examining the same intervention, and the studies’
populations and methods were judged sufficiently similar. If clin-
ical heterogeneity was deemed sufficient to expect differences be-
tween studies in regards to the underlying treatment effects, or if
substantial statistical heterogeneity was detected, random-effects
meta-analysis was used to produce an overall summary. This was
performed if an average treatment effect across studies was con-
sidered clinically meaningful.
In one study (Thornton 2009), which compared four dosing reg-
imens of barusiban with placebo and one study (Goodwin 1996)
comparing four different dosing regimens of atosiban with be-
tamimetics, outcomes from all four dosing regimens were com-
bined in the analyses.
The random-effects summary was treated as the average range of
possible treatment effects and the authors discussed the clinical
implications of treatment effects differing between studies. If the
average treatment effect was deemed to be not clinically meaning-
ful studies were not combined.
Where random-effects analyses were used, the results are presented
as the mean treatment effect with its 95% CI, and the estimates
of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we performed investiga-
tions using subgroup analyses. Considerationwas taken towhether
an overall summary was meaningful, and if deemed relevant, we
performed a random-effects analysis. We assessed subgroup dif-
ferences by interaction tests available within RevMan (RevMan
2012).
A priori subgroup analyses
We planned the following subgroup analyses.
By population
• Women randomised before 28 weeks’ gestation versus those
randomised at 28 weeks or after.
• Women with ruptured membranes at randomisation versus
women with intact membranes.
• Women with a singleton pregnancy versus women with a
multiple pregnancy.
• Women who received maintenance therapy* versus women
who did not.
(*Use of continued tocolytic agents after successful suppression of
threatened preterm labour.)
By intervention
• Oxytocin receptor antagonists compared with placebo,
further subgrouped by type of oxytocin receptor antagonist.
• Oxytocin receptor antagonists compared with other classes
of tocolytic agents, further subgrouped by type of other tocolytic
agent and type of oxytocin receptors antagonist.
We will assess the following outcomes in subgroup analyses.
Fetal/neonatal outcomes
• Perinatal mortality (stillbirth and neonatal death up to 28
days).
• Infant death (up to 12 months).
• Major childhood sensorineural disability.
• Extremely preterm birth (before completion of 28 weeks of
gestation).
• Very preterm birth (before completion of 34 weeks of
gestation).
• Preterm birth (before completion of 37 weeks of gestation).
• Birth less than 48 hours after trial entry.
• Respiratory distress syndrome.
• Intraventricular haemorrhage.
• Necrotising enterocolitis.
• Retinopathy of prematurity.
• Chronic lung disease (need for supplemental oxygen
therapy at 36 weeks’ postmenstrual age).
• Admission to neonatal intensive care unit.
• Neonatal length of hospital stay.
• Quality of life in childhood (measured by validated
instruments).
Maternal outcomes
• Serious maternal outcome.
• Maternal adverse effects requiring cessation of treatment.
• Quality of life after the birth (measured by validated
instruments).
Sensitivity analysis
We planned sensitivity analyses to explore the effect of study
quality assessed by concealment of allocation, high attrition rates
(greater than 20%), or both. The intention was to exclude poor-
quality studies (including those assessed as low or unknown risk
of bias) from the analyses in order to assess whether this made any
difference to the overall result.
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R E S U L T S
Description of studies
Results of the search
In this review, 29 studies were identified as potentially eligible
for inclusion. Nine studies were excluded (Al-Omari 2006; de
Heus 2008;Gagnon 1998;Husslein 2006;Husslein 2007; Poppiti
2009; Steinwall 2005; Valenzuela 1997; Valenzuela 2000). An-
other five studies are awaiting classification pending additional in-
formation from authors (de Heus 2009; Lenzen 2012; Neri 2009;
Renzo 2003; Snidow 2013). For further information please see
Characteristics of studies awaiting classification. One study is on-
going (APOSTEL III).
In this review update, an additional eight studies, involving 790
women testing the effects of oxytocin receptor antagonists for to-
colysis in preterm labour, have been included, giving a total of 14
included studies, involving 2485 women.
Included studies
Fourteen studies, involving 2485 women, are included.
Four studies (854 women) compared an oxytocin receptor an-
tagonists with placebo (Goodwin 1994; Richter 2005; Romero
2000; Thornton 2009). Eight studies compared an oxytocin re-
ceptor antagonist (atosiban) with betamimetics (Cabar 2008;
European 2001; French/Australian 2001; Goodwin 1996; Lin
2009; Moutquin 2000; Nonnenmacher 2009; Shim 2006). Two
studies compared an oxytocin receptor antagonist (atosiban) with
a calcium channel blocker (CCB) (nifedipine) (Kashanian 2005;
Salim 2012).
Participants
The participants in these studies were reasonably homogenous.
In the placebo-controlled studies, the minimum gestational age
at inclusion was 20 weeks, and the maximum gestational age at
inclusion was 37 weeks. In the studies comparing atosiban with
betamimetic agents, the minimum gestational age at study entry
ranged from 20 to 23 weeks and the maximum from 33 to 35
weeks. The presence of ruptured membranes was an exclusion cri-
terion in all studies, except one (Nonnenmacher 2009). Exclusion
of women with ruptured membranes reflects the clinical uncer-
tainty about the role of tocolytic agents in this situation because
infection is more likely to be present and delay in delivery may
harm themother and baby. In all studies, standardmaternal and fe-
tal contraindications to tocolysis were reported, e.g. pre-eclampsia
and gestational hypertension. Exclusion criteria also included the
use of non-steroidal anti-inflammatory agents 12 hours prior to
randomisation in five studies (European 2001; French/Australian
2001; Lin 2009;Moutquin 2000; Shim 2006), and prior tocolytic
therapy within 72 hours in one study (Goodwin 1996) and within
seven days in one study (Thornton 2009). High-order multiple
gestations (triplets ormore)were reported as excluded in six studies
(European 2001; French/Australian 2001; Lin 2009; Moutquin
2000;Richter 2005; Salim2012) and allmultiple pregnancieswere
excluded in three studies (Goodwin 1996; Shim 2006; Thornton
2009).
Tocolysis
Three studies compared atosiban with placebo (Goodwin 1994;
Richter 2005; Romero 2000), one study compared barusiban
with placebo (Thornton 2009), two studies compared atosiban
with a CCB (nifedipine) (Kashanian 2005; Salim 2012) and
eight studies compared atosiban with betamimetics (ritodrine,
fenoterol, salbutamol, terbutaline) (Cabar 2008; European 2001;
French/Australian 2001; Goodwin 1996; Lin 2009; Moutquin
2000; Nonnenmacher 2009; Shim 2006).
In the placebo-controlled studies, two studies (Richter 2005;
Romero 2000) administered atosiban as a initial bolus dose of 6.75
mg intravenously (i.v.) followed by an infusion of 300 µg/min
for three hours, then 100 µg/minutes for 45 hours. In Romero
2000, maintenance therapy was thereafter administered via sub-
cutaneous injections up to 36 weeks. One study (Goodwin 1994)
administered atosiban as a initial bolus dose of 6.75 mg i.v. fol-
lowed by an infusion of 300 µg/minutes for two hours. One study
administered barusiban as a single bolus dose (1 mL of either 0.3
mg, 1 mg, 3 mg or 10 mg barusiban, i.v.). Two of the placebo-
controlled studies included rescue tocolysis as a part of the study
protocol. In Goodwin 1994, the primary aim was to determine
the effect of atosiban on uterine activity during an infusion limited
to two hours. In the atosiban group, 19.6% of the participants
required an additional rescue tocolytic agent versus 32% in the
placebo group. In this study (Goodwin 1994), maintenance ther-
apy after the two hour infusion was not instituted. In Goodwin
1994, of the 120women enrolled, 29 (11 atosiban and 18 placebo)
required additional tocolysis with magnesium sulphate (n = 23) or
subcutaneous terbutaline (n = 6). There is, however, no description
of the doses or duration of this additional tocolysis. In Romero
2000, rescue therapy was given in 42% of the atosiban group and
in 51% of the placebo group. Participants received rescue tocolytic
therapy with an alternate tocolytic of the investigator’s choice after
discontinuation of the study drug. Rescue tocolysis was considered
in this study when preterm labour has progressed after at least one
hour of observation and either of the following occurred: (1) cer-
vical effacement of ≥ 75% (≤ 0.5 cm) with no decrease in the fre-
quency or intensity of contractions and continued cervical change
(at least a 1 cm change in dilatation or effacement); or (2) cervical
dilatation of ≥ 4 cm with a 1 cm increase since the last cervical
examination. Maintenance therapy was started with either atosi-
ban or placebo in women who achieved uterine quiescence with a
10Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
subcutaneous infusion of 0.004 mL (30 µg/minute for atosiban)
and was ceased at the end of the 36th week of gestation, at deliv-
ery, or if progression of labour necessitated an alternate tocolytic
agent. In the third placebo-controlled study (Richter 2005), rescue
tocolysis was not performed. In cases of successful tocolysis but
with persisted cervical dilatation, the woman was informed of the
option of a cerclage and/or total occlusion of the cervix. One study
(Thornton 2009) did not allow any tocolytics as rescue therapy.
In the studies comparing atosiban with nifedipine, one study (
Salim 2012), administered atosiban as a initial bolus dose of 6.75
mg i.v. followed by an infusion of 300 µg/minute for three hours,
then 100 µg/minute for 45 hours. The other study (Kashanian
2005) administered atosiban as an i.v. infusion of 300 µg/minute
up to 12 hours, or six hours after contractions ceased. In one of
the studies comparing atosiban with nifedipine (Kashanian 2005),
rescue tocolysis was not performed. Nifedipine was given at an
initial dose of 10 mg (one capsule) sublingually every 20 minutes
for four doses. Maintenance dose with nifedipine was continued
orally (20 mg) every six hours for the first 24 hours, and then
every eight hours for the following 24 hours, and finally 10 mg
every eight hours for the last 24 hours. In the other nifedipine-
controlled study (Salim 2012), rescue tocolysis was performed if
progression of labour was determined after one hour but before
48 hours, or if adverse effects of the drug were noted, a cross-over
of the study drugs was performed and the alternative tocolytic
drug (i.e. rescue treatment) was initiated. Nifedipine was given as
a loading dose of 20 mg orally followed by another two doses of 20
mg, 20 to 30 minutes apart as needed. Maintenance was started
after six hours with 20 to 40 mg four times daily for a total of
48 hours. If tocolysis failed from both drugs before 48 hours or
admission at a gestational age below 28 weeks, indomethacin as a
second rescue agent was started. Initial dose of indomethacin was
two 100 mg per rectum tablets, one hour apart, followed by oral
tablets of 25 mg four times daily up to a total of 48 hours.
In most of the studies comparing atosiban with betamimetics
(Cabar 2008; European 2001; French/Australian 2001; Lin 2009;
Moutquin 2000;Nonnenmacher 2009; Shim 2006), an initial bo-
lus dose of 6.75 mg (i.v.) atosiban was given, followed by a con-
tinuous infusion of 300 µg/minute for three hours, then 100 µg/
minute for a maximum of 15 to 48 hours. One study (Goodwin
1996) tested four atosiban regimens: 6.5 mg bolus dose followed
by infusion 300 µg/mL, two mg bolus dose followed by infusion
of 100 µg/mL, 0.6 mg bolus dose followed by infusion of 30 µg/
minute. All treatments were continued up to 12 hours. In the stud-
ies comparing atosiban with betamimetics, betamimetic therapy
was administered i.v. for a maximum of 48 hours. Rescue tocolytic
therapy was reported as a part of the study protocol for all stud-
ies in this comparison. In the European study (European 2001),
administration of an alternative tocolytic agent was dependent on
both efficacy and tolerability of study medication and could be
administered when there was recurrence or progression of preterm
labour. In the French/Australian study (French/Australian 2001),
if labour was progressing or women experienced intolerable ad-
verse effects of study drug administration, an alternative tocolytic
agent could be given. There were 58% (n = 69) in the atosiban
group versus 63.1% (n = 77) in the salbutamol group who needed
an alternate tocolytic agent. Goodwin 1996 included an alternate
tocolytic agent to be used when: (1) the cervix dilated 1 cm or
more during therapy; (2) uterine contraction persisted at a same
or higher rate; or (3) labour was not controlled, according to the
judgement of the investigator. In Shim 2006, rescue tocolysis could
be given if the study drug failed either by progression of labour or
intolerable adverse events judged by the investigator. Alternative
drugs could be ritodrine or magnesium sulphate, but not atosiban
as rescue tocolytic in case of failure for women in the ritodrine
group. In Lin 2009, re-treatment with the study drug was allowed
when there was recurrence of preterm labour. In Moutquin 2000,
an alternative tocolytic agent could be given after the study treat-
ment was stopped if labour was progressing, or if any woman had
an intolerable adverse event. Maintenance therapy was used in
at least one study in this comparison (Goodwin 1996); however,
the details of the regimen were not provided. One study reported
that maintenance therapy was not a part of the study protocol
(French/Australian 2001). Maintenance therapy was not used in
the remaining six studies where atosiban therapy was administered
i.v. for a maximum of 48 hours.
Please see Characteristics of included studies for further details.
Outcome measures
Most of the studies included reported on the important clinical
outcome of respiratory distress syndrome (except Cabar 2008;
Kashanian 2005; Nonnenmacher 2009; Richter 2005). Many
studies also reported maternal adverse drug reaction (European
2001; Goodwin 1994; Kashanian 2005; Romero 2000; Salim
2012; Shim 2006; Thornton 2009). The outcome of birth within
48 hours of initiation of treatment was reported in 12 (Cabar
2008; European 2001; French/Australian 2001; Goodwin 1994;
Goodwin 1996; Kashanian 2005; Lin 2009; Moutquin 2000;
Nonnenmacher 2009; Richter 2005; Salim 2012; Shim 2006)
of the 14 included studies and perinatal mortality in four stud-
ies (European 2001; French/Australian 2001; Moutquin 2000;
Romero 2000). Other important outcomes were inconsistently re-
ported including preterm birth, which was reported in four stud-
ies (European 2001; Romero 2000; Salim 2012; Thornton 2009),
andmajor neonatal morbidity, which was largely not well reported
across the studies.
Long-term outcomes up to two years of age were reported as an
abstract (Goodwin 1998a) for infants enrolled in one placebo-
controlled study (Romero 2000). Unfortunately, data were not re-
ported in a format suitable for inclusion In this review. The au-
thors have been contacted for further details before publication
of the previous version of this review, but no further information
has been forthcoming. The following outcomes were assessed: (1)
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illness, accidents, and physical abnormalities; (2) measurements
of infant weight, length, and head circumference; (3) neurological
examinations; (4) Bayley II assessment of mental and motor de-
velopment; and (5) infant deaths. Although the report stated all
infants were followed up and infant death up to 12 months was
reported, only 55% of the infants who were originally included
in the study were assessed for Bayley II Mental and Motor De-
velopment Index (Mean ± SD) and neurological examination at
two years. One study comparing barusiban and placebo reported
long-term outcomes (Thornton 2009) for Bayley Scale evalua-
tions of psychomotor developmental index (PDI) and mental de-
velopmental index (MDI) and physical growth. The long-term
outcomes were assessed at one year of age (Thornton 2009) and,
as this time point was not prespecified, these data have not been
included in this review.
In Romero 2000, data for the outcomes of birth less than 48 hours
after trial entry and birth less than seven days after trial entry were
reported only for women who did not receive alternative tocolytics
and therefore these data were not included in the review.
Please see Characteristics of included studies for further details.
Excluded studies
We excluded nine studies.
One study was excluded on the basis of quasi-random allocation
(Al-Omari 2006). Eight studies were excluded as they did not ful-
fil the intervention inclusion criteria as follows: A study in term
labour (de Heus 2008); studies of maintenance tocolysis (Gagnon
1998; Valenzuela 2000); no comparison between different dosing
regimens or tocolytic treatment (Husslein 2006); undefined treat-
ment in control group (Husslein 2007); repeat course treatment
with tocolysis (Poppiti 2009); did not use an oxytocin receptor
antagonist (Steinwall 2005); study aimed to measure oestradiol
levels before and after treatment (Valenzuela 1997a).
Please see Characteristics of excluded studies for further details.
Risk of bias in included studies
Overall the quality of the included studies was considered fair
to good. Refer to Characteristics of included studies for further
details and to Figure 1 and Figure 2 for a summary of ’Risk of bias’
assessment.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The randomisation sequence generation was judged as adequate
in 10 of the 14 included studies (European 2001; French/
Australian 2001; Goodwin 1994; Goodwin 1996; Kashanian
2005; Moutquin 2000; Romero 2000; Salim 2012; Shim 2006;
Thornton 2009) and therefore assessed as having a low risk of
selection bias. In the remaining four studies, the randomisation
sequence generation process was unclear.
Allocation to treatment was adequately concealed in seven of the
14 included studies (European 2001; French/Australian 2001;
Goodwin 1994; Goodwin 1996; Romero 2000; Salim 2012;
Thornton 2009) and therefore assessed as having low risk of se-
lection bias. In the remaining studies the allocation process was
unclear.
Blinding
Blinding of the intervention and outcome assessment was per-
formed in seven of the 14 included studies (European 2001;
French/Australian 2001; Goodwin 1994; Moutquin 2000;
Romero 2000; Shim 2006; Thornton 2009). These studies were
placebo controlled. For one study, the blinding of the intervention
process was unclear (Cabar 2008). In one study, while a saline in-
fusion control group was used, as different dosing regimens were
used, the study was assessed as having a high risk of bias(Richter
2005). For the remaining studies, the lack of blinding of the in-
tervention may be, in part, as a result of the difficulties with ade-
quately blinding such interventions, i.e. presentation of the inter-
vention as either oral versus intravenous and the well-known side
effects of certain interventions.
Incomplete outcome data
The majority (13 of the 14 included studies) had minimal or no
attrition andwere therefore assessed as having a low risk of attrition
bias. For the remaining study, it was unclear whether outcome
data were complete (Cabar 2008).
Selective reporting
In 12 of the 14 included studies, no reporting bias was evi-
dent (European 2001; French/Australian 2001; Goodwin 1994;
Goodwin 1996; Lin 2009; Moutquin 2000; Nonnenmacher
2009; Richter 2005; Romero 2000; Salim 2012; Shim 2006;
Thornton 2009) and these studies were judged to be at low risk of
bias. In the remaining two studies it was unclear whether reporting
bias was present (Cabar 2008; Kashanian 2005).
Other potential sources of bias
In eight of the 14 included studies, no other potential sources
of bias were apparent European 2001; French/Australian 2001;
Lin 2009; Moutquin 2000; Nonnenmacher 2009; Richter 2005;
Salim 2012; Thornton 2009) based on baseline characteristics
being similar and no other biases were evident. In four studies,
the risk of other bias was unclear (Cabar 2008; Goodwin 1996;
Kashanian 2005; Shim 2006). In two studies, the risk of other bias
was judged to be high (Goodwin 1994; Romero 2000). These two
studies (Goodwin 1994; Romero 2000) included women of lower
gestational age in the atosiban group compared with the placebo
group.One of these studies (Goodwin1994) also recruitedwomen
from five different centres, and the inclusion criteria differed be-
tween the centres, whichmay have introduced bias. In the Romero
2000 trial, there were nearly twice as many atosiban-treated pa-
tients enrolled at < 26 weeks’ gestation. Among the women en-
rolled at less than 26 weeks’ gestation, the number who had ad-
vanced cervical dilation was higher in the atosiban group com-
pared with the placebo group.
Assessment of studies that included multiple pregnancies
Seven studies included data from women with a multiple preg-
nancy (European 2001; French/Australian 2001; Goodwin 1994;
Moutquin 2000; Nonnenmacher 2009; Romero 2000; Salim
2012). Two of these studies (Goodwin 1994; Romero 2000) com-
pared ORA (atosiban) versus placebo, one study (Salim 2012)
compared ORA versus CCB, and four studies compared ORA
(atosiban) versus betamimetics (Nonnenmacher 2009; European
2001; French/Australian 2001; Moutquin 2000). As described
previously (Methods), we have adjusted for clustering in the anal-
yses of infant outcomes.
Effects of interventions
Two main comparisons were undertaken as follows.
Comparison 1: Oxytocin receptor antagonists compared with
placebo further subgrouped by type of oxytocin receptor antago-
nist.
Comparison 2: Oxytocin receptor antagonists compared with
other classes of tocolytic agents by type of other tocolytic agent.
We did not undertake other planned subgroup analyses by popu-
lation characteristics and by intervention due to insufficient data.
Comparison 1: Oxytocin receptor antagonists (ORA)
compared with placebo, further subgrouped by type
of ORA
Four studies are included in this analysis. Three studies in-
cluding 691 women comparing atosiban and placebo (Goodwin
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1994; Richter 2005; Romero 2000) and one study (163 women)
(Thornton 2009) comparing barusiban with placebo are included
in this comparison. For the comparison between atosiban and
placebo, the Romero and Goodwin studies (Goodwin 1994;
Romero 2000) contributed the majority of data (651 women) and
the Richter study (Richter 2005; 40 women) contributed to two
outcomes only; stillbirth and birth less than 48 hours after trial
entry.
Primary outcomes
Birth less than 48 hours after trial entry (Analysis 1.1)
Comparing ORA (atosiban) with placebo, no difference was
shown in birth less within 48 hours after trial entry (average risk
ratio (RR) 1.05, 95% confidence interval (CI) 0.15 to 7.43; ran-
dom-effects, Tau² = 1.08, Chi² = 2.14, df = 1 (P = 0.14), I² =
53%) (two studies with 152 women) Analysis 1.1. A moderate
degree of statistically heterogeneity was evident for this outcome
measure. However, upon exploration of the possible reasons for
the heterogeneity by examining clinical features of the studies, we
considered an overall summary was meaningful using a random-
effects analysis.
No data were available for the subgroup of barusiban versus
placebo.
Perinatalmortality, Stillbirth,Neonatal death and Infant death
(Analysis 1.2) (Analysis 1.3) (Analysis 1.4) (Analysis 1.5)
Comparing ORA versus placebo no difference was shown in peri-
natal mortality (RR 2.25, 95% CI 0.79 to 6.38; two studies
with 729 infants) (Analysis 1.2), stillbirth (average RR 0.40, 95%
CI 0.04 to 4.47 random-effects; four studies with 883 infants)
(Analysis 1.3), or neonatal death (RR 4.09, 95%CI 0.88 to 19.07;
two studies with 729 infants) (Analysis 1.4). These findings are
driven by the subgroup of trials comparing atosiban versus placebo
as no events were reported for the barusiban subgroup including
a single trial (Thornton 2009).
A moderate degree of statistical heterogeneity was evident for the
outcome measure of stillbirth (Heterogeneity: Tau² = 1.82; Chi²
= 2.33, df = 1 (P = 0.13); I² = 57%). However, upon exploration
of the possible reasons for the heterogeneity by examining clinical
features of the studies, we considered an overall summary was
meaningful using a random-effects analysis.
Infant death (up to 12 months) was increased with the use of the
ORA atosiban in one trial (Romero 2000; 566 infants) (RR 6.13,
95%CI 1.38 to 27.13; number needed to treat for harm (NNTH)
28, 95% CI 6 to 377) (Analysis 1.5).
Asmentioned inOther potential sources of bias, it is likely that the
adverse infant outcomes associated with atosiban in the Romero
2000 trial are due to an imbalance in randomisationwhich resulted
inmore womenunder 26weeks’ gestation and fewer over 32weeks
assigned to the atosiban group. It is of note that in the publication
of the trial results, the authors used the denominator of women
who were enrolled less than 28 weeks’ gestation and reported a
non-statistically significant increase in birth less than 28 weeks’
gestation.
Serious maternal outcome (Analysis 1.6)
One study Romero 2000 comparing ORA (atosiban only) with
placebo (501 women) reported that no maternal deaths occurred
during the trial period.
No data were available on other serious maternal outcomes or the
other primary outcomes measure of very preterm birth before 34
weeks’ gestation or long-term outcomes for the child.
Secondary outcomes
For the infant/child
Preterm birth (before 37 weeks gestation) (Analysis 1.10) and
Extremely preterm birth (before completion of 28 weeks of
gestation) (Analysis 1.11)
Comparing ORA versus placebo, no difference was found in
preterm birth (before 37 weeks’ gestation) (RR 1.13, 95%CI 0.97
to 1.32; two studies with 664 women). (Analysis 1.10).
Comparing ORA (atosiban only) with placebo, one trial (Romero
2000) (501women) showed an increase in extremely pretermbirth
(before completion of 28 weeks of gestation) (RR 3.11, 95% CI
1.02 to 9.51; NNTH 31, 95% CI 8 to 3188).
No data were available for the subgroup of barusiban versus
placebo.
No differences were evident according to type of ORA.
Gestational age (Analysis 1.12) and Birthweight (Analysis 1.13)
No difference was shown in gestational age at birth compar-
ing ORA (atosiban only) with placebo (mean difference (MD) -
0.50 weeks, 95% CI -1.57 to 0.57; one study with 112 women)
(Analysis 1.12). ORA (atosiban) was associated with lower birth-
weight (MD -138.86 g, 95% CI -250.53 to -27.18; two studies
with 676 infants) (Analysis 1.13), however the clinical importance
of this difference (139 g) is questionable.
No data were available for the subgroup of barusiban versus
placebo.
Neonatal morbidity
No difference was shown when comparing ORA versus placebo
overall (or by type of ORA where data were available for these
comparisons) for the following outcomes measures.
Respiratory distress syndrome (Analysis 1.14)
For the comparison ORA versus placebo, no difference was shown
in respiratory distress syndrome (RR 1.32; 95% CI 0.96 to 1.82;
three studies with 836 infants).
Intraventricular haemorrhage (Analysis 1.15)
• ORA (atosiban only) versus placebo: RR 0.85, 95% CI
0.45 to 1.62 (one study with 475 infants).
Necrotising enterocolitis (Analysis 1.16)
• ORA (atosiban only) versus placebo: RR 0.21, 95% CI
0.02 to 1.76 (one study with 559 infants).
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Neonatal jaundice (Analysis 1.17)
• ORA (barusiban only) versus placebo: RR 1.31, 95% CI
0.86 to 1.99 (one study with 163 infants).
Admission to neonatal intensive care unit (Analysis 1.18)
• ORA (atosiban only) versus placebo: RR 1.09, 95% CI
0.89 to 1.34 (one study with 544 infants).
For the woman
Maternal adverse effects (Analysis 1.7)
• ORA (atosiban only) resulted in a significant increase in
maternal adverse effects (RR 1.54, 95% CI 1.02 to 2.32; two
studies with 613 women; NNTH 18, 95% CI 8 to 480);
representing 19% of women having an adverse effect in the ORA
group versus 14% in the placebo.
Maternal adverse effects requiring cessation of treatment
(Analysis 1.8)
Maternal adverse effects requiring cessation of treatment was in-
creased for the ORA group when compared to placebo (RR 4.02,
95% CI 2.05 to 7.85; NNTH 12; 95% CI 5 to 33; three studies
with 776 women); representing 16% of women having an adverse
effect in the ORA group versus 4% in the placebo.
These findings are driven by the subgroup of trials comparing
atosiban versus placebo as no events were reported for the barusi-
ban subgroup including a single trial (Thornton 2009).
Caesarean section (Analysis 1.9)
No difference was shown in caesarean section birth comparing
atosiban with placebo (RR 1.63, 95% CI 0.73 to 3.61; one study
with 112 women).
Comparison 2: Oxytocin receptor antagonists (ORA)
compared with other tocolytic agents by type of
other tocolytic agent
Eight studies (with 1402 women) are included in the compari-
son betweenORA (atosiban only) and betamimetics (Cabar 2008;
European 2001; French/Australian 2001; Goodwin 1996; Lin
2009; Moutquin 2000; Nonnenmacher 2009; Shim 2006). Two
studies including 225 women are included in the comparison
of ORA (atosiban only) and calcium channel blockers (CCB)
(nifedipine only) (Kashanian 2005; Salim 2012). All studies used
the ORA atosiban.
Primary outcomes
Birth less than 48 hours after trial entry (Analysis 2.1)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 0.89, 95% CI 0.66 to 1.22
(eight studies with 1389 women).
• ORA versus CCB: average: RR 1.09, 95% CI 0.44 to 2.73
(two studies with 225 women).
Moderate heterogeneity was present for the ORA versus CCB
comparison (Tau² = 0.22; Chi² = 2.04, df = 1 (P = 0.15); I²
= 51%); however, upon exploration of the possible reasons for
heterogeneity by examining clinical features of the studies, we
considered an overall summary was meaningful using a random-
effects analysis.
Very preterm birth (before completion of 34 weeks of gesta-
tion) (Analysis 2.3)
• ORA versus betamimetics: no data were available.
• ORA versus CCB: no statistically significant difference was
shown (RR 1.70, 95% CI 0.89 to 3.23; one study with 145
women).
Perinatal mortality (Analysis 2.2), Stillbirth (Analysis 2.4) and
Neonatal death (Analysis 2.5).
No statistically significant differences were shown within or across
subgroups
• ORA versus betamimetics: perinatal mortality (RR 0.55,
95% CI 0.21 to 1.48; three studies with 816 infants) (Analysis
2.2), stillbirth (RR 0.56, 95% CI 0.05 to 6.05; four studies with
861 infants) (Analysis 2.4) or neonatal death (RR 0.67, 95% CI
0.28 to 1.61; five studies with 1236 infants) (Analysis 2.5).
• ORA versus CCB: the single trial in this comparison (Salim
2012, 179 infants), reported that no neonatal deaths occurred
during the trial period. No data were available on stillbirth or
perinatal mortality.
Serious maternal outcome (Analysis 2.6)
• ORA versus betamimetics: one study with 45 women (Lin
2009) reported that no maternal deaths occurred during the trial
period.
• ORA versus CCB: no data were available.
No other data were available on other serious maternal outcomes
or long-term outcomes for the child.
Secondary outcomes
For the infant/child
Interval between trial entry and birth (Analysis 2.10)
• ORA versus betamimetics: an increase in the Interval
between trial entry and birth was shown with the use of ORA
(MD 22.90 days, 95% CI 18.03 to 27.77; one study with 80
women) (Cabar 2008).
• ORA versus CCB: no difference was shown in the interval
between trial entry and birth (Salim 2012) (MD -5.70 days, 95%
CI -12.36 to 0.96; one study with 145 women) (Salim 2012).
These results were statistically significantly different across sub-
groups; test for subgroup differences:Chi² = 46.16, df = 1 (P <
0.01), I² = 97.8%.
Preterm birth (before completion of 37 weeks of gestation)
(Analysis 2.11)
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• ORA versus betamimetics: no data were available.
• ORA versus CCB: in a single study (145 women) ORA
(atosiban) resulted in significantly more preterm births compared
with CCB (RR 1.56, 95% CI 1.13 to 2.14; NNTH 5, 95% CI
19 to 3).
Extremely preterm birth (before completion of 28 weeks of
gestation) (Analysis 2.12)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 0.84, 95% CI 0.37 to 1.92
(one study with 244 women).
• ORA versus CCB: RR 2.14, 95% CI 0.20 to 23.11 (one
study with 145 women).
Gestational age at birth (Analysis 2.13)
• ORA versus betamimetics: no difference was shown in
gestational age at birth (MD 0.13 weeks, 95% CI -0.32 to 0.59;
six studies with 1005 women).
• ORA versus CCB: a lower mean gestational age for ORA
group (atosiban) compared with CCB (MD -1.20 weeks, 95%
CI -2.15 to -0.25; one study with 145 women).
These results were statistically significantly different across sub-
groups; test for subgroup differences: Chi² = 6.18, df = 1 (P =
0.01), I² = 83.8%.
Birthweight (Analysis 2.14)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: MD 27.16 g, 95% CI -55.46 to
109.77 (seven studies with 1184 infants).
• ORA versus CCB: no difference was shown MD -82.00
weeks, 95% CI -270.78 to 106.78; (one study with 178 infants).
Apgar score less than seven at five minutes (Analysis 2.15)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 0.79, 95% CI 0.47 to 1.33
(five studies with 1008 infants).
• ORA versus CCB: RR 0.54, 95% CI 0.05 to 5.86 (one
study with 179 infants).
Respiratory distress syndrome (Analysis 2.16)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: (average RR 1.08; 95% CI 0.70
to 1.65; random-effects; six studies with 1280 infants). Moderate
heterogeneity was evident (Tau² = 0.11, Chi² = 7.98, df = 4 (P =
0.09), I² = 50%) which was driven by one study (European
2001). However, as no clear reason for the heterogeneity could
be identified, we considered an overall summary was meaningful
using a random-effects analysis.
• ORA versus CCB: (RR 1.39, 95% CI 0.54 to 3.57; one
study with 179 infants).
Use of mechanical ventilation (Analysis 2.17)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 3.00, 95% CI 0.63 to 14.30
(one study with 126 infants).
• ORA versus CCB: RR 1.41, 95% CI 0.65 to 3.04 (one
study with 179 infants).
Duration of mechanical ventilation (Analysis 2.18)
No statistically significant differences were shown.
• ORA versus betamimetics: MD -1.30 days, 95% CI -3.82
to 1.22 (one study with 32 infants).
• ORA versus CCB: no data were available.
Intraventricular haemorrhage (Analysis 2.19)
No statistically significant differences were shown.
• ORA versus betamimetics: RR 1.12, 95% CI 0.48 to 2.58
(two studies with 359 infants).
• ORA versus CCB: RR 2.16, 95% CI 0.41 to 11.51 (one
study with 179 infants).
Necrotising enterocolitis (Analysis 2.20)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 0.24, 95% CI 0.02 to 3.74
(one study with 292 infants).
• ORA versus CCB: RR 9.72, 95% CI 0.53 to 178.00 (one
study with 179 infants).
These results were statistically significantly different across sub-
groups; test for subgroup differences: Chi² = 3.30, df = 1 (P =
0.07), I² = 69.7%
Retinopathy of prematurity (Analysis 2.21)
No statistically significant differences were shown.
• ORA versus betamimetics: no data were available.
• ORA versus CCB: RR 2.16, 95% CI 0.20 to 23.43 (one
study with 179 infants).
Neonatal sepsis (Analysis 2.22)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: RR 0.91, 95% CI 0.56 to 1.46
(four studies with 1109 infants).
• ORA versus CCB: RR 0.72, 95% CI 0.12 to 4.21 (one
study with 179 infants).
Admission to neonatal intensive care unit (Analysis 2.23)
• ORA versus betamimetics: no difference in admission to
neonatal intensive care unit was shown (RR 0.90, 95% CI 0.78
to 1.04; five studies with 1062 infants).
• ORA versus CCB: an increase in admission to neonatal
intensive care unit was shown for the ORA (atosiban) group (RR
1.70, 95% CI 1.17 to 2.47; NNTH 5, 95% CI 3 to 19; one
study with 179 infants).
Neonatal length of hospital stay (Analysis 2.24)
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No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetics: MD 0.10 days, 95% CI -5.13 to
5.33 (one study with 41 infants).
• ORA versus CCB: MD 5.40 days, 95% CI -0.04 to 10.84
(one study with 179 infants).
For the woman
Maternal adverse effects (Analysis 2.7)
• ORA versus betamimetics: maternal adverse effects were
reported by two studies comparing ORA (atosiban) with
betamimetics. Due to substantial statistical heterogeneity when
these data were combined (I² = 95%) results are reported
separately. While both studies showed a reduction in these
events, in one study comparing ORA (atosiban) with
betamimetics (terbutaline) (European 2001), the reduction was
not statistically significant (RR 0.77, 95% CI 0.56 to 1.07). In
the other study comparing ORA (atosiban) with betamimetics
(ritodrine) (Shim 2006), a statistically significant substantial
reduction was shown for ORA (atosiban) (RR 0.11, 95% CI
0.05 to 0.26; NNTB 2, 95% CI 1 to 2).
• ORA versus CCB: a reduction was shown in maternal
adverse effects comparing ORA (atosiban) versus calcium
channel blockers (RR 0.38, 95% CI 0.21 to 0.68; NNTB 6,
95% CI 5 to 11; two studies with 225 women).
Maternal adverse effects requiring cessation of treatment
(Analysis 2.8)
• ORA versus betamimetics: a reduction in maternal adverse
effects requiring cessation of treatment was shown for ORA
(atosiban) compared with betamimetics (RR 0.05, 95% CI 0.02
to 0.11; NNTB 6, 95% CI 6 to 6; five studies with 1161
women).
• ORA versus CCB: no difference in maternal adverse effects
requiring cessation of treatment was shown for ORA (atosiban)
compared with CCB (RR 0.36, 95% CI 0.01 to 8.62; one study
with 145 women).
Caesarean section (Analysis 2.9)
No statistically significant differences were shown within or across
subgroups.
• ORA versus betamimetic: RR 0.87, 95% CI 0.50 to 1.52
(one study with 247 women).
• ORA versus CCB: RR 1.34, 95% CI 0.37 to 4.79 (one
study with 145 women).
D I S C U S S I O N
Summary of main results
Fourteen trials involving 2485 women contributed data to the
review. We compared oxytocin receptor antagonists (ORA) with
placebo (by type of ORA), with betamimetics and with calcium
channel blockers (CCB) (all studies using nifedipine). Apart from
one small study which used barusiban, all included studies used
the ORA atosiban.
In this review, ORA (mainly atosiban) were not shown to prolong
pregnancy or improve short-term neonatal outcomes compared
with either placebo or other tocolytics, i.e. betamimetic and CCB.
The ORA atosiban was used in all placebo-controlled trials apart
from one small trial which used barusiban and the lack of data did
not allow adequate examination of possible differential effects by
type of ORA.
Sixteen per cent of women receiving ORA had an adverse effect
requiring cessation of treatment compared with 4% of those who
received placebo. ORA resulted in fewer maternal adverse effects
than betamimetics or CCB.
Data from one study (Romero 2000), which compared ORA with
placebo, showed an increase in births less than 28 weeks’ gestation
and deaths to 12 months of age (0.7% in placebo group versus
4.2% in theORAgroup), indicating that on average one additional
infant death would occur for every 29 women (and up to 380)
receiving ORA. However, this finding may be confounded due to
randomisation of more women with pregnancy less than 26 weeks’
gestation to the atosiban group.
In one small study (145 infants) Salim 2012, which did not blind
the intervention, an increase in the number of preterm births (be-
fore 37 weeks’ gestation) (RR 1.56, 95% CI 1.13 to 2.14; NNTH
5, 95% CI 3 to 19), a lower gestational age at birth (MD -1.2
weeks, 95% CI -2.15 to -0.25) and an increase in admission to
neonatal intensive care unit (RR 1.70, 95% CI 1.16 to 2.49;
NNTH 5, 95% CI 3 to 20) was shown.
Overall completeness and applicability of
evidence
Although ORA result in fewer maternal side effects than other
tocolytics, there is no evidence of benefit for the infant when com-
pared with other tocolytics or placebo. Limitations of the review
findings include, minimal neonatal outcome data, no long-term
infant outcomes and overall suboptima trial quality.
Short-term outcomes of birth within 48 hours, perinatal mortality,
pretermbirth (less ss than37weeks), respiratory distress syndrome,
admission to neonatal care and maternal adverse drug reaction
were the most frequently reported outcomes. Data on a number
of clinically important neonatal outcomes were limited and the
only included longer-term outcome (reported by one study) was
infant mortality.
An increase in births less than 28 weeks’ gestation and deaths to 12
months of age was shown for ORA when compared with placebo.
However, because the adverse outcomes are nearly entirely the re-
sult of one study (Romero 2000), and because of a paucity of fur-
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ther trials comparing atosiban with placebo, no definite conclu-
sion can be drawn about whether atosiban is beneficial or harm-
ful compared with placebo. Neurological follow-up data from this
study (although not included in this review) showed no difference
between the atosiban and placebo groups at the age of six months,
one year, and two years of age. However, this result should be in-
terpreted with caution due to the potential for bias resulting from
high loss to follow-up.
A plausible explanation for the increase in adverse infant outcome
in the atosiban group could be a chance imbalance in the allocation
of women with threatened preterm labour in very early gestation
(under 26 weeks) with significantly more women in this subgroup
being allocated to the atosiban group. The mean gestational age
on admission was statistically significantly greater for the placebo
group than for the atosiban group, and there were nearly twice
as many atosiban-treated patients enrolled at < 26 weeks’ gesta-
tion. Among the women enrolled at less than 26 weeks’ gestation,
the number who had advanced cervical dilation was higher in the
atosiban group compared with the placebo group. In the same
study (Romero 2000), there were more births before 28 weeks’
gestation in the atosiban group compared with placebo, which
is not surprising given the short prolongation of pregnancy that
most tocolytics can achieve. Another explanation, which was sug-
gested by the US Food and Drug Administration (FDA), is that
fetal vasopressin receptor blockade by atosiban could give changes
in maternal amniotic fluid volume, with resultant alterations to
fetal renal development, and secondary alterations to fetal lung
development (FDA 1998a). A similar increase in adverse events
among infants exposed to atosiban was reported to the FDA for
one study of maintenance therapy (Valenzuela 2000) comparing
placebo and atosiban (FDA 1998b).
The study comparing barusiban versus placebo (Thornton 2009)
presented long-term follow-up data for mental development per-
formance and psychomotor performance at one year of age (not
included in this review). Although the findings were not signif-
icant, the results suggested mildly delayed psychomotor devel-
opment in 4% in the barusiban group and 8% in the placebo
group (Thornton 2009). None of the infants in the placebo group
and 3% of infants in the barusiban group were classified as hav-
ing significantly delayed psychomotor performance (Thornton
2009). In addition, there was mildly delayed mental performance
in 8% of infants in the placebo group and 10% in the barusiban
group (Thornton 2009). Based on the findings in this clinical trial
(Thornton 2009), barusiban is currently not in use for inhibition
of preterm labour.
It is also possible that rescue treatment confounded the estimation
of the true effects of atosiban when compared with placebo. In
the study by Romero et al (Romero 2000), rescue tocolysis was
given in 43% of the atosiban group and in 51% of the placebo
group. In one placebo-controlled study (Goodwin 1994), rescue
tocolysis was used in 20% and 32% of the participants in the
atosiban and placebo groups respectively after a short infusion of
study medication (two hours).
While data are limited on important clinical outcomes when com-
paring ORA with other tocolytics; eight studies (1402 women)
comparing ORA (atosiban only) with betamimetics and two (225
women) comparing ORA (atosiban) with CCB did not show clear
benefit other than reduced maternal adverse effects.
The difficulty in demonstrating that ORA is an effective tocolytic
may relate to its mechanism of action (FDA 1998a). It interacts
with oxytocic receptors in myometrial cells, the density of which is
gestation dependent. It is possible that ORA is more effective for
women inpreterm labour at higher gestations, whereas the pressing
clinical need is for tocolytics effective at lower gestations, where
delay in delivery has greater potential to improve the outcomes for
neonates.
Quality of the evidence
While three of the four placebo-controlled trials were considered
of good quality (allocation to treatment and intervention were
blinded), four of the eight trials comparingORAwith betamimetic
and both trials comparing ORAwith CCB trials considered of low
quality (no blinding of the intervention and often no blinding of
allocation to treatment).
Sample attrition was not considered a serious source of bias as
the majority (13 of the 14 included studies) had minimal or no
attrition. In 12 of the 14 included studies, no reporting bias was
evident and in the remaining studies it was unclear.
For the majority of trials no other sources of bias was evident.
However, in four studies, the risk of other bias was considered to
be unclear (Cabar 2008; Goodwin 1996; Kashanian 2005; Shim
2006) and in two studies, the risk of other bias was judged to be
high (Goodwin 1994; Romero 2000). These latter two studies,
both in the placebo comparison, included women of lower ges-
tational age in the atosiban group compared with placebo group.
One of these studies also recruited women from five different cen-
tres, and the inclusion criteria differed between the centres, which
may have introduced bias. In the largest placebo-controlled trial,
while judged to be at low risk of bias for all other quality criteria,
there were nearly twice as many atosiban-treated patients enrolled
at < 26 weeks’ gestation.
Potential biases in the review process
We are aware that the review process itself is subject to bias, and we
took steps tominimise bias. At least two review authors carried out
data extraction and assessed risk of bias independently; however,
a different review team may not have made identical decisions.
Agreements and disagreements with other
studies or reviews
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We found that although ORA (mainly atosiban) resulted in fewer
maternal side effects than other tocolytics; there is no clear ev-
idence of benefit in terms of prolongation of pregnancy or im-
portant infant outcomes when compared with other tocolytics or
placebo. A recent network meta-analysis (Haas 2012) showed dif-
ferent results, reporting that atosiban was better than placebo in
delaying delivery at 48 hours (odds ratio 2.02; 95% CI 1.1 to
3.8), although it also found that atosiban had a lower probability
of being superior to other tocolytics. We did not show benefit for
ORA in delaying birth for 48 hours when compared with placebo
as in the Haas et al review (Haas 2012). However, due to differ-
ent methodological approaches, findings are difficult to compare.
Further, the review reported that nifedipine (the most commonly
used CCB) is the preferred first-line tocolytic (Haas 2012). An-
other review, using indirect comparison of randomised trials, of
the ORA atosiban with nifedipine concluded that nifedipine was
more effective than atosiban and lowered the incidence of respira-
tory distress syndrome (Coomarasamy 2003). In the Cochrane re-
view on CCB for inhibiting preterm labour, CCB (mainly nifedip-
ine) was shown to prolong pregnancy and reduce neonatal mor-
bidity (update of King 2003 in progress). Similar to our review,
this review found limited trial outcome data comparing ORAwith
CCB (including the same two small studies included in this review
(Kashanian 2005; Salim 2012)). However, in our review, some
indication for benefit of CCB (nifedipine) over the ORA atosiban
was shown in the results of one small trial (145 women) (Salim
2012).
Consistentwith our conclusions,Haas et al (Haas 2012) supported
further well-designed, randomised, placebo-controlled trials to
evaluate ORA in prolonging pregnancy for women in preterm
labour. The CCB, nifedipine has the advantage of ease of oral
administration and is very inexpensive compared with atosiban
(Papatsonis 2004). However, more robust evidence from well-de-
signed, randomised trials with direct comparisons of nifedipine
and ORA are required before strong recommendations for clinical
practice can be made. One such study is ongoing (APOSTEL III).
Adequate comparison of ORAs with COX inhibitors (such as in-
domethacin) for preterm labour is also lacking. COX inhibitors
have been the focus of a recent Cochrane review (Khanprakob
2012), which concluded that, due to insufficient evidence, further
well-designed, placebo-controlled trials are needed and should in-
clude comparisons with other agents and incorporate long-term
follow-up of infants.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review did not demonstrate superiority of oxytocin receptor
antagonists (ORA) (largely atosiban) as a tocolytic agent compared
with placebo, betamimetics or calcium channel blockers (CCB)
(largely nifedipine) in terms of pregnancy prolongation or neona-
tal outcomes, although ORA was associated with fewer maternal
adverse effects than treatment with theCCB or betamimetics. The
finding of an increase in infant deaths andmore births before com-
pletion of 28 weeks of gestation in one placebo-controlled study
warrants caution. However, due to limitations of the small num-
bers studied and methodological quality, there is currently insuffi-
cient evidence on the role of ORA in the management of women
in preterm labour to inform clinical practice.
Implications for research
Further well-designed randomised controlled studies of tocolytic
therapy are needed, in particular comparisons of ORA versus CCB
(which have a better side-effect profile than betamimetics), and
further placebo-controlled studies may also be warranted. All fu-
ture studies with use of tocolytic agents should measure all impor-
tant short- and long-term outcomes for women and infants, and
costs. Future studies should address the possibility that different
tocolytic strategies are needed at different gestational ages in order
to optimise safety and efficacy. At the time of writing this review, a
randomised controlled trial comparing atosiban versus nifedipine
in the management of preterm labour is ongoing in The Nether-
lands, (APOSTEL III) NTR2947 and may help to fill this gap in
knowledge.
A C K N OW L E D G E M E N T S
We would like to acknowledge Drs K Marsal, and TM Goodwin
for providing additional data for this review. We thank James King
for assistance with the development of the protocol and Katie
Welsh, Viviana Rodriguez and Aleena Wojcieszek for assistance
with reference management.
We also acknowledge the guidance and support of Philippa Mid-
dleton in completion of this review, Sonja Henderson for sup-
port and advice regarding theCochrane Pregnancy andChildbirth
Group methods and procedures, and Lynn Hampson for her as-
sistance with searching for potentially eligible trials.
As part of the pre-publication editorial process, this review has
been commented on by four peers (an editor and three referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
20Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Cabar 2008 {published data only}
Cabar FR, Bittar RE, Gomes CM, Zugab M. Atosiban as a
tocolytic agent: a new proposal of a therapeutic approach.
Revista Brasileira de Ginecologia y Obstetricia 2008;30(2):
87–92.
European 2001 {published data only}
∗ The European Atosiban Study Group. The oxytocin
antagonist atosiban versus the ß-agonist terbutaline in
the treatment of preterm labor: a randomized, double-
blind, controlled study. Acta Obstetricia et Gynecologica
Scandinavica 2001;80:413–22.
The Worldwide Atosiban versus Beta-antagonists Study
Group. Effectiveness and safety of the oxytocin antagonist
atosiban versus beta-adrenergic agonists in the treatment of
preterm labour. BJOG 2001;108:133–42.
French/Australian 2001 {published data only}
∗ French/Australian Atosiban Investigators Group.
Treatment of preterm labor with the oxytocin antagonist
atosiban: a double-blind, randomized, controlled
comparison with salbutamol. European Journal Obstetrics,
Gynecology and Reproductive Biology 2001;98:177–85.
The Worldwide Atosiban versus Beta-antagonists Study
Group. Effectiveness and safety of the oxytocin antagonist
atosiban versus beta-adrenergic agonists in the treatment of
preterm labour. BJOG 2001;108:133–42.
Goodwin 1994 {published data only}
∗ Goodwin TM, Paul R, Silver H, Spellacy W, Parsons M,
Chez R, et al. The effect of the oxytocin antagonist atosiban
on preterm uterine activity in the human. American Journal
of Obstetrics and Gynecology 1994;170:474–8.
Goodwin TM, Paul RH, Silver H, Parsons M, Chez R,
Spellacy W, et al. Safety and efficacy of the oxytocin
antagonist atosiban in threatened preterm labor: initial US
trial. American Journal of Obstetrics and Gynecology 1992;
166:359.
Goodwin 1996 {published data only}
Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy
GW, Lane R. Treatment of preterm labor with the oxytocin
antagonist atosiban. American Journal of Perinatology 1996;
13(3):143–6.
∗ Goodwin TM, Valenzuela GJ, Silver H, Creasy G,
Atosiban Study Group. Dose ranging study of the oxytocin
antagonist atosiban in the treatment of preterm labor.
Obstetrics & Gynecology 1996;88(3):331–6.
Kashanian 2005 {published data only}
∗ Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and
nifedipin for the treatment of preterm labor. International
Journal of Gynecology & Obstetrics 2005;91(1):10–4.
Kashanian M, Soltanzadeh M, Sheikh Ansari N. Atosiban
and nifedipin for the treatment of preterm labor. BJOG: an
international journal of obstetrics and gynaecology 2008;115
(s1):69.
Lin 2009 {published data only}
Lin CH, Lin SY, ShyuMK, Chen SU, Lee CN. Randomized
trial of oxytocin antagonist atosiban versus beta-adrenergic
agonists in the treatment of spontaneous preterm labor
in Taiwanese women. Journal of the Formosan Medical
Association = Taiwan Yi Zhi 2009;108(6):493–501.
Moutquin 2000 {published data only}
Moutquin J, Rabinovici J. Comparison of atosiban versus
ritodrine in the treatment of pre-term labour. Acta
Obstetrica et Gynecologica Scandinavica 1997;76(167):33.
∗ Moutquin JM, Sherman D, Cohen H, Mohide PT,
Hochner-Celnikier D, Fejgin M, et al. Double-blind,
randomized, controlled trial of atosiban and ritodrine in the
treatment of preterm labor: a multicenter effectiveness and
safety study. American Journal of Obstetrics and Gynecology
2000;182(5):1191–9.
Nonnenmacher 2009 {published data only}
Nonnenmacher A, Hopp H, Dudenhausen J. Effectiveness
and safety of atosiban vs. pulsatile administration of
fenoterol in the treatment of preterm labour. Zeitschrift fur
Geburtshilfe und Neonatologie 2009;213(5):201–6.
Richter 2005 {published data only}
Richter ON, Dorn C, van de Vondel P, Ulrich U,
Schmolling J. Tocolysis with atosiban: experience in
the management of premature labor before 24 weeks of
pregnancy. Archives of Gynecology and Obstetrics 2005;272
(1):26–30.
Romero 2000 {published data only}
Goodwin TM. 1st International preterm labour congress.
Strategies to prevent the morbidity and mortality associated
with prematurity; 2002 June 27-30. Le Montreux Palace,
Montreux Switzerland. 2002.
Goodwin TM. Long-term safety with oxytocin antagonists.
4th World Congress on Controversies in Obstetrics,
Gynecology and Infertility; 2003 April 24-27; Berlin,
Germany. 2003:291.
Goodwin TM, Randall H, Perry K, Menard MK, Bauer C,
Shangold G, et al. A report on infant outcomes at 6 and
12 months after the use of atosiban in the management of
preterm labor. 46th ACOG Annual Meeting; 1998 May 9-
13; New Orleans, Louisiana. 1998.
Goodwin TM, Randall H, Perry K, Menard MK, Bauer
C, Shangold G, et al. A report on infant outcomes up to
24 months after the use of atosiban in the management of
preterm labor. 46th ACOG Annual Meeting; 1998 May 9-
13; New Orleans, Louisiana. 1998.
∗ Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ,
Veille JC, Tabor B, et al. An oxytocin receptor antagonist
(atosiban) in the treatment of preterm labor: a randomized,
double-blind, placebo-controlled trial with tocolytic rescue.
American Journal of Obstetrics and Gynecology 2000;182(5):
1173–83.
Sibai B, Romero R, Sanchex-Ramos L, Valenzuela G,
Veille J, Tabor B, et al. A double-blind placebo-controlled
21Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
trial of an oxytocin-receptor antagonist (antocin) in the
treatment of preterm labor. American Journal of Obstetrics
and Gynecology 1997;176(1 Pt 2):S2.
Silver H, Valenzuela G, Sanchez-Ramos L, Romero R, Sibai
B, Goodwin T, et al. Maternal side effects and safety of the
oxytocin receptor antagonist antocin. American Journal of
Obstetrics and Gynecology 1997;176(1 Pt 2):S45.
Salim 2012 {published data only}
Garmi G. Nifedipine compared to atosiban for treating
preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)].
accessed 9 April 2008.
∗ Salim R, Garmi G, Nachum Z, Zafran N, Baram S,
Shalev E. Nifedipine compared with atosiban for treating
preterm labor: A randomized controlled trial. Obstetrics and
Gynecology 2012;120(6):1323–31.
Shim 2006 {published data only}
Shim JY, Park YW, Yoon BH, Cho YK, Yang JH, Lee Y, et
al. Multicentre, parallel group, randomised, single-blind
study of the safety and efficacy of atosiban versus ritodrine
in the treatment of acute preterm labour in Korean women.
BJOG 2006;113(11):1228–34.
Thornton 2009 {published data only}
Arce JC. A proof of concept study assessing the effect of
four different stage bolus intravenous doses of FE200440
and placebo on stopping preterm labor (ongoing trial).
ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21
March 2006).
Thornton S, Goodwin TM, Greisen G, Hedegaard M, Arce
JC. The effect of a selective oxytocin antagonist (barusiban)
in threatened preterm labour: a randomized, double-blind,
placebo-controlled trial. 55th Annual Meeting of the
Society of Gynecologic Investigation; 2008 March 26-29;
San Diego, USA. 2008:Abstract no: 129.
Thornton S, Goodwin TM, Greisen G, Hedegaard M,
Arce JC. The effect of barusiban on plasma concentrations
and uterine contractility in threatened preterm labour: a
randomised, double-blind, placebo-controlled trial. Archives
of Disease in Childhood. Fetal and Neonatal Edition 2008;93
(Suppl 1):Fa11–Fa12.
∗ Thornton S, Goodwin TM, Greisen G, Hedegaard M,
Arce JC. The effect of barusiban, a selective oxytocin
antagonist, in threatened preterm labor at late gestational
age: a randomized, double-blind, placebo-controlled trial.
American Journal of Obstetrics and Gynecology 2009;200(6):
627.e1–627.e10.
References to studies excluded from this review
Al-Omari 2006 {published data only}
∗ Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM,
Ahmed KW. Atosiban and nifedipine in acute tocolysis:
a comparative study. European Journal of Obstetrics &
Gynecology and Reproductive Biology 2006;128(1-2):129–34.
Al-Omari WR, Al-Tikri E, Al-Shammaa H. Atosiban and
nifedipine in acute tocolysis, comparative study. XVIIIth
European Congress of Obstetrics and Gynaecology; May
12-15; Athens, Greece. 2004:103.
de Heus 2008 {published data only}
de Heus R, Mulder EJ, Derks JB, Korver PH, van
Wolfswinkel L, Visser GH. A prospective randomized trial
of acute tocolysis in term labour with atosiban or ritodrine.
European Journal of Obstetrics, Gynecology, and Reproductive
Biology 2008;139(2):139–45.
Gagnon 1998 {published data only}
Gagnon D, Martens L, Creasy G, Henke C. An economic
analysis of atosiban maintenance therapy in preterm labor.
American Journal of Obstetrics and Gynecology 1998;178(1
Pt 2):S181.
Husslein 2006 {published data only}
Anonymous. TREASURE (Tractocile efficacy assessment
survey in Europe). Trial to commence in July. http://
www.ferring.com/ (accessed 24 May 2004).
∗ Husslein P, Roura LC, Dudenhausen J, Helmer H,
Frydman R, Rizzo N, et al. Clinical practice evaluation of
atosiban in preterm labour management in six European
countries. BJOG: an international journal of obstetrics and
gynaecology 2006;113(Suppl 3):105–10.
Husslein 2007 {published data only}
Husslein P, Cabero Roura L, Dudenhausen JW, Helmer
H, Frydman R, Rizzo N, et al. Atosiban versus usual care
for the management of preterm labor. Journal of Perinatal
Medicine 2007;35(4):305–13.
Poppiti 2009 {published data only}
Poppiti R, Nazzaro G, De Placido G, Palmieri T, Locci M.
Prevention of preterm delivery in twin pregnancies with
atosiban. Journal of Maternal-Fetal & Neonatal Medicine
2009;22(Suppl 1):61.
Steinwall 2005 {published data only}
Steinwall M, Bossmar T, Brouard R, Laudanski T, Olofsson
P, Urban R, et al. The effect of relcovaptan (SR 49059), an
orally active vasopressin V1a receptor antagonist, on uterine
contractions in preterm labor. Gynecological Endocrinology
2005;20(2):104–5.
Valenzuela 1997 {published data only}
Valenzuela G, Diaz A, Germain A, Foster T, Hayashi R,
Seron-Ferre M. Estradiol levels are increased before and after
preterm labor treatment with an oxytocin (OT) antagonist:
evidence for chronic activation of the mechanism of labor.
Acta Obstetricia et Gynecologica Scandinavica 1997;76(167):
88.
Valenzuela 2000 {published data only}
Sanchez-Ramos L, Valenzuela G, Romero R, Silver H,
Koltun W, Millar L, et al. A double-blind placebo-
controlled trial of oxytocin receptor antagonist (antocin)
maintenance therapy in patients with preterm labor.
American Journal of Obstetrics and Gynecology 1997;176(1
Pt 2):S30.
∗ Valenzuela GJ, Sanchez-Ramos L, Romero R, Silver HM,
Koltun WD, Millar L, et al. Maintenance treatment of
preterm labor with the oxytocin antagonist atosiban. The
atosiban ptl-098 study group. American Journal of Obstetrics
and Gynecology 2000;182(5):1184–90.
22Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies awaiting assessment
de Heus 2009 {published data only}
de Heus R, Mulder EJ, Derks JB, Visser GH. The effects of
the tocolytics atosiban and nifedipine on fetal movements,
heart rate and blood flow. Journal of Maternal-Fetal &
Neonatal Medicine 2009;22(6):485–90.
Lenzen 2012 {published data only}
Lenzen V, Bartz C, Rath WH. Atosiban versus fenoterol
treatment of pre-term labour: randomised, prospective,
multicentre study [Atosiban versus fenoterol zur
behandlung vorzeitiger wehen: randomisierte, prospektive
multizenterstudie]. Archives of Gynecology and Obstetrics
2012;286(Suppl 1):S197–S198.
Neri 2009 {published data only}
Neri I, Monari F, Valensise H, Facchinetti F, Bellafronte M,
Volpe A. Computerized evaluation of fetal heart rate during
tocolytic treatment: comparison between atosiban and
ritodrine. Journal of Maternal-Fetal and Neonatal Medicine
2008;21(Suppl 1):22.
∗ Neri I, Monari F, Valensise H, Vasapollo B, Facchinetti
F, Volpe A. Computerized evaluation of fetal heart rate
during tocolytic treatment: comparison between atosiban
and ritodrine. American Journal of Perinatology 2009;26(4):
259–63.
Renzo 2003 {published data only}
Renzo DGC, Mignosa MM, Rosati A, Burnelli L, Epicoco
G, Luzi G. Can we effectively arrest premature labour in
women with multiple gestations or other high-risk factors?
. 4th World Congress on Controversies in Obstetrics,
Gynecology & Infertility; 2003 April 24-27; Berlin,
Germany. 2003:286–90.
Snidow 2013 {published data only}
Anonymous. The safety, tolerability and metabolism of
GSK221149A, in pregnant women (34-36 weeks), in
preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/)
(accessed 21 June 2007).
∗ Snidow J, Miller H, Valenzuela G, Thornton S, Stier B,
Clayton L, et al. A multicenter, randomized, double-blind,
placebo-controlled phase 2 trial of retosiban, a selective
oxytocin receptor antagonist, for the management of
preterm labor. American Journal of Obstetrics and Gynecology
2013;208(1 Suppl 1):S155.
References to ongoing studies
APOSTEL III {published data only}
Heida K. Nifedipine versus Atosiban in the treatment
of threatened preterm labour: APOSTEL III. http://
www.trialregister.nl/trialreg/admin/rctview.asp?TC=2947
(accessed 6 January 2014).
Additional references
Akerlund 1999
Akerlund M, Bossmar T, Brouard R, Kostrzewska A,
Laudanski T, Lemancewicz A, et al. Receptor binding of
oxytocin and vasopressin antagonists and inhibitory effects
on isolated myometrium from preterm and term pregnant
women. British Journal of Obstetrics and Gynaecology 1999;
106(10):1047–53.
Anotayanonth 2006
Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S.
Betamimetics for inhibiting preterm labour. Cochrane
Database of Systematic Reviews 2006, Issue 4. [DOI:
10.1002/14651858.CD004352.pub2]
Blencowe 2012
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller
AB, Narwal R, et al. National, regional, and worldwide
estimates of preterm birth rates in the year 2010 with
time trends since 1990 for selected countries: a systematic
analysis and implications. Lancet 2012 Jun 9;379(9832):
2162–72.
Borthwick 2013
Borthwick AD, Liddle J. Retosiban and epelsiban: potent
and selective orally available oxytocin antagonists. In:
Dömling A editor(s). Protein-Protein Interactions in Drug
Discovery. KGaA,Weinheim, Germany: Wiley-VCH Verlag
GmbH & Co, 2013:225–56.
Chang 2013
Chang HH, Larson J, Blencowe H, Spong CY, Howson CP,
Cairns-Smith S, et al. Preventing preterm births: analysis
of trends and potential reductions with interventions in 39
countries with very high human development index. Lancet
2013;381(9862):223–34.
Coomarasamy 2003
Coomarasamy A, Knox EM, Gee H, Song F, Khan KS.
Effectiveness of nifedipine versus atosiban for tocolysis in
preterm labour: a meta-analysis with an indirect comparison
of randomised trials. BJOG: an international journal of
obstetrics and gynaecology 2003;110:1045–9.
Crowley 1996
Crowley P. Prophylactic corticosteroids for preterm birth.
Cochrane Database of Systematic Reviews 1996, Issue 2.
[DOI: 10.1002/14651858.CD000065.pub2]
Crowther 2002
Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate
for preventing preterm birth in threatened preterm labour.
Cochrane Database of Systematic Reviews 2002, Issue 4.
[DOI: 10.1002/14651858.CD001060]
Dorling 2008
Dorling JS, Field DJ. Value and validity of neonatal disease
severity scoring systems. Archives of Disease in Childhood.
Fetal and Neonatal Edition 2008;93(2):F80–F82.
Doyle 2009
Doyle LW, Crowther CA, Middleton P, Marret S, Rouse
D. Magnesium sulphate for women at risk of preterm
birth for neuroprotection of the fetus. Cochrane Database
of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/
14651858.CD004661.pub3]
Duckitt 2002
Duckitt K, Thornton S. Nitric oxide donors for the
treatment of preterm labour. Cochrane Database of
23Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Systematic Reviews 2002, Issue 3. [DOI: 10.1002/
14651858.CD002860]
FDA 1998a
Advisory Committee for Reproductive Health Drugs.
Issue-NDA 20-797 Antocin, (atosiban injection) for use
in the management of preterm labor. Centre for Drug
Evaluation and Research, Food and Drug Administration.
Gaithersburg, Maryland April 20 1998:83–5.
FDA 1998b
Advisory Committee for Reproductive Health Drugs.
Issue-NDA 20-797 Antocin, (atosiban injection) for use
in the management of preterm labor. Centre for Drug
Evaluation and Research, Food and Drug Administration.
Gaithersburg, Maryland April 20 1998:81.
FDA 2011
U.S. Food, Drug Administration. Drug Safety
Communication: New warnings against use of terbutaline
to treat preterm labor. http://www.fda.gov/Drugs/
DrugSafety/ucm243539.htm.
Gates 2004
Gates S, Brocklehurst P. How should randomised trials
including multiple pregnancies be analysed?. BJOG 2004;
111(3):213–9.
Goldenberg 2008
Goldenberg RL, Culhane JF, Iams JD, Romero R.
Epidemiology and causes of preterm birth. Lancet 2008;
371(9606):75–84..
Goodwin 1996b
Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy
GW, Lane R. Treatment of preterm labor with the oxytocin
antagonist atosiban. American Journal of Perinatology 1996;
13(3):143–6.
Goodwin 1998a
Goodwin TM, Randall H, Perry K, Menard MK, Bauer C,
Shangold G, et al. A report on infant outcomes up to 24
months of age after the use of atosiban in the management
of preterm labour. 46th ACOG annual meeting; 1998 May
9-13; New Orleans, Louisiana. 1998.
Goodwin 1998b
Goodwin TM, Zograbyan A. Oxytocin receptor antagonists.
Update. Clinics in Perinatology 1998;25(4):859–71.
Gyetvai 1999
Gyetvai K, Hannah M, Hodnett E, Ohlsson A. Tocolysis for
preterm labor: a systematic review. Obstetrics & Gynecology
1999;94(5):869–77.
Haas 2012
Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ,
Welton NJ. Tocolytic therapy for preterm delivery:
systematic review and network meta-analysis. BMJ 2012;
345:e6226.
Higgins 2002
Higgins J, Thompson S. Quantifying heterogeneity in
meta-analysis. Statistics in Medicine 2002;21:1559–74.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions. The Cochrane
Collaboration, 2011. Available from www.cochrane-
handbook.org, Version 5.1.0 [updated March 2011]..
Khanprakob 2012
Khanprakob T, Laopaiboon M, Lumbiganon P,
Sangkomkamhang US. Cyclo-oxygenase (COX) inhibitors
for preventing preterm labour. Cochrane Database of
Systematic Reviews 2012, Issue 10. [DOI: 10.1002/
14651858.CD007748.pub2]
King 1988
King JF, Grant A, Keirse MJNC, Chalmers I. Beta-
mimetics in preterm labour: an overview of the randomized
controlled trials. British Journal of Obstetrics and Gynaecology
1988;95:211–22.
King 2003
King JF, Flenady VJ, Papatsonis DNM, Dekker GA,
Carbonne B. Calcium channel blockers for inhibiting
preterm labour. Cochrane Database of Systematic Reviews
2003, Issue 1. [DOI: 10.1002/14651858.CD002255]
King 2005
King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase
(COX) inhibitors for treating preterm labour. Cochrane
Database of Systematic Reviews 2005, Issue 2. [DOI:
10.1002/14651858.CD001992.pub2]
Koks 1998
Koks CA, Brolmann HA, de Kleine MJ, Manger PA. A
randomized comparison of nifedipine and ritodrine for
suppression of preterm labor. European Journal of Obstetrics
& Gynecology and Reproductive Biology 1998;77(2):171–6.
Lasswell 2010
Lasswell SM, Barfield WD, Rochat RW, Blackmon L.
Perinatal regionalization for very low-birth-weight and very
preterm infants: a meta-analysis. JAMA 2013;304(9):
992–1000.
Liu 2012
Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et
al. Global, regional, and national causes of child mortality:
an updated systematic analysis for 2010 with time trends
since 2000. Lancet 2012;379(9832):2151–61.
Melin 1994
Melin P. Development of an oxytocin antagonist atosiban.
Research Clinical Forums 1994;16:155–68.
Nilsson 2003
Nilsson L, Reinheimer T, Steinwall M, Akerlund M. FE 200
440: a selective oxytocin antagonist on the term-pregnant
human uterus. BJOG 2003;110(11):1025–8.
Papatsonis 2004
Papatsonis DNM, Decker GA. Nifedipine in the
management of preterm labour: evidence from the
literature. In: Critchley H, Bennett P, Thornton S editor(s).
Preterm Birth. London: RCOG Press, 2004:296–307.
Petrou 2011
Petrou S, Eddama O, Mangham L. A structured review
of the recent literature on the economic consequences of
24Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
preterm birth. Archives of Disease in Childhood. Fetal and
Neonatal Edition 2011;96(3):F225–F232.
Plunkett 2008
Plunkett J, Muglia LJ. Genetic contributions to preterm
birth: implications from epidemiological and genetic
association studies. Annals of Medicine 2008;40:167–95.
RevMan 2012 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.2. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2012.
Roberts 2006
Roberts D, Dalziel SR. Antenatal corticosteroids for
accelerating fetal lung maturation for women at risk of
preterm birth. Cochrane Database of Systematic Reviews 2006,
Issue 3. [DOI: 10.1002/14651858.CD004454.pub2]
Schappin 2013
Schappin R, Wijnroks L, Uniken Venema MMAT,
Jongmans MJ. Rethinking stress in parents of preterm
infants: a meta-analysis. PLoS ONE 2013;8(2):e54992.
Spector 1991
Spector TD, Thompson SG. The potential and limitations
of meta-analysis. Journal of Epidemiology and Community
Health 1991;45:89–92.
Su 2010
Su LL, Samuel M, Chong YS. Progestational agents for
treating threatened or established preterm labour. Cochrane
Database of Systematic Reviews 2010, Issue 1. [DOI:
10.1002/14651858.CD006770.pub2]
Tsatsaris 2004
Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm
labour. Drugs 2004;64:375–82.
Tucker 2004
Tucker J, McGuire W. Epidemiology of preterm birth.
BMJ. 2004;329(7467):675–8.
Vrachnis 2011
Vrachnis N, Malamas FM, Sifakis S, Deligeorogluo E,
Iliodromiti Z. The oxytocin-oxytocin receptor system and
its antagonists as tocolytic agents. International Journal of
Endocrinology 2011;2011:350546. [DOI: 10.1155/2011/
350546]
WHO 2012
Howson CP, Kinney MV, Lawn JE (editors). Born Too Soon:
The Global Action Report on Preterm Birth. Geneva: World
Health Organization, 2012.
Yelland 2011
Yelland L, Salter A, Ryan P, Makrides M. Analysis of binary
outcomes from randomised trials including multiple births:
when should clustering be taken into account?. Paediatric
and Perinatal Epidemiology 2011;25(3):283–97.
Zeitlin 2008
Zeitlin J, Draper ES, Kollée L, Milligan D, Boerch K,
Agostino R, et al. for the MOSAIC research group.
Differences in rates and short-term outcome of live births
before 32 weeks of gestation in Europe in 2003: results from
the MOSAIC cohort. Pediatrics 2008;121(4):e936–e944.
References to other published versions of this review
Papatsonis 2005
Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin
receptor antagonists for inhibiting preterm labour. Cochrane
Database of Systematic Reviews 2005, Issue 3. [DOI:
10.1002/14651858.CD004452.pub2]
∗ Indicates the major publication for the study
25Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cabar 2008
Methods Randomised trial.
Participants 80womenwith singletonpregnancy at 23 to 33 completedweekswith intactmembranes,
uterine contractions every 5 min, cervical dilation 1-3 cm, cervical effacement greater
than 50%, amniotic fluid index: 5-25
Exclusion criteria: maternal diseases (pre-eclampsia, chronic hypertension, diabetes mel-
litus, congenital heart defects, hyperthyroidism, asthma, collagenosis, antiphospholipid
syndrome, anaemia, allo immunity), fetal or placental diseases, fetal growth restriction
(< 10th percentile), cervical incompetence, chorioamnionitis or temperature > 38ºC
Interventions ORA group: atosiban. Initial bolus dose of 6.75 mg (i.v.) followed by 300 µg/min for 3.
5 h and 100 µg/min for 3.5 h. Thereafter, as required, 100 µg/min for 12.5 h repeated
for up to 45 h
Control group: terbutaline. Administered as i.v. infusion of 2.5mg in 500mL5%glucose
at a rate of 20 mL/h. If uterine activity persisted, infusion rate was increased by 20 mL/
h until contractions ceased and the dose was maintained for 24 h
Outcomes Evaluating the safety and maternal and fetal side effects of atosiban
Notes Publication has been translated to English by the Cochrane Pregnancy and Childbirth
Group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unable to determine how randomisation was performed.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
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Cabar 2008 (Continued)
Other bias Unclear risk Not able to determine.
European 2001
Methods Multicentre, randomised, placebo-controlled trial.
Participants 249 women with singleton pregnancies in preterm labour defined as regular uterine
contractions of > 30 sec, duration≤ 4/30min. Cervical effacement > 50% and dilatation
0-3 cm (nullipara), 1-3 cm (primi- multiparas) and at 23-33 completed weeks’ gestation
Exclusion criteria: high-order multiple pregnancy (≥ triplets), ruptured membranes, se-
vere pre-eclampsia/hypertension, use of NSAID therapy≤ 12 h prior to randomisation,
temperature > 37.5ºC (UK and Czech Republic) or 38ºC (Sweden and Denmark), alco-
hol or drug abuse, hypersensitivity to any components of study drugs, contraindications
to the use of terbutaline, participation in clinical trial < 1 month, fetal/placental abnor-
malities (e.g. chorioamnionitis, abruptio placenta, placenta praevia, intrauterine growth
retardation, fetal distress/death, major congenital anomaly, hydramnios, retained in-
trauterine device), serious maternal disease (e.g. cardiovascular disease, hyperthyroidism,
uncontrolled diabetes mellitus, pheochromocytoma, asthma), study standard maternal
or fetal contraindications to tocolysis
Interventions ORA group: atosiban. Bolus dose of 6.75 mg (i.v.) followed by infusion of 300 µg/min
for 3 h, then 100 µg/min up to 18 h. Separate but simultaneous i.v. infusion of 5%
dextrose given as placebo
Control group: terbutaline. Given in 5% dextrose at 10-25 µg/min (i.v.). Simultaneous
bolus dose (0.9 mLNaCl) injection followed by infusion of 5% dextrose (i.v.) were given
as placebo
Both infusions were given up to 18 h.
Outcomes Primary goals were the safety and effectiveness of atosiban versus terbutaline as tocolytic
agents, assessed as women undelivered after 48 h and 7 days and maternal side effects
Secondary outcomes: contraction rate with time, gestational age at delivery, proportion
of women re-treated with study medication, proportion of infants born at differing
gestational age and number of infants requiring neonatal intensive care
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation lists
for each center was used to allocate women
to study treatment and women were strat-
ified by gestational age at enrolment.”
The review authors consider this approach
low risk.
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European 2001 (Continued)
Allocation concealment (selection bias) Low risk Prepared by Ferring Pharmaceuticals: com-
puter-generated randomisation stratified
by GA and centre, supplied to pharmacists
at each centre in pre-randomised boxes la-
belled with country code and case number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Through the use of a double-blind, dou-
ble-dummy technique, the utmost effort
was made to keep the study blinded. […]
the somewhat obvious side effects profile
of terbutaline may have compromised the
blinding.”
The review authors consider this approach
low risk.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Probably low risk as double-placebo tech-
nique was used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman in the atosiban group and 4
women in the terbutaline group were lost
to follow-up
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
French/Australian 2001
Methods Multicentre, randomised, placebo-controlled trial.
Participants 241 women with preterm labour, defined as duration of contractions ≥ 30 sec at a rate
of ≥ 4/30 min, cervical dilation 0-3 cm (nullipara) or 1-3 cm (primi- or multipara) and
effacement ≥ 50%, at 23-33 completed weeks’ gestation and ≥ 18 years of age
Exclusion criteria: multiple pregnancy (> twins), ruptured membranes, major vaginal
bleeding, use of NSAID’s within 12 h (Australia), ß-agonists within 30min andNSAID’s
or calcium channel blockers within 24 h (France), severe pre-eclampsia or hyperten-
sion, temperature > 37.5ºC, urinary tract infection, fetal/placental abnormalities (e.g.
chorioamnionitis, abruptio placenta, placenta praevia, intrauterine growth retardation,
fetal distress/death, major congenital anomaly, hydramnios, retained intrauterine device)
, serious maternal disease (e.g. cardiovascular disease, hyperthyroidism, uncontrolled di-
abetes mellitus, pheochromocytoma, asthma), contraindication to salbutamol, alcohol
or drug abuse, hypersensitivity to any components of the study drugs, participation in a
clinical trial < 1 month, significant renal impairment (Australia)
Interventions ORA group: atosiban. Bolus dose 6.75 mg (i.v.) followed by infusion at 300 µg/min
for 3 h then 100 µg/min up to 48 h. A placebo i.v. infusion of 5% dextrose was given
separately but simultaneously
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French/Australian 2001 (Continued)
Control group: salbutamol. Bolus injection of 0.9 mL NaCl followed by i.v. infusion of
5% dextrose. Separately but simultaneously salbutamol was given as an i.v. infusion in
5% dextrose at 5-25 µg/min (France) or 2.5-45 µg/min (Australia)
Both infusions were continued for 48 h.
Outcomes Primary goals were the safety and effectiveness of atosiban versus terbutaline as tocolytic
agents, assessed as women undelivered after 48 h and 7 days and maternal side effects
Secondary outcomes: contraction rate with time, gestational age at delivery, proportion
of women re-treated with study medication, proportion of infants born at differing
gestational age and number of infants requiring neonatal intensive care
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation lists
for each center was used to allocate women
to study treatment and women were strat-
ified by gestational age at enrolment.”
The review authors consider this approach
low risk.
Allocation concealment (selection bias) Low risk Prepared by Ferring Pharmaceuticals: com-
puter-generated randomisation stratified
by GA and centre, supplied to pharmacists
at each centre in pre-randomised boxes la-
belled with country code and case number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Through the use of a double-blind, dou-
ble-dummy technique, the utmost effort
was made to keep the study blinded. […]
the somewhat obvious side effects profile
of terbutaline may have compromised the
blinding.”
The review authors consider this approach
low risk.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Probably low risk as double-placebo tech-
nique was used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman in the salbutamol group was lost
to follow-up.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
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Goodwin 1994
Methods Multicentre, randomised, placebo-controlled trial.
Participants 120 women with preterm labour defined as number of contractions: ≥ 6/h (4 centres)
and > 4/last 30 min (1 centre), cervical dilatation and effacement: < 2 cm/50% (1 centre)
, ≤ 3 cm/50% (1 centre), ≤ 3 cm (1 centre), < 2 cm/80% (1 centre), unspecified (1
centre) at gestational age: 20-35 (1 centre), 20-34 (1 centre), 25-35 (1 centre), < 35 (1
centre) and 28-37 (1 centre) weeks with no change in cervix during ≥ 1 h
Exclusion criteria: prior study participation, ruptured membranes, amnionitis, con-
traindications to tocolysis, abruptio placenta, fetal distress, lethal fetal anomaly, fetal
death
Interventions ORA group: atosiban. Infusion rate 300 µg/min for 2 h (i.v.)
Control group: placebo. Infusion for 2 h (i.v.).
Outcomes Percentage change in contractions per h.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomisation
schedule with a block size of four.”
The review authors consider this approach
low risk.
Allocation concealment (selection bias) Low risk “the pharmacist would open the sequen-
tially numbered, opaque, sealed envelope.”
The review authors consider this approach
low risk.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The personnel preparing the drug was not
involved in patient care, and the treat-
ment allocation was not revealed to per-
sonnel involved with patient care. The
study was placebo-controlled. The review
authors consider this approach low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Intervention was blinded and risk of out-
come assessment bias canbe considered low
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 women in each treatment group were ex-
cluded from analyses.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
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Goodwin 1994 (Continued)
Other bias High risk The average gestational age in the atosiban
group was lower than that of the placebo.
The authors consider this to be high risk of
introducing bias
Centres had different inclusion criteria
which may introduce bias
Goodwin 1996
Methods Multicentre, randomised trial.
Participants 302 women with preterm labour (1-3 cm dilatation and 75% effacement or 3 cm dilata-
tion and 50% effacement at contraction rate 4/30 min, with progressive cervical change,
defined as 1 cm change or > 50% change in effacement) at 20-35 weeks’ gestation
Exclusion criteria: PROM , prior enrolment in the study, cervix dilation > 3 cm, multiple
gestation, blood pressure of 150/100 mmHg or pre-eclampsia, > 1 prior preterm labour,
temperature > 100ºF, urinary tract infection, trauma, fetal anomaly, retained intrauterine
device, hydramniosis, alcohol or drug abuse, prior tocolytic therapy within 72 h, serious
maternal disease, contraindication to tocolysis
Interventions ORA group: atosiban. 4 dosing regimens; I. 6.5 mg bolus dose of atosiban followed by
i.v. infusion of atosiban at 300 µg/min; II. Placebo bolus dose followed by i.v. infusion
of atosiban at 300 µg/min; III. 2 mg bolus dose of atosiban followed by i.v. infusion of
atosiban at 100 µg/min; IV. 0.6 mg bolus dose of atosiban followed by i.v. infusion of
atosiban at 30 µg/min. Treatment was continued for 6 h after last contraction up to 12
h
Control group: ritodrine. Infusion (i.v.) started at 0.1 mg/min and increased up to 0.35
mg/min or until cessation of contractions
Outcomes To establish the minimal effective dose regimen for atosiban in the initial treatment of
preterm labour and to evaluate the effect of a bolus atosiban
Notes Treatment was discontinued if: cervical dilation ≥ 1 cm, uterine contractions > 6 h, or
severe adverse side effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were assigned to one of five arms according
to a computer-generated randomisation schedule […].
The randomisation was stratified by institution.” The
review authors consider this approach low risk
Allocation concealment (selection bias) Low risk “assignments were maintained in sealed, opaque en-
velopes in the pharmacy at each site.”
The review authors consider this approach low risk.
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Goodwin 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “double-blind (between atosiban arms).”
Participants and personnel were not blinded to type of
treatment, only dosage of atosiban. The review authors
consider this approach high risk
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The non-blinded approach of treatment allocation sug-
gests non-blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No post-randomisation exclusions or losses at follow-
up reported
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Unclear risk The distribution of women to the different treatments
was unequal in regards to gestational age; fewer women
at 25-29 weeks’ gestation were enrolled in the ritodrine
arm which may introduce bias
Atosiban therapy was limited to 12 h whereas ritodrine
was unlimited which may introduce bias
Kashanian 2005
Methods Randomised controlled trial.
Participants 80 women with preterm labour, defined by contraction frequency 4/20 min or 8/60 min
and cervical dilation ≥ 1 cm and cervical effacement≥ 50% at 26 to 34 weeks’ gestation
(confirmed by definite last menstrual period and first trimester sonography). Multiple
pregnancy included
Exclusion criteria: PROM, vaginal bleeding, fetal death or fetal distress, IUGR, history of
trauma, cervical dilatation > 3 cm, maternal systemic disorders, known uterine anomaly
(by history or sonography), blood pressure < 90/50 mmHg.
Interventions ORA group: atosiban. Administered at 300 µg/min (i.v.) up to 12 h, or up to 6 h after
the contractions ceased
Control group: nifedipine. Initially 10 mg sublingually every 20 min for 4 doses. If
contractions inhibited, nifedipine continued orally 20 mg every 6 h for 24 h, and then
every 8 h for 24 h
Outcomes Maternal: delivery within 7 days; delivery within 48 h; maternal adverse drug reactions
No neonatal outcomes.
Notes Drug side effect distributive - some women experienced 2-3 side effects
Risk of bias
Bias Authors’ judgement Support for judgement
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Kashanian 2005 (Continued)
Random sequence generation (selection
bias)
Low risk “4-part, ABCD, block-random allocation was used.”
The review authors consider this approach low risk.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “ because the two drugs are completely different in shape
and form a blind study was not an option.”
Unblinded study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “All vaginal examinations and drug administration were
performed by the same investigator.”
Because of the unblinded nature of this study, it is likely
that outcome assessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No post-randomisation exclusions or losses at follow-up
reported
Selective reporting (reporting bias) Unclear risk Minimal neonatal outcome data reported.
Other bias Unclear risk Not able to determine.
Lin 2009
Methods Randomised, unblinded, controlled trial.
Participants 45 women with spontaneous preterm labour (duration of contractions 30 sec or more
at a rate of ≥ 4/min, cervical dilation of 0-3 cm and cervical effacement of ≥ 50%) at
24-33 weeks’ gestation
Exclusion criteria: multiple pregnancy (> twins), ruptured membranes, major vaginal
bleeding (continuous vaginal bleeding or bleeding volume > 100 mL); pre-eclampsia or
hypertension (blood pressure > 140/90 mmHg), temperature > 37.5°C, urinary tract
infection, fetal placental/amniotic abnormalities (e.g. major fetal anomalies, chorioam-
nionitis, polyhydramnios, fetal growth restriction or placenta praevia), serious maternal
disease (e.g. cardiovascular disease, hyperthyroidism, diabetes, pheochromocytoma or
asthma), contraindications to the use of betamimetics, alcohol or drug abuse, exposure
to NSAID tocolytic drugs < 12 hr of study entry, hypersensitivity to any component of
the study drugs and participation in an clinical trial < 1 month
Interventions ORA group: atosiban. A bolus dose (6.75 mg in 0.9 mL saline, i.v.) followed by infusion
at 18 mg/h (300 µg/min) for 3 h and then 6 mg/h (100 µg/min) for 15 h
Control group: ritodrine. Initial infusion of 20 mL/h (66.6 µg/min, i.v.) and increased
by 10 mL/h (33.3 µg/min) every 10-30 min, until the desirable uterine response (uterine
quiescence < 4 contractions/h) was obtained
Both atosiban and ritodrine was administered for maximum 18 h during first treatment
Outcomes Compare the tocolytic efficacy and safety profile of atosiban and ritodrine in an Asian
population. Monitoring of adverse events, particularly tachycardia
Primary endpoint: to compare the proportion of women who did not deliver and did
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Lin 2009 (Continued)
not receive an alternative tocolytic therapy after 7 days of treatment
Secondary endpoints: proportion of women who did not deliver after 2 days of treatment
and did not require an alternative tocolytic
Other parameter measured: frequency of uterine contractions, gestational age at delivery,
birthweight, maternal and fetal deaths and early drug discontinuation with/without
alternative tocolytic treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Women were computer-randomized into
two groups.”
Unable to determine how randomisation
was performed.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk There was no blinding of outcome assess-
ment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women were included in the intention-
to-treat analysis.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
Moutquin 2000
Methods Multicentre, randomised, placebo-controlled trial.
Participants 252 women with preterm labour defined as contractions≥ 30 sec in duration and≥ 4/30
min, cervical dilation 0-3 cm (nullipara) or 1-3 cm (primi- or multipara) and effacement
≥ 50% at 23 and 33 completed weeks’ gestation
Exclusion criteria: multiple pregnancy (≥ triplets), ruptured membranes, major vaginal
bleeding, use of NSAID’s within 12 h prior to study, severe pre-eclampsia or hyperten-
sion, temperature > 37.5ºC, urinary tract infection, fetal or placental abnormalities (e.
g. chorioamniotic, abruptio placenta, placenta praevia, IUGR, fetal distress/death, ma-
jor congenital anomaly, hydramnios, incompetent cervix), serious maternal disease (e.g.
cardiovascular disease, hyperthyroidism, diabetes mellitus, pheochromocytoma, asthma)
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Moutquin 2000 (Continued)
, contraindications to tocolysis, alcohol or drug abuse, hypersensitivity to components
of study drugs, previous study participation < 1 month
Interventions ORA group: atosiban. Bolus dose 6.75 mg (i.v.) followed by infusion of 300 µg/min for
3 h, then 100 µg/min up to 18 h. A placebo infusion of 5% dextrose (i.v.) was given
separately but simultaneously
Control group: ritodrine. Bolus placebo dose was administered followed by an i.v. 5%
dextrose infusion. Separately but simultaneously ritodrine was given as an i.v. infusion
in 5% dextrose at 0.10-0.35 mg/min, by increments every 10 minutes as required until
contractions ceased
Both infusions were continued for 18 h.
Outcomes Primary outcomes: effectiveness and safety of atosiban versus ritodrine, assessed aswomen
who remained undelivered at 48 h and 7 days and maternal side effects and neonatal
morbidity
Secondary outcomes: change in uterine contraction rate over time, gestational age at
delivery and number of infants requiring neonatal intensive care
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated block randomisa-
tion […] stratified by gestational age.”
The authors consider this approach low
risk.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This study was placebo controlled. The au-
thors consider this technique to be low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It is likely that the placebo-controlled ap-
proach is low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women were included in analyses.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
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Nonnenmacher 2009
Methods Prospective, randomised, controlled trial.
Participants 105 women > 18 years at 24-33 completed weeks’ gestation, ≥ 4 contractions every 30
min lasting ≥ 30 seconds, opening of the uterine orifice and/or an ultrasound-verified
residual cervix < 25 mm for single pregnancies and < 20 mm for multiple pregnancies
Exclusion criteria: heavy vaginal bleeding, severe pre-eclampsia, extreme high blood
pressure, temperature > 37.5ºC, fetal or placental abnormalities (e.g. chorioamnionitis,
premature separation of the placenta, delayed intrauterine growth, fetus in a stressed
state, intrauterine fetal death, severe dysplasia, severematernal health problems, e.g. heart
or circulatory disease, hyperthyroidism, alcohol or drug abuse and hypersensitivity to
any component of the study drug
Interventions ORA group: atosiban. Bolus injection of 6.75 mg, then 18 mg/h for 3 h (i.v.) and
thereafter 6 mg/h up to 45 h
Control group: fenoterol. 2 x 0.5 mg ampoules in 50 mL NaCl solution by pulsatile
administration with an allowance of 1000 IU heparin. Initial dose 1.5 µg/min or 2.0 µg/
min; if no improvement was seen after 30 min, the dose was incrementally increased to
3.5 µg/min. At cessation of labour the dose was reduced within 3-6 h to 1 µg/min and
0.5 µg/min
Outcomes Percentage of women who experienced a prolongation of pregnancy
Primary endpoints: proportion of women who experienced a prolongation of pregnancy
of 48 h and 7 days
Secondary endpoints: time to reduction of contractions to ≤ 1/30min, maternal and
fetal side effects and neonatal outcomes
Notes Publication has been translated to English by the Cochrane Pregnancy and Childbirth
Group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unable to determine how randomisation
was performed.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unlikely.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised were included in
analysis.
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Nonnenmacher 2009 (Continued)
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
Richter 2005
Methods Prospective, randomised trial.
Participants 40 women with preterm labour (contraction duration > 30 sec, rate > 4/30 min, cervical
effacement > 50%, cervical dilation of 0-3 cm (nullipara) or 1-3 cm (primi- and multi-
para) at 18-24 weeks’ gestation
Exclusion criteria: serious maternal disease, temperatures > 37.5ºC, PROM with an-
hydraemia, major vaginal bleeding, major congenital syndrome, growth restriction,
chorioamnionitis, polyhydramnios, intrauterine fetal death, multiple pregnancy (≥
triplets), alcohol and drug abuse, hypersensitivity to atosiban and its components, pre-
vious study participation within the last 6 months
Interventions ORA group: atosiban. Administered in accordance with standard protocol: bolus in-
jection (i.v., 6.75 mg in 0.9 mL NaCl), followed by 300 µg/min in 0.9% NaCl 3 h.
Thereafter 100 µg/min (i.v.) for 45 h
Control group: saline solution. Administered as continuous infusion (i.v.)
Both groups: antibiotic treatment was administered if vaginal infection was evident. If
needed, vaginal pH was corrected. If inhibition of uterine contractions was achieved but
with persistent cervical dilatation, women were offered cerclage and/or total occlusion
of the cervix
Outcomes To assess the effectiveness and safety of atosiban. Effectiveness was assessed by: 1.Measur-
ing the time to the onset of the tocolytic effect; 2. The interval until uterine contractions
completely ceased; 3. The duration of complete absence of uterine contractions; and 4.
The average prolongation of pregnancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A prospective, randomised design was chosen.”
Unable to determine how randomisation was per-
formed.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Different administration regimens were sued for the
atosiban and control groups: “In the treatment group
atosibanwas administered as follows in accordance with
the standard protocol: initial i.v. bolus injection (ap-
proximately 1 min, 6.75 mg of atosiban in 0.9 mL of
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sodiumchloride), followed immediately by high-dosage
saturation infusion with atosiban in 0.9% sodium chlo-
ride for 3 h (300 µg/min) followed by a low-dosage con-
tinuous infusion with atosiban in 0.9% sodium chlo-
ride for up to 45 h (100 µg/min). In the control group
saline solution was continuously given via i.v. infusion.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised were included in analysis.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
Romero 2000
Methods Randomised, placebo-controlled trial.
Participants 531 women with preterm labour assessed by ≥ 4 contractions over 30 min of ≥ 40 sec
and cervical criteria: dilation 1-3 cm/effacement > 50% or 1 cm increase in dilation or
50% increase in effacement
Exclusion criteria: fetal or placental abnormalities, fetal distress, chorioamnionitis, ma-
ternal indications for delivery, urinary tract infection, substance abuse
Interventions ORA group: atosiban. Bolus dose of 6.75 mg followed by an infusion of 300 µg/min for
3 h, then 100 µg/min up to 45 h
Control group: bolus dose of placebo followed by an infusion of placebo up to 48 h
Maintenance therapy with subcutaneous placebo or atosiban until 36 weeks
Outcomes Primary end-point: time to delivery or therapeutic failure (progression of labour neces-
sitating an alternate tocolytic agent)
Secondary end-points: proportion of women successfully treated up to 24 h, 48 h, and
7 days, and maternal-fetal side effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomisation sched-
ule according to permuted blocks of 6.”
The authors consider the approach low risk.
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Romero 2000 (Continued)
Allocation concealment (selection bias) Low risk “Prenumbered randomisation envelopes pro-
vided to the pharmacist at each study site cen-
ter were to be opened in sequential order.”
The authors consider this approach low risk.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Investigators, study personnel and monitors
remained blinded throughout the study.”
The trial was also placebo controlled. The au-
thors consider this approach low risk
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Investigators, study personnel and monitors
remained blinded throughout the study.”
The authors consider this approach low risk.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15 women in each treatment group were ex-
cluded post-randomisation
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias High risk “The mean gestational age on admission was
statistically significantly greater for the placebo
group than for the atosiban group, and there
were nearly twice as many atosiban-treated pa-
tients enrolled at <26 weeks’ gestation. Among
patients enrolled at <26 weeks, the percent-
age who had advanced cervical status (modified
Bishop score≥4)was greater for those allocated
to the atosiban group.” The authors consider
these factors to be high risk
Salim 2012
Methods Randomised controlled trial between January 2008 and December 2011
Participants 149 women in preterm labour with intact membranes diagnosed between 24 to 33+6
weeks’ gestation were included in the study. Preterm labour was identified as > 4 con-
tractions lasting > 30 seconds within 30 min and confirmed by external topography,
50% cervical effacement and < 4 cm dilation (nullipara) or 1-4 cm dilation (multipara)
. Singletons and twins included
Exclusion criteria: rupture of membranes, vaginal bleeding resulting from placenta prae-
via or placental abruption, temperature > 38ºC, severe pre-eclampsia, maternal cardio-
vascular or liver diseases, systolic blood pressure < 90 mmHg, known uterine malforma-
tion, IUGR < 5th percentile, non reassuring fetal status, antepartum diagnosis of major
fetal malformations, multiple gestations (≥ triplets) or fetal death
Interventions ORA group: atosiban. Given as a loading dose of 6.75 mg in 0.9% sodium chloride
solution (i.v.), followed by i.v. infusion of 300 µg/min in 0.9% sodium chloride solution
for the first 3 h and then 100 µg/min for another 45 hours
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Salim 2012 (Continued)
Control group: nifedipine. Given as a loading dose of 20 mg orally followed by 2 x 20
mg, 20-30 minutes apart “as needed”. Maintenance was started after 6 h with 20-40 mg
4 times daily for 48 h
Both groups: rescue treatment with the alternative study drug was initiated if labour
progressed between 1-48 h or if adverse reactions occurred. If both drugs failed and
gestational age was ≤ 28 weeks, indomethacin treatment was initiated. Drug treatment
continued for 48 h. Corticosteroids and group B strep prophylactic treatment were
administered according to standard protocol
Outcomes Tocolytic efficacy and tolerability profile by pregnancy prolongation for 48 h without
the need for an alternate tocolytic, pregnancy prolongation for 7 days without the need
for an alternate tocolytic, pregnancy prolongation for 48 h and 7 days, preterm birth,
interval between enrolment and delivery, maternal adverse drug effects, gestational age
at delivery, neonatal morbidity and mortality related to prematurity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization of the groups was per-
formed in blocks of 10 using a computer
randomisation sequence generation pro-
gram.”
Probably done.
Allocation concealment (selection bias) Low risk “…the randomisation results were kept in
the labor anddeliveryward in a closed study
box. The sequence was concealed until in-
tervention was assigned, i.e., just before ad-
ministrating the tocolytic drug.”
Allocation concealment was done.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because the study drugs were adminis-
tered by different roots, blinding of partici-
pants or care providers was not performed.
”
Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2women in each groupwere excluded from
analysis.
Selective reporting (reporting bias) Low risk The trial was registered in a publicly avail-
able trials registry and all outcomes were
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reported as expected
Other bias Low risk None apparent.
Shim 2006
Methods Multicentre, randomised, placebo-controlled trial.
Participants 128 women presenting with uterine contractions (≥ 30 sec in duration, rate 4/30 min
or more, confirmed by minimum 1 h tocography), cervical dilation 0-3 cm and cervical
effacement of≥ 50%. Gestational age between 24-33+6 weeks (confirmed by ultrasound
< 20 weeks and/or reliable menstrual dates)
Exclusion criteria: multiple pregnancy, ruptured membranes, major vaginal bleeding, se-
vere pre-eclampsia or hypertension, temperature > 37.5ºC, urinary tract infection, fetal/
placental/amniotic fluid abnormalities (major fetal anomalies, chorioamnionitis, poly-
hydramnios, fetal growth restriction, placental previa), serious maternal disease (cardio-
vascular disease, hyperthyroidism, diabetes, pheochromocytoma, asthma), contraindica-
tion to beta-agonists, alcohol or drug abuse, use of NSAID tocolytic drugs within 12 h
prior to study entry, hypersensitivity to components of the study drugs and participation
in clinical trials ≤ 1 month
Interventions ORA group: atosiban. Administered as a bolus dose (6.75 mg in 0.9 mL NaCl, i.v.),
followed by 300 µg/min in 5% dextrose infusion for 3 h and 100 mg/min in 5% dextrose
up to 48 h. Simultaneous placebo i.v. infusion of 5% dextrose was given, corresponding
to ritodrine treatment
Control group: ritodrine. Administered in 5% dextrose (i.v.) at a rate of 0.1-0.35 mg/
min up to 48 h, with 0.05 mg/min increments every 10 minutes as required, or until
contractions ceased. After 12 h of continuous infusion at the effective dose or when
contractions ceased, the dose was decreased every 30min by 0.05-mg/min. Simultaneous
injection of placebo (i.v. bolus dose of 0.9 mL sodium chloride) followed by i.v. infusion
of 5% dextrose was administered, corresponding to atosiban treatment
Both groups: corticosteroids were administered as required.
Outcomes Comparison of tocolytic efficacy and safety of atosiban and ritodrine in the treatment
of preterm labour in Korean women
Primary end-points: proportion of women who were not delivered and did not need an
alternative tocolytic therapy after 48 h and 7 days. Days to delivery, therapeutic failure
maternal adverse events and neonatal morbidity were also assessed
Secondary end-points: frequency of contractions with time, gestational age at birth,
birthweight, duration of stay in neonatal intensive care unit, duration of ventilatory care,
concomitant diseases in neonate and neonatal death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Shim 2006 (Continued)
Random sequence generation (selection
bias)
Low risk “Two computer-generated randomisation
lists were prepared and issued by.”
The authors consider the approach to be
low risk.
Allocation concealment (selection bias) Unclear risk “…[the study drugs] were supplied in ran-
domised boxes labelledwith the centre code
and case number.”
Allocation concealment is unclear.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All infusates were […] administered by a
piggy-back method.”
The authors consider thismethod to be low
risk.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The authors consider the risk to be low be-
cause of the administration method
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women in the ritodrine group were lost
to follow-up.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Unclear risk 8 women in the atosiban group and 1
woman in the ritodrine group were given
tocolysis prior to randomisation, with a 6
h wash-out period between dosing
Thornton 2009
Methods Randomised, double-blind, placebo-controlled trial.
Participants 163 women with uterine contractions (duration≥ 30 sec, rate≥ 6/30min) at gestational
age between 34 + 0 and 35 + 6 inclusive. Cervical length ≤ 15 mm (by transvaginal
ultrasound) and cervical dilatation > 1 cm and 4 cm (by vaginal examination)
Exclusion criteria: contraindications to tocolysis, diabetes mellitus (existing or gesta-
tional), eclampsia or severe pre-eclampsia, previous major uterine surgery, congenital
uterine abnormality, large leiomyomas, retained intrauterine contraceptive device, rup-
turedmembranes, placenta praevia, oligohydramnios or polyhydramnios (amniotic fluid
index < 7.2 cm or > 27.8 cm), fetal weight outside 2 standard deviations for gestational
age (based on ultrasound), cervical cerclage, multiple pregnancy, suspected abnormal
karyotype ormajormalformations, abnormal fetal heart rate consistent with fetal distress,
suspected or history of thromboembolic disorders, hypo coagulability or coagulation
deficiency, known or suspected haemoglobinopathies, known or suspected or history
(last 12 months) of alcohol or drug abuse, treatment with anticoagulants or fibrinolytics
before screening with betamimetics, atosiban, or progesterone within 7 days before ran-
domisation or with nifedipine, prostaglandin synthase inhibitors, magnesium sulphate,
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or any investigational drug during the current pregnancy
Interventions ORA group: barusiban. Administered as a single bolus dose (1 mL, i.v.) of 1 of the
following treatments: 0.3 mg (n = 32), 1 mg (n = 31), 3 mg (n = 32) or 10 mg (n = 36)
barusiban
Control group: placebo. Administered as a single bolus dose (1 mL, i.v.) of acetate buffer
Outcomes Primary end-point: percentage of women who did not deliver within 48 h
Secondary end-points: percentage of women who did not deliver within 12 and 48 h,
time to delivery, percentage change from baseline in number of uterine contractions at
each h during the initial 12 h and at each assessment time point during the 12-48 h
after dosing, incidence and severity of adverse maternal, fetal and neonatal outcomes,
time from delivery to expulsion of the placenta, incidence and severity of postpartum
haemorrhage, change in haemoglobin level from screening to 24-48 h after delivery,
time from delivery to established lactation, percentage of mothers lactating 5 days after
delivery, pharmacokinetic parameters of barusiban; plasma concentration-time curve
AUC, Cmax and t1/2.
Notes For this review, outcomes for all barusiban dosing regimens have been combined for the
comparison between barusiban and placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was computer generated
for each participating site by an indepen-
dent statistician [...] At each site, randomi-
sation took place after the screening assess-
ment and before any investigational medic-
inal product was administered.”
The authors consider this approach to be
low risk.
Allocation concealment (selection bias) Low risk “Each site was given a coded envelope for
randomization.”
The authors consider this approach low
risk.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All participants and study personnel, in-
cluding those assessing the outcomes, were
blinded to treatment assignment for the du-
ration of the study.”
The authors consider this approach low
risk.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As stated above: “...including those assess-
ing the outcomes, were blinded [...] for the
duration of the study.”
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The authors consider this approach low
risk.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women were included in analysis.
Selective reporting (reporting bias) Low risk All outcomes were reported as expected.
Other bias Low risk None apparent.
GA: gestational age
h: hour
i.m.: intramuscular
i.v.: intravenous
IUGR: intrauterine growth restriction
mg: milligram
min: minutes
NaCl: saline
NSAID: nonsteroidal anti-inflammatory drug
ORA: oxytocin receptor antagonists
PROM: premature rupture of membranes
µg: microgram
sec: seconds
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Omari 2006 Quasi-random allocation.
de Heus 2008 A prospective randomised trial in term labour comparing the effects of atosiban with ritodrine for acute tocolysis
or intrauterine resuscitation
Gagnon 1998 Trial of maintenance tocolysis.
Husslein 2006 Comparison of 2 similar atosiban doses scheme where depending upon the criteria the atosiban was given early or
standard. No comparison between 2 different tocolytic agents or 2 different doses scheme was performed. Data
are from the treasure study group containing the treasure study
Husslein 2007 The control group was described as “usual care” and “included treatment with betamimetics, calcium channel
blockers, magnesium sulphate, or any other tocolytic, alone or in combination, and/or bedrest”
Poppiti 2009 The trial compares atosiban immediately versus atosiban + 2 weeks later repeat course atosiban treatment for
women in preterm labour
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Steinwall 2005 Study concerning an vasopressin receptor antagonist for inhibiting preterm labour
Valenzuela 1997 Trial was to measure oestradiol levels before and after treatment with atosiban
Valenzuela 2000 Trial of maintenance tocolysis which is not within the scope of this review
Characteristics of studies awaiting assessment [ordered by study ID]
de Heus 2009
Methods Randomised controlled trial of fetal effects of tocolytic treatment
Participants Women between 25-33 weeks’ gestation with no previous tocolytic treatment
Exclusion criteria: multiple pregnancy, severe vaginal bleeding, fetal congenital anomaly and signs of intrauterine
infection
Interventions ORA group: atosiban. Single i.v. dose 6.75 mg in 0.9 mL NaCl, followed by i.v. infusion 300 µg/min in 5% dextrose
for 3 h, then 100 µg/min in 5% dextrose up to 48 h
Control group: nifedipine. 4 oral 10 mg capsules given 15 min apart, thereafter 30 mg slow-release 8 h apart up to
48 h
Both groups: 2 doses of betamethasone 12 mg 24 h apart.
Outcomes Primary outcomes: effects of tocolysis on fetal heart rate and its variation. Secondary endpoints: effects on fetal
movement and blood flow parameters (umbilical artery and middle cerebral artery)
Notes No data are available for the parameters of interest in this review - awaiting response from authors request for
additional data
Lenzen 2012
Methods A randomised, prospective multicentre study.
Participants Women between 24-33 completed weeks’ gestation.
Exclusion criteria: multiple pregnancy, PPROM, vaginal bleeding
Interventions ORA group: atosiban. Standard dose as per product information
Control group: fenoterol. 2 µg/min (i.v.) followed by 1.5-3 µg/min
Outcomes Primary outcomes: the rate of the mother’s side effects and acceptance of treatment
Secondary outcomes: efficacy of tocolysis to prolong pregnancy for at least 48 h
Notes No data are available for the parameters of interest in this review - awaiting response from authors to request for
additional data
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Methods Randomised trial.
Participants 62 women with singleton pregnancies and preterm labour at 26-33 weeks’ gestation with intact membranes were
enrolled. Preterm labour was defined as > 6 contractions in 60 min (confirmed by external tocography) and cervical
dilatation and/or effacement
Exclusion criteria: cervical dilatation ≥ 3 cm, vaginal bleeding, pre-eclampsia or gestational hypertension, severe
maternal diseases, intrauterine growth restriction, oligohydramnios, impaired utero-placental blood flow, or clinical
suspicion of chorioamnionitis (white cells ≥ 15,000/mm3 µL, C-reactive protein ≥1 mg/dL).
Interventions ORA group: atosiban. Bolus-dose 6.75 mg (i.v.) followed by infusion of 37.5 mg in 250 mL saline at 24 mL/h for 3
h and then 8 mL/h for 48 h
Control group: ritodrine. 150 mg in 500 mL saline infused at 100-350 µg/min until uterine contractions ceased or
until maternal heart rate reached 140 bpm
Both groups: corticosteroids (betamethasone, 12 mg 24 h apart, i.m.) were given to both groups
Outcomes To compare the fetal cardiovascular effects of ritodrine and atosiban treatment by analysing the computerised nonstress
test
Notes Antenatal steroids administered at the same time, 12 mg i.m. 24 h apart, 2 doses
Renzo 2003
Methods Clinical trial comparing atosiban with ritodrine.
Participants 43 women with preterm labour (defined as uterine contractions > 30 sec in duration at a rate of > 4/30 min, cervical
dilatation 0-3 cm (nullipara) or 1-3 cm (primi- or multipara) and effacement > 50%) between 23-33 completed
weeks’ gestation
Interventions ORA group: atosiban. Bolus dose 6.75 mg in 0.9 mL NaCl followed by 300 µg/min in 5% dextrose (i.v.) for 3 h,
then 100 µg/min in 5% dextrose up to 45 h
Control group: ritodrine. 0.1 up to 0.35 mg/min in 5% NaCl (i.v.) in increments every 10 min as required or until
contractions ceased
Outcomes Tocolytic effectiveness assessed as total number of women who had not delivered at 48 h and 7 days after starting
treatment. Safety assessed as maternal side effects
Notes No data are available for the parameters of interest in this review - awaiting response from authors to additional data
request
Snidow 2013
Methods A multicentre, randomised, double-blind, placebo-controlled phase 2 trial
Participants Women with singleton pregnancy between 30-35 weeks’ gestation with spontaneous preterm labour defined as
contraction rate ≥ 4/30 min or ≥ 6/h and cervical dilatation between 1-4 cm
Interventions Women were randomised to receive 48 h treatment with i.v. retosiban or placebo
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Snidow 2013 (Continued)
Outcomes To determine the efficacy and safety of retosiban given to women in spontaneous preterm labour
Notes No data are available for the parameters of interest in this review - awaiting response from authors to request for
additional data
bpm: beats per minute
h: hour
i.v.: intravenous
min: minutes
ORA: oxytocin receptor antagonists
PPROM: preterm premature rupture of membranes
Characteristics of ongoing studies [ordered by study ID]
APOSTEL III
Trial name or title APOSTEL III
Methods Randomised controlled trial.
Participants Women≥ 18 years old with a singleton pregnancy with a gestational age of 25-34 weeks in threatened preterm
labour, as defined by:
uterine contractions, ≥ 3 contractions per 30 minutes, and 1 of the following:
1. cervical length of ≤ 10 mm or;
2. cervical length of 11-30 mm and a positive Fibronectin test or;
3. ruptured amniotic membranes.
Interventions ORA group: atosiban. Bolus dose 6.75 mg (i.v.), followed by 18 mg/h for 3 h (i.v.) then 6 mg/h for 45 h
Control group: nifedipine. Bolus dose of 20 mg orally, followed by 20 mg every 6 h for 47 h
Outcomes Primary outcome: composite poor neonatal outcome, includingbronchopulmonary dysplasia (BPD), periven-
tricular leucomalacia (PVL) > grade 1, intracerebral haemorrhage > grade 2, necrotising enterocolitis (NEC)
> stage 1, proven sepsis and in-hospital death
Starting date 21 June 2011
Contact information Dr K Heida
Dept. of Obstetrics UMC Utrecht
Utrecht
The Netherlands
Notes NTR:2947
h: hour
i.v.: intravenous
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D A T A A N D A N A L Y S E S
Comparison 1. Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Birth less than 48 hours after
trial entry
2 152 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.15, 7.43]
1.1 Atosiban versus placebo 2 152 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.15, 7.43]
2 Perinatal mortality (stillbirth and
neonatal death up to 28 days)
2 729 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [0.79, 6.38]
2.1 Atosiban versus placebo 1 566 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [0.79, 6.38]
2.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Stillbirth 4 883 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.04, 4.47]
3.1 Atosiban versus placebo 3 720 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.04, 4.47]
3.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Neonatal death 2 729 Risk Ratio (M-H, Fixed, 95% CI) 4.09 [0.88, 19.07]
4.1 Atosiban versus placebo 1 566 Risk Ratio (M-H, Fixed, 95% CI) 4.09 [0.88, 19.07]
4.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Infant death (up to 12 months) 1 566 Risk Ratio (M-H, Fixed, 95% CI) 6.13 [1.38, 27.13]
5.1 Atosiban versus placebo 1 566 Risk Ratio (M-H, Fixed, 95% CI) 6.13 [1.38, 27.13]
6 Maternal death 1 501 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 Atosiban versus placebo 1 501 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Maternal adverse effects 2 613 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.02, 2.32]
7.1 Atosiban versus placebo 2 613 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.02, 2.32]
8 Maternal adverse effects
requiring cessation of treatment
3 776 Risk Ratio (M-H, Fixed, 95% CI) 4.02 [2.05, 7.85]
8.1 Atosiban versus placebo 2 613 Risk Ratio (M-H, Fixed, 95% CI) 4.02 [2.05, 7.85]
8.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Caesarean section 1 112 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.73, 3.61]
9.1 Atosiban versus placebo 1 112 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.73, 3.61]
10 Preterm birth (before
completion of 37 weeks of
gestation)
2 664 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.97, 1.32]
10.1 Atosiban versus placebo 1 501 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.99, 1.37]
10.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.59, 1.51]
11 Extremely preterm birth
(before completion of 28 weeks
of gestation)
1 501 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [1.02, 9.51]
11.1 Atosiban versus placebo 1 501 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [1.02, 9.51]
12 Gestational age (weeks) 1 112 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.57, 0.57]
12.1 Atosiban versus placebo 1 112 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.57, 0.57]
13 Birthweight (grams) 2 676 Mean Difference (IV, Fixed, 95% CI) -138.86 [-250.53, -
27.18]
13.1 Atosiban versus placebo 2 676 Mean Difference (IV, Fixed, 95% CI) -138.86 [-250.53, -
27.18]
14 Respiratory distress syndrome 3 836 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.96, 1.82]
14.1 Atosiban versus placebo 2 673 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.93, 1.77]
14.2 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 2.69 [0.36, 20.06]
49Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15 Intraventricular haemorrhage 1 475 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.45, 1.62]
15.1 Atosiban versus placebo 1 475 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.45, 1.62]
16 Necrotising enterocolitis 1 559 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.02, 1.76]
16.1 Atosiban versus placebo 1 559 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.02, 1.76]
17 Neonatal jaundice 1 163 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.86, 1.99]
17.1 Barusiban versus placebo 1 163 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.86, 1.99]
18 Admission to neonatal intensive
care unit
1 544 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.89, 1.34]
18.1 Atosiban versus placebo 1 544 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.89, 1.34]
Comparison 2. Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Birth less than 48 hours after
trial entry
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 ORA versus betamimetics 8 1389 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.66, 1.22]
1.2 ORA versus calcium
channel blockers
2 225 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.44, 2.73]
2 Perinatal mortality 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 ORA versus betamimetics 3 816 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.21, 1.48]
3 Very preterm birth (before
completion of 34 weeks of
gestation)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 ORA versus calcium
channel blockers
1 145 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.89, 3.23]
4 Stillbirth 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ORA versus betamimetics 4 861 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.05]
5 Neonatal death 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 ORA versus betamimetics 5 1236 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.28, 1.61]
5.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Maternal death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 ORA versus betamimetics 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Maternal adverse effects 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 ORA versus betamimetics 2 371 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.35, 0.62]
7.2 ORA versus calcium
channel blockers
2 225 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.21, 0.68]
8 Maternal adverse effects
requiring cessation of treatment
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 ORA versus betamimetics 5 1161 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.02, 0.11]
8.2 ORA versus calcium
channel blockers
1 145 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.62]
9 Caesarean section 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 ORA versus betamimetics 1 247 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.50, 1.52]
9.2 ORA versus calcium
channel blockers
1 145 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.37, 4.79]
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10 Interval between trial entry and
birth (days)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 ORA versus
betamimetics
1 80 Mean Difference (IV, Fixed, 95% CI) 22.9 [18.03, 27.77]
10.2 ORA versus calcium
channel blockers
1 145 Mean Difference (IV, Fixed, 95% CI) -5.70 [-12.36, 0.96]
11 Preterm birth (before
completion of 37 weeks of
gestation)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 ORA versus calcium
channel blockers
1 145 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.13, 2.14]
12 Extremely preterm birth
(before completion of 28 weeks
of gestation)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 ORA versus
betamimetics
1 244 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.37, 1.92]
12.2 ORA versus calcium
channel blockers
1 145 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.20, 23.11]
13 Gestational age (weeks) 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 ORA versus
betamimetics
6 1005 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.32, 0.59]
13.2 ORA versus calcium
channel blockers
1 145 Mean Difference (IV, Fixed, 95% CI) -1.20 [-2.15, -0.25]
14 Birthweight (grams) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 ORA versus
betamimetics
7 1184 Mean Difference (IV, Fixed, 95% CI) 27.16 [-55.46, 109.
77]
14.2 ORA versus calcium
channel blockers
1 178 Mean Difference (IV, Fixed, 95% CI) -82.0 [-270.78, 106.
78]
15 Apgar score less than 7 at 5
minutes
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 ORA versus
betamimetics
5 1008 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.47, 1.33]
15.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.86]
16 Respiratory distress syndrome 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 ORA versus
betamimetics
6 1280 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.70, 1.65]
16.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.54, 3.57]
17 Use of mechanical ventilation 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 ORA versus
betamimetics
1 126 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.63, 14.30]
17.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.65, 3.04]
18 Duration of mechanical
ventilation (days)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 ORA versus
betamimetics
1 32 Mean Difference (IV, Fixed, 95% CI) -1.30 [-3.82, 1.22]
19 Intraventricular haemorrhage 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 ORA versus
betamimetics
2 359 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.48, 2.58]
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19.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [0.41, 11.51]
20 Necrotising enterocolitis 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 ORA versus
betamimetics
1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.02, 3.74]
20.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 9.72 [0.53, 178.00]
21 Retinopathy of prematurity 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 2.16 [0.20, 23.43]
22 Neonatal sepsis 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 ORA versus
betamimetics
4 1109 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.56, 1.46]
22.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.12, 4.21]
23 Admission to neonatal intensive
care unit
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 ORA versus
betamimetics
5 1062 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.78, 1.04]
23.2 ORA versus calcium
channel blockers
1 179 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.17, 2.47]
24 Neonatal length of hospital stay
(days)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
24.1 ORA versus
betamimetics
1 41 Mean Difference (IV, Fixed, 95% CI) 0.10 [-5.13, 5.33]
24.2 ORA versus calcium
channel blockers
1 179 Mean Difference (IV, Fixed, 95% CI) 5.4 [-0.04, 10.84]
Analysis 1.1. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 1
Birth less than 48 hours after trial entry.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 1 Birth less than 48 hours after trial entry
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Atosiban versus placebo
Goodwin 1994 5/56 2/56 57.0 % 2.50 [ 0.51, 12.35 ]
Richter 2005 1/20 3/20 43.0 % 0.33 [ 0.04, 2.94 ]
Total (95% CI) 76 76 100.0 % 1.05 [ 0.15, 7.43 ]
Total events: 6 (ORA), 5 (Placebo)
Heterogeneity: Tau2 = 1.08; Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 2
Perinatal mortality (stillbirth and neonatal death up to 28 days).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 2 Perinatal mortality (stillbirth and neonatal death up to 28 days)
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 11/280 5/286 100.0 % 2.25 [ 0.79, 6.38 ]
Subtotal (95% CI) 280 286 100.0 % 2.25 [ 0.79, 6.38 ]
Total events: 11 (ORA), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 Barusiban versus placebo
Thornton 2009 0/131 0/32 Not estimable
Subtotal (95% CI) 131 32 Not estimable
Total events: 0 (ORA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 411 318 100.0 % 2.25 [ 0.79, 6.38 ]
Total events: 11 (ORA), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 3
Stillbirth.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 3 Stillbirth
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Atosiban versus placebo
Goodwin 1994 0/57 0/57 Not estimable
Richter 2005 0/20 5/20 38.8 % 0.09 [ 0.01, 1.54 ]
Romero 2000 3/280 3/286 61.2 % 1.02 [ 0.21, 5.02 ]
Subtotal (95% CI) 357 363 100.0 % 0.40 [ 0.04, 4.47 ]
Total events: 3 (ORA), 8 (Placebo)
Heterogeneity: Tau2 = 1.82; Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.75 (P = 0.46)
2 Barusiban versus placebo
Thornton 2009 0/131 0/32 Not estimable
Subtotal (95% CI) 131 32 Not estimable
Total events: 0 (ORA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 488 395 100.0 % 0.40 [ 0.04, 4.47 ]
Total events: 3 (ORA), 8 (Placebo)
Heterogeneity: Tau2 = 1.82; Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 4
Neonatal death.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 4 Neonatal death
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 8/280 2/286 100.0 % 4.09 [ 0.88, 19.07 ]
Subtotal (95% CI) 280 286 100.0 % 4.09 [ 0.88, 19.07 ]
Total events: 8 (ORA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
2 Barusiban versus placebo
Thornton 2009 0/131 0/32 Not estimable
Subtotal (95% CI) 131 32 Not estimable
Total events: 0 (ORA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 411 318 100.0 % 4.09 [ 0.88, 19.07 ]
Total events: 8 (ORA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 5
Infant death (up to 12 months).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 5 Infant death (up to 12 months)
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 12/280 2/286 100.0 % 6.13 [ 1.38, 27.13 ]
Total (95% CI) 280 286 100.0 % 6.13 [ 1.38, 27.13 ]
Total events: 12 (ORA), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 6
Maternal death.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 6 Maternal death
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 0/246 0/255 Not estimable
Total (95% CI) 246 255 Not estimable
Total events: 0 (ORA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.7. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 7
Maternal adverse effects.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 7 Maternal adverse effects
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 1/56 1/56 3.1 % 1.00 [ 0.06, 15.59 ]
Romero 2000 48/250 31/251 96.9 % 1.55 [ 1.03, 2.36 ]
Total (95% CI) 306 307 100.0 % 1.54 [ 1.02, 2.32 ]
Total events: 49 (ORA), 32 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 8
Maternal adverse effects requiring cessation of treatment.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 8 Maternal adverse effects requiring cessation of treatment
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 0/56 0/56 Not estimable
Romero 2000 40/250 10/251 100.0 % 4.02 [ 2.05, 7.85 ]
Subtotal (95% CI) 306 307 100.0 % 4.02 [ 2.05, 7.85 ]
Total events: 40 (ORA), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000048)
2 Barusiban versus placebo
Thornton 2009 0/131 0/32 Not estimable
Subtotal (95% CI) 131 32 Not estimable
Total events: 0 (ORA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 437 339 100.0 % 4.02 [ 2.05, 7.85 ]
Total events: 40 (ORA), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000048)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 9
Caesarean section.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 9 Caesarean section
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 13/56 8/56 100.0 % 1.63 [ 0.73, 3.61 ]
Total (95% CI) 56 56 100.0 % 1.63 [ 0.73, 3.61 ]
Total events: 13 (ORA), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 10
Preterm birth (before completion of 37 weeks of gestation).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 10 Preterm birth (before completion of 37 weeks of gestation)
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 144/246 128/255 85.7 % 1.17 [ 0.99, 1.37 ]
Subtotal (95% CI) 246 255 85.7 % 1.17 [ 0.99, 1.37 ]
Total events: 144 (ORA), 128 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
2 Barusiban versus placebo
Thornton 2009 50/131 13/32 14.3 % 0.94 [ 0.59, 1.51 ]
Subtotal (95% CI) 131 32 14.3 % 0.94 [ 0.59, 1.51 ]
Total events: 50 (ORA), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 377 287 100.0 % 1.13 [ 0.97, 1.32 ]
Total events: 194 (ORA), 141 (Placebo)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 0.72, df = 1 (P = 0.40), I2 =0.0%
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Analysis 1.11. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 11
Extremely preterm birth (before completion of 28 weeks of gestation).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 11 Extremely preterm birth (before completion of 28 weeks of gestation)
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 12/246 4/255 100.0 % 3.11 [ 1.02, 9.51 ]
Total (95% CI) 246 255 100.0 % 3.11 [ 1.02, 9.51 ]
Total events: 12 (ORA), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 12
Gestational age (weeks).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 12 Gestational age (weeks)
Study or subgroup ORA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 56 37.8 (3.5) 56 38.3 (2.1) 100.0 % -0.50 [ -1.57, 0.57 ]
Total (95% CI) 56 56 100.0 % -0.50 [ -1.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 13
Birthweight (grams).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 13 Birthweight (grams)
Study or subgroup ORA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 57 2996 (750) 57 3224 (525) 22.1 % -228.00 [ -465.66, 9.66 ]
Romero 2000 278 2336.8 (787.3) 284 2450.4 (741.6) 77.9 % -113.60 [ -240.11, 12.91 ]
Total (95% CI) 335 341 100.0 % -138.86 [ -250.53, -27.18 ]
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 14
Respiratory distress syndrome.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 14 Respiratory distress syndrome
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Goodwin 1994 3/57 0/57 0.9 % 7.00 [ 0.37, 132.51 ]
Romero 2000 63/275 53/284 96.1 % 1.23 [ 0.89, 1.70 ]
Subtotal (95% CI) 332 341 97.0 % 1.28 [ 0.93, 1.77 ]
Total events: 66 (ORA), 53 (Placebo)
Heterogeneity: Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Barusiban versus placebo
Thornton 2009 11/131 1/32 3.0 % 2.69 [ 0.36, 20.06 ]
Subtotal (95% CI) 131 32 3.0 % 2.69 [ 0.36, 20.06 ]
Total events: 11 (ORA), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 463 373 100.0 % 1.32 [ 0.96, 1.82 ]
Total events: 77 (ORA), 54 (Placebo)
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.48), I2 =0.0%
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Analysis 1.15. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 15
Intraventricular haemorrhage.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 15 Intraventricular haemorrhage
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 16/236 19/239 100.0 % 0.85 [ 0.45, 1.62 ]
Total (95% CI) 236 239 100.0 % 0.85 [ 0.45, 1.62 ]
Total events: 16 (ORA), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 16
Necrotising enterocolitis.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 16 Necrotising enterocolitis
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 1/275 5/284 100.0 % 0.21 [ 0.02, 1.76 ]
Total (95% CI) 275 284 100.0 % 0.21 [ 0.02, 1.76 ]
Total events: 1 (ORA), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 17
Neonatal jaundice.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 17 Neonatal jaundice
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Barusiban versus placebo
Thornton 2009 75/131 14/32 100.0 % 1.31 [ 0.86, 1.99 ]
Total (95% CI) 131 32 100.0 % 1.31 [ 0.86, 1.99 ]
Total events: 75 (ORA), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 18
Admission to neonatal intensive care unit.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 1 Oxytocin receptor antagonists versus placebo (by type of ORA)
Outcome: 18 Admission to neonatal intensive care unit
Study or subgroup ORA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Atosiban versus placebo
Romero 2000 112/266 107/278 100.0 % 1.09 [ 0.89, 1.34 ]
Total (95% CI) 266 278 100.0 % 1.09 [ 0.89, 1.34 ]
Total events: 112 (ORA), 107 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 1 Birth less than 48 hours after trial entry.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 1 Birth less than 48 hours after trial entry
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ORA versus betamimetics
Cabar 2008 1/40 9/40 2.4 % 0.11 [ 0.01, 0.84 ]
European 2001 17/115 22/129 28.5 % 0.87 [ 0.48, 1.55 ]
French˙x002f˙Australian 2001 8/119 6/121 9.1 % 1.36 [ 0.49, 3.79 ]
Goodwin 1996 14/244 5/58 10.0 % 0.67 [ 0.25, 1.77 ]
Lin 2009 4/23 4/22 6.1 % 0.96 [ 0.27, 3.36 ]
Moutquin 2000 19/126 16/121 25.3 % 1.14 [ 0.62, 2.11 ]
Nonnenmacher 2009 7/51 11/54 12.8 % 0.67 [ 0.28, 1.60 ]
Shim 2006 5/63 4/63 6.0 % 1.25 [ 0.35, 4.44 ]
Subtotal (95% CI) 781 608 100.0 % 0.89 [ 0.66, 1.22 ]
Total events: 75 (ORA), 77 (Other tocolytics)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.47, df = 7 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 ORA versus calcium channel blockers
Kashanian 2005 7/40 10/40 52.6 % 0.70 [ 0.30, 1.66 ]
Salim 2012 10/70 6/75 47.4 % 1.79 [ 0.68, 4.66 ]
Subtotal (95% CI) 110 115 100.0 % 1.09 [ 0.44, 2.73 ]
Total events: 17 (ORA), 16 (Other tocolytics)
Heterogeneity: Tau2 = 0.22; Chi2 = 2.04, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 2.2. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 2 Perinatal mortality.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 2 Perinatal mortality
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 3/126 7/149 57.0 % 0.51 [ 0.13, 1.92 ]
French˙x002f˙Australian 2001 1/126 4/140 33.7 % 0.28 [ 0.03, 2.45 ]
Moutquin 2000 2/143 1/132 9.2 % 1.85 [ 0.17, 20.12 ]
Subtotal (95% CI) 395 421 100.0 % 0.55 [ 0.21, 1.48 ]
Total events: 6 (ORA), 12 (Other tocolytics)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 3 Very preterm birth (before completion of 34 weeks of gestation).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 3 Very preterm birth (before completion of 34 weeks of gestation)
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus calcium channel blockers
Salim 2012 19/70 12/75 100.0 % 1.70 [ 0.89, 3.23 ]
Subtotal (95% CI) 70 75 100.0 % 1.70 [ 0.89, 3.23 ]
Total events: 19 (ORA), 12 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 4 Stillbirth.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 4 Stillbirth
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 0/126 0/149 Not estimable
French˙x002f˙Australian 2001 1/126 2/140 100.0 % 0.56 [ 0.05, 6.05 ]
Lin 2009 0/23 0/22 Not estimable
Moutquin 2000 0/143 0/132 Not estimable
Subtotal (95% CI) 418 443 100.0 % 0.56 [ 0.05, 6.05 ]
Total events: 1 (ORA), 2 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 5 Neonatal death.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 5 Neonatal death
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 3/126 7/149 50.8 % 0.51 [ 0.13, 1.92 ]
French˙x002f˙Australian 2001 0/126 2/140 18.8 % 0.22 [ 0.01, 4.58 ]
Goodwin 1996 4/238 0/56 6.4 % 2.15 [ 0.12, 39.30 ]
Moutquin 2000 2/143 1/132 8.2 % 1.85 [ 0.17, 20.12 ]
Shim 2006 1/63 2/63 15.8 % 0.50 [ 0.05, 5.38 ]
Subtotal (95% CI) 696 540 100.0 % 0.67 [ 0.28, 1.61 ]
Total events: 10 (ORA), 12 (Other tocolytics)
Heterogeneity: Chi2 = 2.05, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 ORA versus calcium channel blockers
Salim 2012 0/86 0/93 Not estimable
Subtotal (95% CI) 86 93 Not estimable
Total events: 0 (ORA), 0 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 6 Maternal death.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 6 Maternal death
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
Lin 2009 0/23 0/22 Not estimable
Subtotal (95% CI) 23 22 Not estimable
Total events: 0 (ORA), 0 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.7. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 7 Maternal adverse effects.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 7 Maternal adverse effects
Study or subgroup Favours ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 39/116 56/129 53.5 % 0.77 [ 0.56, 1.07 ]
Shim 2006 5/63 46/63 46.5 % 0.11 [ 0.05, 0.26 ]
Subtotal (95% CI) 179 192 100.0 % 0.47 [ 0.35, 0.62 ]
Total events: 44 (Favours ORA), 102 (Other tocolytics)
Heterogeneity: Chi2 = 20.70, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 5.10 (P < 0.00001)
2 ORA versus calcium channel blockers
Kashanian 2005 7/40 16/40 49.4 % 0.44 [ 0.20, 0.95 ]
Salim 2012 5/70 17/75 50.6 % 0.32 [ 0.12, 0.81 ]
Subtotal (95% CI) 110 115 100.0 % 0.38 [ 0.21, 0.68 ]
Total events: 12 (Favours ORA), 33 (Other tocolytics)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
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Analysis 2.8. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 8 Maternal adverse effects requiring cessation of treatment.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 8 Maternal adverse effects requiring cessation of treatment
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 2/116 17/129 15.6 % 0.13 [ 0.03, 0.55 ]
French˙x002f˙Australian 2001 1/119 13/122 12.4 % 0.08 [ 0.01, 0.59 ]
Goodwin 1996 1/244 15/58 23.4 % 0.02 [ 0.00, 0.12 ]
Moutquin 2000 1/126 36/121 35.5 % 0.03 [ 0.00, 0.19 ]
Shim 2006 0/63 13/63 13.1 % 0.04 [ 0.00, 0.61 ]
Subtotal (95% CI) 668 493 100.0 % 0.05 [ 0.02, 0.11 ]
Total events: 5 (ORA), 94 (Other tocolytics)
Heterogeneity: Chi2 = 3.63, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 7.17 (P < 0.00001)
2 ORA versus calcium channel blockers
Salim 2012 0/70 1/75 100.0 % 0.36 [ 0.01, 8.62 ]
Subtotal (95% CI) 70 75 100.0 % 0.36 [ 0.01, 8.62 ]
Total events: 0 (ORA), 1 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =30%
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Analysis 2.9. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 9 Caesarean section.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 9 Caesarean section
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
Moutquin 2000 20/126 22/121 100.0 % 0.87 [ 0.50, 1.52 ]
Subtotal (95% CI) 126 121 100.0 % 0.87 [ 0.50, 1.52 ]
Total events: 20 (ORA), 22 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 ORA versus calcium channel blockers
Salim 2012 5/70 4/75 100.0 % 1.34 [ 0.37, 4.79 ]
Subtotal (95% CI) 70 75 100.0 % 1.34 [ 0.37, 4.79 ]
Total events: 5 (ORA), 4 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.55), I2 =0.0%
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Analysis 2.10. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 10 Interval between trial entry and birth (days).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 10 Interval between trial entry and birth (days)
Study or subgroup ORA Other tocolytics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ORA versus betamimetics
Cabar 2008 40 28.2 (15.6) 40 5.3 (1.8) 100.0 % 22.90 [ 18.03, 27.77 ]
Subtotal (95% CI) 40 40 100.0 % 22.90 [ 18.03, 27.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.22 (P < 0.00001)
2 ORA versus calcium channel blockers
Salim 2012 70 31.76 (20.6) 75 37.46 (20.3) 100.0 % -5.70 [ -12.36, 0.96 ]
Subtotal (95% CI) 70 75 100.0 % -5.70 [ -12.36, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Chi2 = 46.16, df = 1 (P = 0.00), I2 =98%
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Analysis 2.11. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 11 Preterm birth (before completion of 37 weeks of gestation).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 11 Preterm birth (before completion of 37 weeks of gestation)
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus calcium channel blockers
Salim 2012 45/70 31/75 100.0 % 1.56 [ 1.13, 2.14 ]
Subtotal (95% CI) 70 75 100.0 % 1.56 [ 1.13, 2.14 ]
Total events: 45 (ORA), 31 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0070)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 12 Extremely preterm birth (before completion of 28 weeks of gestation).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 12 Extremely preterm birth (before completion of 28 weeks of gestation)
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 9/115 12/129 100.0 % 0.84 [ 0.37, 1.92 ]
Subtotal (95% CI) 115 129 100.0 % 0.84 [ 0.37, 1.92 ]
Total events: 9 (ORA), 12 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 ORA versus calcium channel blockers
Salim 2012 2/70 1/75 100.0 % 2.14 [ 0.20, 23.11 ]
Subtotal (95% CI) 70 75 100.0 % 2.14 [ 0.20, 23.11 ]
Total events: 2 (ORA), 1 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 2.13. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 13 Gestational age (weeks).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 13 Gestational age (weeks)
Study or subgroup ORA Other tocolytics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ORA versus betamimetics
European 2001 115 35.11 (4.19) 129 34.29 (4.525) 17.3 % 0.82 [ -0.27, 1.91 ]
French˙x002f˙Australian 2001 119 36.5 (3) 122 36.3 (3.7) 28.6 % 0.20 [ -0.65, 1.05 ]
Lin 2009 23 37.1 (2.5) 19 37.4 (2.4) 9.3 % -0.30 [ -1.79, 1.19 ]
Moutquin 2000 126 35.1 (4.2) 121 35.2 (4) 19.7 % -0.10 [ -1.12, 0.92 ]
Nonnenmacher 2009 51 34.1 (4.2) 54 34.3 (3.4) 9.6 % -0.20 [ -1.67, 1.27 ]
Shim 2006 63 37.3 (3.5) 63 37.3 (3.1) 15.5 % 0.0 [ -1.15, 1.15 ]
Subtotal (95% CI) 497 508 100.0 % 0.13 [ -0.32, 0.59 ]
Heterogeneity: Chi2 = 2.31, df = 5 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 ORA versus calcium channel blockers
Salim 2012 70 35.2 (3) 75 36.4 (2.8) 100.0 % -1.20 [ -2.15, -0.25 ]
Subtotal (95% CI) 70 75 100.0 % -1.20 [ -2.15, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Chi2 = 6.18, df = 1 (P = 0.01), I2 =84%
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Analysis 2.14. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 14 Birthweight (grams).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 14 Birthweight (grams)
Study or subgroup ORA Other tocolytics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ORA versus betamimetics
Cabar 2008 40 2554 (530) 40 2448 (439) 15.0 % 106.00 [ -107.27, 319.27 ]
European 2001 126 2473 (819) 149 2299 (939) 15.8 % 174.00 [ -33.80, 381.80 ]
French˙x002f˙Australian 2001 126 2708 (743) 140 2619 (743) 21.3 % 89.00 [ -89.83, 267.83 ]
Lin 2009 23 2900 (500) 19 2800 (400) 9.2 % 100.00 [ -172.22, 372.22 ]
Moutquin 2000 143 2314 (825) 132 2478 (759) 19.5 % -164.00 [ -351.21, 23.21 ]
Nonnenmacher 2009 57 2213 (889) 63 2211 (756) 7.7 % 2.00 [ -294.84, 298.84 ]
Shim 2006 63 2906 (763) 63 3017 (631) 11.4 % -111.00 [ -355.49, 133.49 ]
Subtotal (95% CI) 578 606 100.0 % 27.16 [ -55.46, 109.77 ]
Heterogeneity: Chi2 = 8.44, df = 6 (P = 0.21); I2 =29%
Test for overall effect: Z = 0.64 (P = 0.52)
2 ORA versus calcium channel blockers
Salim 2012 86 2326 (627) 92 2408 (658) 100.0 % -82.00 [ -270.78, 106.78 ]
Subtotal (95% CI) 86 92 100.0 % -82.00 [ -270.78, 106.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 1.08, df = 1 (P = 0.30), I2 =7%
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Analysis 2.15. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 15 Apgar score less than 7 at 5 minutes.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 15 Apgar score less than 7 at 5 minutes
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 4/127 13/126 43.9 % 0.31 [ 0.10, 0.91 ]
French˙x002f˙Australian 2001 5/126 5/135 16.2 % 1.07 [ 0.32, 3.61 ]
Moutquin 2000 5/141 4/132 13.9 % 1.17 [ 0.32, 4.26 ]
Nonnenmacher 2009 8/57 7/63 22.4 % 1.26 [ 0.49, 3.26 ]
Shim 2006 1/53 1/48 3.5 % 0.91 [ 0.06, 14.08 ]
Subtotal (95% CI) 504 504 100.0 % 0.79 [ 0.47, 1.33 ]
Total events: 23 (ORA), 30 (Other tocolytics)
Heterogeneity: Chi2 = 4.46, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.90 (P = 0.37)
2 ORA versus calcium channel blockers
Salim 2012 1/86 2/93 100.0 % 0.54 [ 0.05, 5.86 ]
Subtotal (95% CI) 86 93 100.0 % 0.54 [ 0.05, 5.86 ]
Total events: 1 (ORA), 2 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 2.16. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 16 Respiratory distress syndrome.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 16 Respiratory distress syndrome
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ORA versus betamimetics
European 2001 27/127 46/149 31.7 % 0.69 [ 0.46, 1.04 ]
French˙x002f˙Australian 2001 20/126 19/140 24.7 % 1.17 [ 0.65, 2.09 ]
Goodwin 1996 20/236 5/56 14.4 % 0.95 [ 0.37, 2.42 ]
Lin 2009 0/23 0/22 Not estimable
Moutquin 2000 32/143 19/132 27.2 % 1.55 [ 0.93, 2.60 ]
Shim 2006 3/63 0/63 2.0 % 7.00 [ 0.37, 132.79 ]
Subtotal (95% CI) 718 562 100.0 % 1.08 [ 0.70, 1.65 ]
Total events: 102 (ORA), 89 (Other tocolytics)
Heterogeneity: Tau2 = 0.11; Chi2 = 7.98, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 0.33 (P = 0.74)
2 ORA versus calcium channel blockers
Salim 2012 9/86 7/93 100.0 % 1.39 [ 0.54, 3.57 ]
Subtotal (95% CI) 86 93 100.0 % 1.39 [ 0.54, 3.57 ]
Total events: 9 (ORA), 7 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.63), I2 =0.0%
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Analysis 2.17. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 17 Use of mechanical ventilation.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 17 Use of mechanical ventilation
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
Shim 2006 6/63 2/63 100.0 % 3.00 [ 0.63, 14.30 ]
Subtotal (95% CI) 63 63 100.0 % 3.00 [ 0.63, 14.30 ]
Total events: 6 (ORA), 2 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
2 ORA versus calcium channel blockers
Salim 2012 13/86 10/93 100.0 % 1.41 [ 0.65, 3.04 ]
Subtotal (95% CI) 86 93 100.0 % 1.41 [ 0.65, 3.04 ]
Total events: 13 (ORA), 10 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
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Analysis 2.18. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 18 Duration of mechanical ventilation (days).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 18 Duration of mechanical ventilation (days)
Study or subgroup ORA Other tocolytics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ORA versus betamimetics
Lin 2009 17 0.4 (1) 15 1.7 (4.9) 100.0 % -1.30 [ -3.82, 1.22 ]
Subtotal (95% CI) 17 15 100.0 % -1.30 [ -3.82, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 19 Intraventricular haemorrhage.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 19 Intraventricular haemorrhage
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
Goodwin 1996 19/189 5/44 89.0 % 0.88 [ 0.35, 2.24 ]
Shim 2006 3/63 1/63 11.0 % 3.00 [ 0.32, 28.07 ]
Subtotal (95% CI) 252 107 100.0 % 1.12 [ 0.48, 2.58 ]
Total events: 22 (ORA), 6 (Other tocolytics)
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
2 ORA versus calcium channel blockers
Salim 2012 4/86 2/93 100.0 % 2.16 [ 0.41, 11.51 ]
Subtotal (95% CI) 86 93 100.0 % 2.16 [ 0.41, 11.51 ]
Total events: 4 (ORA), 2 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 2.20. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 20 Necrotising enterocolitis.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 20 Necrotising enterocolitis
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
Goodwin 1996 1/236 1/56 100.0 % 0.24 [ 0.02, 3.74 ]
Subtotal (95% CI) 236 56 100.0 % 0.24 [ 0.02, 3.74 ]
Total events: 1 (ORA), 1 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 ORA versus calcium channel blockers
Salim 2012 4/86 0/93 100.0 % 9.72 [ 0.53, 178.00 ]
Subtotal (95% CI) 86 93 100.0 % 9.72 [ 0.53, 178.00 ]
Total events: 4 (ORA), 0 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 3.30, df = 1 (P = 0.07), I2 =70%
0.01 0.1 1 10 100
Favours ORA Favours Other tocolytics
86Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.21. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 21 Retinopathy of prematurity.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 21 Retinopathy of prematurity
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus calcium channel blockers
Salim 2012 2/86 1/93 100.0 % 2.16 [ 0.20, 23.43 ]
Subtotal (95% CI) 86 93 100.0 % 2.16 [ 0.20, 23.43 ]
Total events: 2 (ORA), 1 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 22 Neonatal sepsis.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 22 Neonatal sepsis
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 13/127 21/149 58.0 % 0.73 [ 0.38, 1.39 ]
French˙x002f˙Australian 2001 1/126 1/140 2.8 % 1.11 [ 0.07, 17.58 ]
Goodwin 1996 12/236 1/56 4.8 % 2.85 [ 0.38, 21.45 ]
Moutquin 2000 11/143 11/132 34.3 % 0.92 [ 0.41, 2.06 ]
Subtotal (95% CI) 632 477 100.0 % 0.91 [ 0.56, 1.46 ]
Total events: 37 (ORA), 34 (Other tocolytics)
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 ORA versus calcium channel blockers
Salim 2012 2/86 3/93 100.0 % 0.72 [ 0.12, 4.21 ]
Subtotal (95% CI) 86 93 100.0 % 0.72 [ 0.12, 4.21 ]
Total events: 2 (ORA), 3 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
Favours ORA Favours Other tocolytics
88Oxytocin receptor antagonists for inhibiting preterm labour (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.23. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 23 Admission to neonatal intensive care unit.
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 23 Admission to neonatal intensive care unit
Study or subgroup ORA Other tocolytics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ORA versus betamimetics
European 2001 43/126 63/149 26.3 % 0.81 [ 0.59, 1.10 ]
French˙x002f˙Australian 2001 27/126 29/140 12.5 % 1.03 [ 0.65, 1.65 ]
Moutquin 2000 87/143 94/132 44.5 % 0.85 [ 0.72, 1.01 ]
Nonnenmacher 2009 24/57 28/63 12.1 % 0.95 [ 0.63, 1.43 ]
Shim 2006 14/63 10/63 4.6 % 1.40 [ 0.67, 2.91 ]
Subtotal (95% CI) 515 547 100.0 % 0.90 [ 0.78, 1.04 ]
Total events: 195 (ORA), 224 (Other tocolytics)
Heterogeneity: Chi2 = 2.65, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
2 ORA versus calcium channel blockers
Salim 2012 44/86 28/93 100.0 % 1.70 [ 1.17, 2.47 ]
Subtotal (95% CI) 86 93 100.0 % 1.70 [ 1.17, 2.47 ]
Total events: 44 (ORA), 28 (Other tocolytics)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Chi2 = 9.80, df = 1 (P = 0.00), I2 =90%
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Analysis 2.24. Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type
of other tocolytic), Outcome 24 Neonatal length of hospital stay (days).
Review: Oxytocin receptor antagonists for inhibiting preterm labour
Comparison: 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)
Outcome: 24 Neonatal length of hospital stay (days)
Study or subgroup ORA Other tocolytics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ORA versus betamimetics
Lin 2009 22 7.6 (7.8) 19 7.5 (9.1) 100.0 % 0.10 [ -5.13, 5.33 ]
Subtotal (95% CI) 22 19 100.0 % 0.10 [ -5.13, 5.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 ORA versus calcium channel blockers
Salim 2012 86 16.5 (18.9) 93 11.1 (18.2) 100.0 % 5.40 [ -0.04, 10.84 ]
Subtotal (95% CI) 86 93 100.0 % 5.40 [ -0.04, 10.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 1.89, df = 1 (P = 0.17), I2 =47%
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A P P E N D I C E S
Appendix 1. Methods used to assess trials in the earlier version of this review
We used the standard methods of The Cochrane Collaboration as described in the Cochrane Reviewers’ Handbook (Alderson 2004a).
Two review authors (Vicki Flenady, Dimitri Papatsonis) considered trials for inclusion, evaluated methodological quality and extracted
trial data independently. We resolved differences in interpretation by discussion. Where necessary, we contacted investigators of
identified trials for additional information or data. We contacted the authors of seven trials for additional outcome data (Al-Omari
2004; Anonymous 2004; European 2001; French/Australian 2001; Goodwin 1994; Renzo 2003; Romero 2000), and at the time of
this review we received additional data for two trials (European 2001; Goodwin 1994). When there was consensus about the additional
data received from the original authors, we included these data in the analysis; when there was no consensus among the review authors
or the data were incomplete, we asked the original authors again for additional data or comments.
Quality assessment
We conducted quality assessment according to the methods described in Section six of the Cochrane Reviewers’ Handbook (Alderson
2004b). We considered four major sources of potential bias and methods of avoidance of these biases when assessing trial quality: (1)
selection bias - blinding of randomisation; (2) performance bias - blinding of intervention; (3) attrition bias - complete follow up; (4)
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detection bias - blinding of outcome assessment. We assigned a quality rating to each trial for the criterion of blinding of randomisation
as follows: (A) adequate, (B) unclear, (C) inadequate, or (D) not used. We assigned a quality rating of (A) yes, (B) cannot tell, or (C)
no, to the other quality components (blinding of intervention, completeness of follow up and blinding of outcome assessment). High-
quality trials were defined as those receiving an A rating for blinding of randomisation (central computerised randomisation service or
sealed opaque envelopes) and for blinding of the intervention (use of a placebo). The quality assessment rating included in the table of
’Characteristics of Included Studies’ refers to blinding of randomisation in the studies.
Data collection and analysis
We conducted data management and analysis using the Review Manager software (RevMan 2003) (method of data extraction is
described above). For individual trials mean differences (and 95% confidence intervals), where possible, were reported for continuous
variables. For continuous variables we have, where possible, reported mean differences (and 95% confidence intervals) for individual
trials. For categorical outcomes, we reported the relative risk and risk difference (and 95% confidence intervals).
One trial (Goodwin 1996b) randomised women to one of five groups: four atosiban groups of different dosing regimens and one
ritodrine group. For the meta-analysis we combined the four atosiban treatment arms.
Where more than 20% of outcomes for participants were missing, data were not included in the review. This applied to the only trial
which reported longer term infant outcomes (Romero 2000), where data on neurodevelopmental outcome at one and two years were
excluded due to a 35% and 45% loss to follow-up respectively. However, data on infant death (to 12 months of age) reported in this
trial were included in the review, as the follow-up appeared to be complete.
We conducted meta-analysis using the fixed-effect model. We assessed heterogeneity by visual inspection of the outcomes tables and
by using two statistics (H and I² test) of heterogeneity (Higgins 2002).
Using a fixed-effect model, statistical heterogeneity was evident for three non-statistically significant outcomes in the comparison of
atosiban versus betamimetics. These were birthweight, respiratory distress syndrome and admission to neonatal intensive care unit. Use
of a random-effects model for these outcomes did not alter our interpretation of the results. On visual inspection of the graphs and
through sensitivity analyses, we identified one trial (Moutquin 2000) as an outlier for all of these outcomes. A possible explanation
could be, as the authors of the trial stated themselves, that more women with a multiple pregnancy were randomised to the atosiban
group. Although, there was no difference in the mean gestational age at entry into the trial or the mean gestational age at delivery
between the two groups in this trial or when compared to the other trials, multiple gestation could have independently affected these
outcomes. It is unclear why there was an imbalance in randomisation for multiple gestations in this study.
Due to insufficient data, planned subgroup analyses by population characteristics, tocolytic regimens that include use of maintenance
therapy, and oxytocin receptor antagonist compared with calcium channel blockers were not undertaken.
F E E D B A C K
Goodwin, September 2005
Summary
I have a number of concerns about this review. First, the inclusion of two reports (Goodwin 1994 and Goodwin 1996) is misleading,
as neither study had delay in delivery or prolongation of pregnancy as endpoints. Information was collected on these endpoints, but
the studies were not designed to demonstrate efficacy. In Goodwin 1994 the intervention was an intravenous infusion of atosiban for
just 2 hours. This aim of this study was to describe the effect on uterine activity as measured by external tocodynamometry. Women
were specifically chosen as having uterine activity, but unlikely to be in true preterm labor. Goodwin 1996 was a dose ranging study in
which most women (3 of 4 arms) received doses far below what is currently recommended. Any effect of atosiban would therefore be
underestimated. As these studies were not designed and executed as efficacy trials it seems inappropriate to use them in a discussion of
efficacy.
Second, the excess perinatal mortality in Romero 2000 is overemphasized. This excess has not been seen in other trials, and had a
plausible explanation based on study design. Although this is acknowledged in the review, the finding is given undo emphasis in the
conclusions. The statement in the discussion that the excess mortality in Romero 2000 reaches statistical significance when the 2 infant
deaths up to 12 months are included seems to rely on counting these 2 deaths between 28 days and 12 months twice.
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Third, the concern about long term follow up of exposed infants, because of 45% being lost to follow up, is arbitrary. There are few
precedents for attempting to follow up a cohort in which 90% of the children are well. The only other study to attempt follow up on
this scale (the Canadian Preterm Labor Investigators Trial) simply avoided the problem by selecting an available portion for follow up.
Finally, the exclusion of Romero 2000 from any discussion of efficacy (and the inappropriate inclusion of other trials - see above) is
confusing. The pre-specified endpoint of delay without requirement for an alternate tocolytic (approved by the US FDA) remains the
only way to describe a placebo trial in the US. To simply say that it is not included oversimplifies the complexity of studying and
understanding tocolytics. It is true to say there is insufficient evidence of a tocolytic benefit, but it is an overstatement to say that there
is no such evidence.
One of the main reasons I wish to comment on the review is that the acknowledgement of my assistance may give the impression that
I concur with the conclusions. While I was happy to help with gathering of some information, I feel that this analysis is flawed and
not up to the high standards of Cochrane Reviews.
(Summary of comment from Murphy Goodwin, September 2005)
Reply
To respond to these comments in the order in which they are made:
First, our pre-specifiedmethods did not exclude studies based on either duration or dose of tocolysis. Both Goodwin 1994 andGoodwin
1996 where therefore eligible for inclusion. We disagree that trials should have been excluded if delay in delivery or prolongation of
pregnancy were not primary endpoints. Also, both these studies enrolled women judged to be in preterm labour based on definitions
that are consistent with those used in the other trials within the review, and that meet commonly used clinical criteria for tocolysis.
Although Goodwin 1996 was a dose-finding study, three of the four treatment arms used doses that are now considered reasonable
clinical regimens.
Second, we disagree that the excess in perinatal and infant mortality in Romero 2000 is overemphasized. The explanation given by the
trial authors for the excess perinatal mortality is that it may have been due to an unexpected imbalance in randomisation between the
atosiban and placebo groups for women randomised before 26 weeks (13/255 versus 24/246). We are not aware they have published
an analysis controlling for gestational age to support this explanation, however. Also, our attempts to obtain further information from
the authors about possible reasons for this imbalance between the placebo and atosiban groups have been unsuccessful. In particular,
it would be helpful to clarify whether this imbalance was likely to be due to chance alone, or whether there was any possibility of
bias at trial entry, or an error in the randomisation sequence. We do not think we have double counted any infant deaths. Romero
2000 reported 10 infant deaths in the treatment group versus 2 in the placebo group, a difference which achieves statistical significance
(RR 5.12, 95% CI 1.13-23.17). Our understanding is that there were two additional deaths in the atosiban group. This is based on
unpublished data in the document “Antocin Final Two-Year Infant Safety report” (issued 15 July 1999) which was initially supplied
by Ferring UK to the Royal College of Obstetricians and Gynaecologist in the UK, and which Ferring later kindly agreed to share with
us. This document describes 12 infant deaths plus 3 fetal deaths (total 15 deaths) in the atosiban group and 2 infant deaths plus 3 fetal
deaths (total 5 deaths) in the placebo group. Thus, for infant deaths this 12 versus 2. If there is any dispute about these data it would
be helpful if the results of this two-year follow-up study could be presented for public scrutiny in a peer reviewed journal.
Third, high attrition is a common problem in long-term follow. It is reassuring that the losses were similar between the groups and
that the majority of children were neurologically normal. Nevertheless, in the absence of any explanation for the high loss to follow up,
concerns remain about potential systematic differences between the groups amongst those who were not contacted and assessed. Once
again, to help allay such concerns it would be helpful if this follow-up study could be published.
Finally, the outcome measures in our review were all prespecified. Romero 2000 did not report outcome for all women who remained
undelivered after 24 hours, 48 hours or 7 days. Data were only available for women who remained undelivered and did not require an
additional (rescue) tocolytic drug. Data for the outcomes in our review have been requested from the trial authors, but to date have
not been received.
It was not our intention to imply that Professor Goodwin agreed with our conclusions. We remain grateful for his help in supplying
additional data, and agree that such assistance in no way implies concurrence with our conclusions.
(Summary of response from Dimitri Papatsonis, January 2006)
Contributors
Murphy Goodwin
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Åkerlund et al, December 2005
Summary
The authors conclude that the review failed to demonstrate the superiority of atosiban over placebo or betamimetics in terms of either
tocolytic efficacy or infant outcomes. We disagree with this conclusion for the following reasons:
For the comparison of atosiban with placebo
In Goodwin 1994 the decrease in uterine contractions was significantly greater with atosiban than placebo. There was a complete
cessation of contractions for 25% of women receiving atosiban and 5% of women receiving placebo. Romero 2000 and Valenzuela
2000 followed different study protocols with different primary end-points, and provide data for safety analyses only.
In Romero 2000 and Valenzuela 2000 women in the placebo group were treated with bed-rest and hydration. Hydration reduces
oxytocin secretion, which may have contributed to the decrease in contractions in the placebo group. Atosiban is also a vasopressin
V1a receptor- inhibiting compound, more potent than an oxytocin antagonist. Vasopressin may well be involved in the aetiology of
preterm labour, and its secretion may also be reduced by hydration.
For the comparison of atosiban with betamimetics
The reviewers state that atosiban is no better than other classes of drug in delaying preterm birth. However, in European 2001 atosiban
was significantly better, in terms of fewer women undelivered and not requiring alternative tocolysis after 7 days of treatment, than
either ritodrine, salbutamol or pooled data for three betamimetics.
For infant outcomes
In European 2001 1.2% of the infants died in the atosiban group versus 2.3% for betamimetics. There were no differences in infant
deaths between atosiban and placebo in Goodwin 1994, Romero 2000 or Valenzuela 2000. The only exception to this was for infants
of women randomised before 26 weeks gestation in Romero 2000.
Our main criticism of the review is that the rationale underlying the selection of trials for inclusion is unclear. For example, the reviewers
included Valenzuela 2000, even though it was excluded from other perspectives. Furthermore, the studies were not designed to have
infant follow up and so these data were incomplete.
Romero 2000 is included as a high-quality trial, despite an imbalance between the atosiban and placebo groups for women randomised
before 26 weeks gestation. To compare tocolytic efficacy and infant outcome of these data is not relevant. That was also the attitude of
authorities when atosiban was registered in European countries.
Finally, the conclusions state that calcium channel blockers are superior to betamimetics, although this comparison is not part of the
review. Meta-analysis is an efficient way of providing the basis for evidence-based medicine. However, the weaknesses of this method,
such as selection bias and lack of quality weighting, are well recognized (Spector 1991). This Cochrane review exemplifies the drawbacks
of meta-analysis, and its limitation in yielding valid conclusions.
(Summary of comments from Mats Åkerlund, Karel Marsl, and Ingemar Ingemarsson, December 2005)
Reply
First, to clarify any misunderstanding about whether there was a rationale for the selection of trials to include in our review. The
criteria used for selecting trials were described a priori in the protocol, published on The Cochrane Database of Systematic Reviews.
These methods adhere to the rigorous process defined by the Cochrane Collaboration, and followed by the Cochane Pregnancy and
Childbirth Group. Therefore, the threat to the internal validity of our review from bias in selection of which studies to include was
minimised.
Quality weighting in a meta-analysis has not be shown empirically to impact on reliability of the summary statistic, hence why it was
not done within our review
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For the comparison of atosiban with placebo
We agree that Goodwin 1994 reported a cessation of contractions for 25% of women receiving atosiban compared with 5% of those
receiving placebo. As this was a small study, however, these data are based on just 14 women versus 5 women who ceased contractions.
Also, a more clinically important measure of tocolytic efficacy is the proportion of women who delivered within 48 hours. This outcome
was not statistically significant between the groups (relative risk 2.50, 95% CI 0.51 to 12.35).
Valenzuela 2000 was excluded from the review because it evaluated maintenance tocolysis, and so did not meet our inclusion criteria.
The impact of hydration in the placebo group on any decrease in contraction is likely to be limited. The effect of atosiban and hydration
on vasopressin V1a receptors is known, although its impact, if any, on preterm labour is less clear. Our view is that the overall effect of
hydration on the incidence of preterm labour is limited, although hydration could lead to some reduction in oxytocin release.
Atosiban is also a vasopressin receptor antagonist. The human placenta is permeable to atosiban and the fetus has functional vasopressin
receptors in the third trimester. The exact effect of fetal vasopressin receptor blockade on the fetus, following administration of atosiban,
is unclear. Also unclear is whether a decrease in vasopressin due to hydration has any effect on preterm labour. For Romero 2000 this
is not an issue, however, as hydration seems to have been similar in both groups.
For the comparison of atosiban with betamimetics
The conclusion that atosiban is no better than betamimetics in delaying preterm birth is based on the lack of clear benefit for atosiban
on the number of infants delivered after seven days of starting treatment, or any other prespecified outcome. We did not use the
composite outcome “delay in delivery and no alternate tocolytic agent”. This was because the decision to start an alternative tocolytic
may have been biased by awareness of the study treatment allocation, due to maternal signs and symptoms such as palpitations, flushing
and tachycardia associated with betamimetics. The potential benefit of atosiban on this composite outcome measure, reported by some
trials in the review, is clearly questionable as this benefit did not translate into improved outcome for the infants.
For infant outcomes
The incidence of infant deaths was similar in the trials comparing atosiban and betamimetics.
Although Romero 2000 met the criteria for inclusion in the review, we agree there were methodological concerns and these are described
under ’methodological quality of included studies’. There was an imbalance between the groups in women randomised before 26 weeks’
gestation (24/246 [10%] atosiban versus 13/255 [5%] placebo), with fewer women randomised after 32 weeks allocated atosiban
compared with placebo (96/246 [4%] versus 116/255 [5%]). The increase in fetal-neonatal deaths in the atosiban group may, therefore,
be explained by this imbalance. However, we are not aware of an analysis of infant outcome controlling for this imbalance. As the
randomisation sequence was adequately concealed at trial entry, the risk of this imbalance having been due to bias seems to be low.
While the reason for the imbalance remains unclear, and has not been provided by the principal investigators nor the pharmaceutical
company sponsoring the trial, it is possible that it occurred by chance alone due to the fact that randomisation was not stratified by
gestational age.
Although some of included trials were not designed for follow-up, this is not a reason to exclude them from the analysis of short term
outcomes.
When a new tocolytic drug is being developed, the question most parents are likely to want answered is whether there is any beneficial
effect for the child. Trials of tocolytic drugs should be designed to establish any such effect. It is therefore surprising that the authorities
in Europe did not ask for any evidence of tocolytic efficacy or benefit for the fetus before approving atosiban for use in Europe, in
contrast to similar authorities in the USA who did require such evidence.
Finally, we stand by the conclusions of our systematic review that the superiority of atosiban over placebo or betamimetics was not been
demonstrated, in terms of either delay in delivery or any short or longer term neonatal morbidity or mortality.
(Summary by Dimitri Papatsonis, on behalf of the review authors, May 2006)
Contributors
Mats Åkerlund, Karel Marsl, and Ingemar Ingemarsson
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Thornton S et al, July 2006
Summary
We are concerned about the conclusions and implications for clinical practice in this review. In particular, (i) the trial methodology may
not allow reliable evaluation of outcome; (ii) there seems undue importance attached to the risk of infant deaths in one study (Romero
2000) with imbalance at baseline, and (iii) the conclusion that calcium channel blockers are associated with a better neonatal outcome
is not qualified.
First, the review acknowledges that some women in the trials of oxytocin receptor antagonists required rescue tocolysis. In practice,
this means that women are randomised to treatment or comparator/placebo, and those who progress in labour are given an alternative
tocolytic. This means that any women could be given an effective drug for rescue, which prevents direct comparison of outcome. It is
therefore not possible to categorically say that one of the agents administered initially is superior, or inferior, to the other. The most
reasonable inferences that can be drawn, in studies where co-intervention is likely to have a substantial impact on outcome, concern
the effects observed under treatment combinations. The effectiveness of initial tocolytic agents alone cannot be studied. What can be
studied is the effect of initial plus rescue tocolysis allowed in the care protocol. Therefore it is acknowledged that in such trials direct
comparison of many (including neonatal) outcomes is inappropriate (Romero 2000). For this reason the endpoint of delay in delivery
without alternate tocolytic has been used in that study. Given that it is inappropriate to compare neonatal outcomes in such trials, it is
disappointing that the outcomes are given such importance in the conclusion.
Second, it is also disappointing that the abstract states Atosiban is associated with an increase in infant deaths at 12 months of age
compared with placebo. As‘the trial randomised more women in the Atosiban arm at very early gestational ages, this would be expected
to increase mortality. Randomisation (when methodologically sound) uses a chance procedure for group allocation, which may produce
imbalances in important prognostic variables at baseline by chance alone. If such differences are observed, an appropriate analysis of
the trial would include statistical corrections for baseline differences to have valid results. Moreover, it is not clear why it was felt that
mortality at one year should be included in the analysis when outcomes up to two years were excluded. If Atosiban were associated
with an increase in mortality risk for the child, it is likely that this would have been demonstrated in the numerous other large clinical
trials. As there is no increase in mortality in other trials, it is a reasonable assumption that the excess mortality in the placebo controlled
trial was due to the disproportionate allocation to Atosiban at early gestational ages.
Finally, the conclusion suggests that calcium channel blockers are associated with better neonatal outcome and fewer maternal side
effects than betamimetics. Although it is stated that no trials have directly compared nifedipine with placebo, it is not acknowledged
that the clinical studies on calcium channel blockers were not blinded, that comparison was often with an extremely high dose of
ritodrine and that these studies also often included rescue tocolysis. The conclusions regarding the possible improvement in outcome
with calcium channel blockers must therefore be taken in context.
(Summary of comments from Steve Thornton, Khalid S Khan, and Patrick FW Chien, July 2006)
Potential conflict of interest: Steve Thornton provides consultancy advice for the pharmaceutical industry. Khalid Khan has a UKNHS
HTA research grant on prevention of preterm birth.
Reply
Responding to the comments in the order in which they were made:
First, we do not agree that the use of rescue tocolysis means direct comparison of outcome is inappropriate. We used the standard
methods as described in theCochrane ReviewersHandbook (Higgins 2011). The inclusion criteria, outcomemeasures and comparisons,
as with all methods of this review, were pre-specified on the basis of ensuring that a clinically relevant “real life” question was addressed.
Rescue tocolysis is a real life situation and therefore was handled in a necessarily pragmatic approach in this review. Our pre-specified
methods did not exclude studies based on having an alternative (rescue) tocolytic agent. Romero 2000 did report that a substantial
number of women received an alternate “rescue tocolytic agent” (42% in the atosiban arm versus 51% in the placebo). However, we
remain convinced that this study, and its outcomes, should be included in our review as it fulfils the inclusion criteria. We remain
convinced that the pre-specified clinically important outcomes of all women undelivered after 24 hours, 48 hours or 7 days should
remain. The outcome used in Romero 2000, of women who were undelivered and did not require an alternate tocolytic agent, does
not reflect real life and is more susceptible to bias. Despite repeated requests to the authors of Romero 2000 for data on the outcome
of delay in delivery, in a format which would enable inclusion in this review, no such data have been forthcoming.
Secondly, as discussed in an earlier response to a comment on this Cochrane review, we disagree that the excess in perinatal and
neonatal mortality in Romero 2000 is overemphasized. Our view is that the data on outcome for this trial are presented and discussed
appropriately. Although the trial authors stated that the excess mortality may have been attributable to an imbalance between the groups
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in women randomised before 26 weeks gestation. Without an analysis controlling for gestation this remains a tentative explanation. We
are not aware that any such analysis has been undertaken.We have attempted on numerous occasions to obtain further information from
the trial authors, but to date have been unsuccessful. As central computer randomisation was used, we concluded that the imbalance
was most likely due to the lack of stratification by gestational age (random error) and not bias due to flaws in the allocation concealment,
and have clearly stated this in the review.
Finally, whilst we agree with Prof Thornton that there were no placebo controlled trials in the Cochrane review on calcium channel
blockers compared with betamimetics, we also agree with the conclusions of the relevant review about the superiority of calcium channel
blockers in terms of safety and neonatal outcomes. Blinding of studies, when comparing calcium channel blockers with betamimetics,
is almost impossible because of the cardiovascular side effects of betamimetics, such as palpitations and anxiety. In these studies the
additional rescue tocolysis used was comparable for the different study arms.
We are aware that because there is only indirect comparison between atosiban and nifedipine as tocolytic agents (and therefore the
evidence for which of two tocolytic agents is most effective and safe is inconclusive) both tocolytic agents are currently advocated by
obstetricians across several countries. Cost and mode of administration are also important considerations in the choice of tocolytic
agent. We therefore believe that a well designed trial comparing oxytocin receptor antagonists and calcium channel blockers for the
management of preterm labour is important in the advancement of care for women in preterm labour.
(Reply from Dimitri Papatsonis, on behalf of the review authors, August 2007)
Contributors
Steve Thornton, Khalid S Khan, and Patrick FW Chien
Thornton J, July 2006
Summary
I am concerned that there is unintentional bias in favour of the use of calcium channel blockers and against oxytocin antagonists in
two recent Cochrane reviews, this one and the review of calcium channel blocker trials (King 2003).
Objective judgement of trial quality
Four studies of oxytocin antagonists (European 2001; French/Australian 2001; Moutquin 2000; and Romero 2000) are recorded as
’Blinding outcome assessment: unknown’ despite their using a double dummy technique with no mention that the blinding was broken.
Another, Goodwin 1994, is classified as ’Blinding outcome assessment: no’ despite the review authors correctly noting that a double
dummy technique was used. The relevant section of the published paper reads as follows: “the pharmacist would open the envelope to
reveal the patient’s treatment assignment for the purpose of preparing the study drug infusion solution. The treatment assignment was
not revealed to other persons, and the individual preparing the drug was not involved in patient care.” Surely all five trials should be
classified as ’Blinding outcome assessment: yes’.
Subjective judgement of trial quality
In the text of the calcium channel review (King 2003), the trials are classified as of reasonable quality and no statement is made about
quality in the abstract.
In fact none were blinded; they were all relatively small (mean group size 43) and only four had performed a sample size calculation.
The lack of blinding is particularly important since all the reported outcomes favouring calcium channel blockers are susceptible to
biased ascertainment, and the only hard outcome, perinatal death, showed a trend against calcium channel blockers (see below).
In contrast the oxytocin antagonist reviewers classify Goodwin 1996 as ’not high quality’ because it was unblinded.
Choice of outcomes to report in the abstract
The calcium channel review (King 2003) abstract finds space to report seven beneficial effects of calcium channel blockers on surrogate
outcomes, either prolongation of labour or surrogate fetal outcomes, but fails to mention perinatal deaths which had a relative risk
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1.65 (95% CI 0.74-3.64) favouring other tocolytics. Nor are total pregnancy losses mentioned. These would include the four neonatal
deaths reported by Koks 1998 in a ratio of 3:1 against calcium channel blockers.
In the oxytocin antagonist review abstract, five unfavourable conclusions against placebo are reported. Although all of them might be
explained by the gestational age imbalance at trial entry in the relevant trial (Romero 2000), this qualification is only mentioned in
relation to one, infant death, and is removed from the synopsis where the association is repeated. In the comparison with beta-mimetics,
the first outcome reported is birth weight under 1,500g, an outcome which was not pre-specified in the review methods and which is
the only statistically significant outcome out of 21 reported for this comparison. Only later is the reduction in adverse drug reactions
compared to beta-mimetics reported.
Choice of language
In the review of calcium channel blockers (King 2003), all of the seven sentences in the abstract conclusions and the plain language
summary contain a favourable opinion of calcium channel blockers. The single exception is a call for research into the effect of different
dosing regimes, with the implication that the primary effectiveness question has been answered.
The authors’ conclude: “it is considered unlikely that [placebo controlled trials of calcium
channel blockers] will be conducted given the unequivocal impact that this method of tocolysis has on short term postponement of
delivery” This statement is much too strong. It is based entirely on unblended trials against other tocolytics. Two of the five relevant
outcomes (birth prior to 37 weeks, and birth within 48 hours) showed only a non-significant effect, two (birth prior to 34 weeks and
within seven days) just reached the 0.05 level, and the final outcome (pregnancy prolongation in days), while statistically significant,
shows significant heterogeneity between trials.
In neither the abstract nor the conclusion section of the calcium channel blocker review is it mentioned that there have been no placebo-
controlled trials of calcium channel blockers in preterm labour.
In contrast, instead of saying that oxytocin antagonists had shown equivalent efficacy to other tocolytics in four high quality trials, the
authors phrase their summaries as either ’has failed to demonstrate superiority’ or ’is no better than other drugs’. This seems gratuitous
negativity.
Choice of outcomes to report
The outcomes selected for the oxytocin review differ significantly from those chosen for the calcium channel blocker review. The reason
is not clear.
Finally, the oxytocin antagonist review claims to be going to look at predefined outcomes measured related to the prolongation of
pregnancy. However the predefined outcomes for the two placebo-controlled trials, namely ’time to delivery’ or ’therapeutic failure’
were not reported.
Authorship of the reviews
I note that both these reviews share an author, Dimitri Papatsonis, who is the first author of the largest trial of calcium channel blockers,
upon which many of the favourable calcium channel blocker meta analyses depend.
I recognise that it is probably impossible to always avoid using trial authors to write systematic reviews, and that Dr Papatsonis
acknowledges his possible conflict of interest. Nor do I accuse him, or any of the review authors, of any intentional bias. Nevertheless, I
am concerned about possible unintentional bias against commercially developed pharmacological agents. This risks harming the future
development of drugs for use in pregnancy, something which I am sure everyone would support.
Conflict of Interest
I have acted as advisor to Ferring and when I was editor of BJOG the journal received sponsorship from Ferring to publish supplements.
Jim Thornton, July 2006
Reply
On behalf of the review authors, we respond to Professor Thornton’s comments about the review of calcium channel blockers (CCB)
[King 2003] and the review of oxytocin receptor antagonists (ORA) [New Reference] for preventing preterm birth.
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Judgement of trial quality
For the ORA review, blinding of the intervention is not synonymous with blinding of outcome assessment. Unless authors stated
so in their original reports, or in response to further queries, we cannot presume that those assessing the outcome of interest were
blinded to the allocated intervention. For example, in trials comparing betamimetics with atosiban, blinding of the intervention is
difficult due to the maternal and fetal side effects of betamimetics, particularly tachycardia and maternal palpitations. Therefore, until
further information is received from the trial authors, blinding of assessment of outcome is classified as “unknown” for these four trials
(European 2001; French/Australian 2001; Moutquin 2000; and Romero 2000). We agree Goodwin 1994 should also be classified as
“unknown”, and this is now corrected.
We disagree that assessment of trial quality was subjective. The statements “reasonable quality” used in the calcium channel blocker
(CCB) review and “not high quality” in the ORA review are intended to imply that the trials were neither poor quality nor high quality.
Studies were judged to be of poor quality if no adequate method of allocation concealment was described, as this is one of the most
important quality indicators regardless of whether the intervention was blinded. In accordance with Cochrane methodology, small
numbers and lack of sample size calculations were not considered indicators of trial quality.
Choice of outcomes to report in the abstract
For the CCB review, we believe we have adequately acknowledged the potential for bias in the ascertainment of neonatal outcomes.
We also note that the results were consistent across the included trials, but acknowledge that this does not rule out bias. A statement
regarding trial quality will be included in the abstract for the next update of the CCB review
The outcome measures in the abstract of the CCB review were considered to be clinically important outcomes for this review. We will
include the outcome of perinatal mortality in the abstract for the next update of the review.
In the ORA review abstract, the potential for bias due to the gestational age imbalance at trial entry in the Romero trial is acknowledged.
We have made it clearer how this relates to the other data presented by stating at the start of this paragraph the number of trials and
women in this comparison. We prespecified birthweight as a clinically important outcome measure for the review, and considered it
reasonable to include the finding of birthweight <1500gms in the abstract. In the abstract results, the ordering of text on maternal drug
reaction for the comparison of ORA with betamimetics provides consistency with the reporting of the outcomes for the comparison of
atosiban versus placebo.
Choice of language
We appreciate that the upper confidence interval for a number of the statistically significant outcomes reported approached 1, no
difference. However, based on the point estimates of the effects and the consistency in the findings across these outcomes, we believe
that the conclusions of the CCB review and wording of the abstract accurately reflects the findings. The statistical heterogeneity found
for the outcome of pregnancy prolongation we believe was appropriately managed in this review with the use of a random-effects model
for the meta-analysis of this outcome.
While we feel the language used in the ORA review abstract accurately reflects the results, we will rephrase to take account of the
perception we may have been too negative about atosiban.
Choice of outcomes to report
We accept the outcomes for the ORA and CCB reviews differ, as they do in other tocolysis reviews, and that this is not helpful for
readers of the review. As there is overlap between the review teams for these two reviews, we will rectify this during the next update of
these reviews.
Regarding the use of ’predefined’ outcomes, this term relates to outcomes chosen by the reviewers as clinically meaningful and defined
in the review protocol before the review begins. These outcomes may or may not match those reported for individual trials. If reported
outcomes did not match those pre-specified for the review, wherever possible, additional information was sought from authors. For
the placebo controlled trials in the ORA review, data on pregnancy prolongation was not provided in a format to enable inclusion in
the review; while additional data were sought from the authors, these were not forthcoming. The outcome of “therapeutic failure” was
reported in the individual trials, but was not chosen as an outcome for either the ORA or CCB reviews as it was considered susceptible
to bias.
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Authorship of the reviews
Whilst it is appropriate and common practice for experts to undertake systematic reviews within their area of expertise, we agree that
this carries with it the potential for bias. For Cochrane reviews, however (including the ORA and CCB reviews), a number of steps
are in place to ensure that this risk is minimised. These steps include: transparency of the review process through publication of the
protocol for the review prior to commencement, rigorous peer review (including an external referee) of the protocol and the review,
multiple review authors aiming for a mix of expertise and experience, and a feedback system which allows anyone to comment on
reviews and protocols. In addition, the regular updating of reviews means that any errors or misperceptions can be corrected. We think
it unlikely therefore that any harm will come to future development of drugs for use in pregnancy due to bias, whether intentional or
not, in our review.
(Summary of response, October 2007: Vicki Flenady, Dimitri Papatsonis, James King and Helen Liley on behalf of the authors for the
ORA and CCB reviews.)
Contributors
Feedback: Jim Thornton
Response: Vicki Flenady, Dimitri Papatsonis, James King and Helen Liley on behalf of the authors for the ORA and CCB reviews
WH A T ’ S N E W
Last assessed as up-to-date: 1 December 2013.
Date Event Description
1 December 2013 New citation required but conclusions have not
changed
Review updated.
1 December 2013 New search has been performed Search updated in December 2013. This updated re-
view includes eight additional trials involving 790
women, giving a total of 14 trials involving 2485
women included in the review. We revised primary and
secondary outcomes - see Differences between protocol
and review for details. We also aligned comparisons
between oxytocin receptor antagonists and other to-
colytic drugs with the Cochrane Pregnancy and Child-
care Group consensus statement on tocolysis for in-
hibiting preterm labour
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 3, 2005
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Date Event Description
17 September 2009 Amended Search updated. Twenty-one new reports added to ’Studies awaiting classi-
fication’
24 April 2008 Amended Converted to new review format.
31 July 2006 Feedback has been incorporated Feedback from Steve Thornton, Khalid S Khan, and Patrick FW Chien
added, with a reply fromDimitri Papatsonis on behalf of the review authors
Feedback from Jim Thornton added, with a reply from Vicki Flenady,
Dimitri Papatsonis, James King and Helen Liley on behalf of the authors
for the ORA and CCB reviews
1 December 2005 Feedback has been incorporated Feedback from Mats Åkerlund, Karel Marsl and Ingemar Ingemarsson
added, with a reply fromDimitri Papatsonis on behalf of the review authors
1 September 2005 Feedback has been incorporated Feedback fromMurphy Goodwin added, with a reply from Dimitri Papat-
sonis
C O N T R I B U T I O N S O F A U T H O R S
In the first version of the is review Dimitri Papatsonis lead the review with Vicki Flenady working collaboratively in all aspects of the
review including selection of studies and data extraction and quality assessment. Vicki Flenady lead this review update in collaboration
with Dimitri Papatsonis. Eashan Tambimuttu assisted with data extraction for studies identified in this update of the review. Hanna
Reinebrant undertook data extraction and quality assessment for all studies included in the review, undertook data entry and completion
of the ’Risk of bias’ tables. Helen Liley assisted with resolving differences in data extraction, revised the background for this update and
assisted with editing throughout the review. All authors were involved in interpretation of the results of the review and final editing.
D E C L A R A T I O N S O F I N T E R E S T
Dimitri Papatsonis is the first author on a completed multicentre trial of nifedipine tocolysis. Vicki Flenady and Dimitri Papatsonis
are authors on a Cochrane review titled ’Calcium channel blockers for inhibiting preterm birth’ (update of King 2003 in progress). Vicki
Flenady is an author on a Cochrane review titled ’Cyclo-oxygenase (COX) inhibitors for treating preterm labour’ (King 2005).
S O U R C E S O F S U P P O R T
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Internal sources
• Centre for Clinical Studies - Women’s and Children’s Health, Mater Hospital, South Brisbane, Queensland, Australia.
• Division of Obstetrics and Gynaecology, John Hunter Hospital, New South Wales, Australia.
• Department of Obstetrics and Gynaecology, Amphia Hospital Breda, Breda, Netherlands.
• Department of Neonatology, Mater Mothers’ Hospital, South Brisbane, Queensland, Australia.
External sources
• Department of Health and Ageing, Commonwealth Government, Canberra, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We revised the primary and secondary outcomes to more clearly and comprehensively address important outcome measures and to
enhance consistency with other Cochrane reviews of tocolytics for preterm birth.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Albuterol [therapeutic use]; Infant, Extremely Low Birth Weight; Obstetric Labor, Premature [∗drug therapy]; Oligopeptides
[∗therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Oxytocin [∗antagonists & inhibitors]; Ritodrine [therapeutic
use]; Terbutaline [therapeutic use]; Tocolytic Agents [∗therapeutic use]; Vasotocin [∗analogs & derivatives; therapeutic use]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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